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Bolstad, David B. Ph.D., July 2006 Chemistry
Synthesis of Novel 6-Nitroquipazine Analogs for Imaging the Serotonin 
Transporter by Positron Emission Tomography
Chairperson: John M. Gerdes
A positron emission tomography (PET) imaging agent that can effectively 
quantify the serotonin transporter (SERT) in brain regions with moderate to low 
densities of SERT has yet to be identified. The recent literature has suggested 
that the need for such an agent may be filled by a selective, high affinity SERT 
ligand that displays extended in vivo kinetic profiles, concurrent with a reduction 
of in vivo nonspecific binding. Recently, our group has identified 2’-alkyl-6- 
nitroquipazine analogs as novel SERT ligands displaying very high affinity for 
SERT (picomolar concentration range). We have utilized the 6-nitroquipazine 
molecular construct for the development of new SERT PET imaging agents, by 
generating a series of racemic 2’-alkyl-6-nitroquipazine analogs that can 
incorporate the carbon-11 or the longer-lived fluorine-18 radionuclides. We 
expect that the increased SERT affinity of our new ligands will afford more 
efficacious SERT PET agents that can effectively quantify low density SERT 
regions in living brain.
A large focus of the present study was to expand our initial racemic lead agents 
by synthesizing each of them in enantiomerically pure form. Our synthetic 
strategy utilized an efficient asymmetric synthesis of the piperazine head-group 
from amino acid starting materials. The syntheses afforded non-radiolabelled 
target ligands and the appropriate radioligand precursors in good yields. 
Preliminary pharmacological data suggests a marked difference in binding affinity 
between the enantiomers of our agents. Furthermore, using racemic amino 
acids and the same asymmetric synthetic strategy, we were also able to 
generate novel 2’-aryl-6-nitroquipazine analogs that were not synthetically 
accessible using our derived methods for the 2’-alkyl agents.
The racemic radiotracer [18F]2’-(3-fluoropropoxymethyl)-6-nitroquipazine agent 
was synthesized and evaluated in rat for initial radiotracer distribution. The 
studies in rat have demonstrated favorable accumulation of the tracer in the brain 
indicating efficient passage through the blood brain barrier. Furthermore, these 
studies indicate the greatest concentration of radiotracer in regions of the brain 
with known SERT density. The studies of the initial, racemic tracer have shown 
that [18F]2’-(3-fluoropropoxymethyl)-6-nitroquipazine demonstrates potential as a 
new SERT PET imaging agent.
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CHAPTER 1
INTRODUCTION, BACKGROUND AND PURPOSE
1.1 Serotonin Biology
Serotonin (5-hydroxytryptamine, 5-HT) 1 is a biogenic indolamine 
neurotransmitter that is present in the central nervous system (CNS) and 
peripheral regions of both vertebrates and invertebrates. Within living systems, 
serotonin is synthesized from L-tryptophan 2 in two steps (Figure 1.1). Step one 
is an aromatic hydroxylation facilitated by tryptophan hydroxylase to provide 5- 
hydroxytryptophan 3 that undergoes decarboxylation by amino acid 
decarboxylase to provide 5-HT 1.1
NH.tryptophan HO. 
hydroxylase
32
NH2
HO.amino acid 
decarboxylase
1, Serotonin, 5-HT
Figure 1.1: The biosynthesis of serotonin.
Within the mammalian CNS, the serotonergic neurons are located 
primarily in the raphe that is located within the brain stem. Neuronal projections 
from the raphe extend to the cerebral cortex, hippocampus, hypothalamus and 
thalamus thereby providing high densities of serotonergic neurons in these 
regions.2 Interneuronal signaling with 5-HT occurs primarily at the synapse. The
1
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synapse is a junction between an axon terminal of one neuron (presynaptic 
neuron) and the dendrite of another (postsynaptic neuron) (Figure 1.2).
Action PotentialPresynaptic Neuron
Synaptic
Vessicle
Ca2+ Influx
/  / i  •*%
5-HT
Vesicular I  
Transporter
Exocytosis
Serotonin
Transporter
Synaptic Cleft
Postsynaptic Receptor 
Activation
Postsynaptic Neuron
Response
Figure 1.2: A general representation of a serotonergic synapse.
The space between the neurons is approximately 20 nm and is called the 
synaptic cleft. When an action potential traveling along the presynaptic neuron 
reaches the axon terminal, voltage-gated Ca2+ channels in the membrane open 
allowing for an influx of Ca2+ ions. The influx of calcium ions causes the synaptic 
vesicles to fuse with the cellular membrane and release their neurotransmitter 
contents (e.g. 5-HT, 1) into the synaptic cleft through the process of exocytosis.
2
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Once in the synaptic cleft, the neurotransmitters reach the postsynaptic neuron 
through diffusion, and a response is afforded though activation of postsynaptic 
receptor proteins.3 Following neurotransmission, transport proteins located 
within the presynaptic membrane clear neurotransmitter from the synaptic cleft. 
For 5-HT, the transport protein is the serotonin transporter (SERT, see Section
1.2 for a more detailed discussion). Once transported, 1 is packaged back into 
vesicles through the action of a vesicular transporter. Additional removal of 1 
from the synaptic cleft is facilitated by the oxidative degradation of 1 by 
monoamine oxidase (MAO).1
A wide variety of serotonergic receptors exist in the CNS and in the 
periphery. Currently there are fourteen serotonin receptors that have been 
identified and characterized to various extents.4 These receptors are grouped 
into families based on their similar biochemical characteristics (primary structure, 
genes), pharmacology and signaling mechanisms 4 Currently three functional 
classes of serotonin receptors are known. Most of the receptors (twelve of 
fourteen) are G protein-coupled receptors, one is a ligand-gated ion-channel and 
the last is the serotonin transporter (SERT). These receptors and a brief listing 
of their known function^ are summarized in Table 1.1.2, 4-6 In peripheral 
regions, serotonin receptors are found in blood platelets,7 the smooth muscle of 
the digestive tract8 and circulatory system9 and on peripheral neurons where 5- 
HT has been shown to have a role in pain signaling and analgesia following 
tissue injury.10
3
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Table 1.1: A table of known serotonin receptors, their functional class, location in the 
vertebrate/invertebrate body and associated functions.
Receptor Type Location Functions
5-HT1A G-protein CNS-per Sleep, anxiety, thermoregulation, depression
5-HT1b G-protein CNS-per Migraine, vaso., aggression, bipolar disorder, gastric 
motility
5-HT1d G-protein CNS-per Migraine
5-HT1e G-protein CNS Largely unknown
5-HT1f G-protein CNS-per Migraine, vaso.
5-HT2A G-protein CNS-per Schizophrenia, anxiety
5-HT2B G-protein CNS-per Migraine, gastric motility, vaso., appetite
5-HT2C G-protein CNS Depression, anxiety, obesity, cognition, 
schizophrenia
5-HT3 Ion Chan. CNS-per IBS, emesis, cognition
5 -HT4 G-protein CNS-per IBS, gastric motility
5-HTs G-protein CNS Largely unknown
5-HT6 G-protein CNS Bipolar disorder, Parkinson's, Alzheimer's, learning, 
seizures, appetite
5-HT7 G-protein CNS-per Sleep, migraine, depression, cognition, 
schizophrenia, IBS
SERT transporter CNS-per Uptake of 5-HT into cells
Key: G-Protein = G Protein-coupled receptor, ion chan. = ligand-gated ion channel, CNS = 
central nervous system, per = periphery, vaso. = vasocon-striction, IBS = irritable bowel 
syndrome
1.2 The Serotonin Transporter
The serotonin transporter (SERT) is a member of the 
sodium/neurotransmitter symporter protein family (SNF). The SNF proteins 
utilize the co-transport of sodium and chloride ions down a concentration gradient 
to provide the energy for transport of substrate.11 Other transport proteins in the 
SNF family include those for the other biogenic amine neurotransmitters; 
dopamine (dopamine transporter, DAT) and norepinephrine (norepinephrine 
transporter, NET). Hydropathy analysis of the primary amino acid sequences of 
the biogenic amine transport proteins predicts a common tertiary structure with 
twelve transmembrane a-helical domains (TMD’s). The SNF transporters are
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membrane bound and have their carboxy and amino terminals on the intracellular 
(cytoplasmic) side of the membrane. The human SERT (hSERT) contains 630 
amino acids.12
To date, a high-resolution molecular structure determination (e.g. x-ray 
crystal structure) of SERT, or the other biogenic amine transporters, has yet to 
be put forward. The majority of knowledge about SERT structure as it relates to 
function comes from mutation studies probing the biochemical changes in 
receptor function as a result of amino acid substitutions or deletions.13-18 Several 
studies have used these results to model the transport binding region of SERT to 
suggest the relative arrangements of the TMD’s.11,15
Recently, the structures of two major facilitator superfamily (MFS) 
transport proteins, the glycerol-3-phosphate transporter (GIpT) and the lactose 
permease (LacY), have been reported.19,20 Proteins of the MFS are related to 
the SNF transporters structurally (12 TMD’s, intracellular amino and carboxi 
termini) and functionally (ion coupled membrane transport proteins) and both 
belong to the larger group of secondary transporters. Because of the structural 
similarities between the MFS and SNF transporter families, the LacY tertiary 
structure was recently utilized as a template to generate a refined three- 
dimensional model of SERT.21
More recently, a prokaryotic homolog of the biogenic amine transporters 
was crystallized and a structural determination made.22 The bacterial protein, 
called LeuTAa, is a sodium dependent transport protein that is responsible for the 
movement of leucine into bacterial cells. LeuTAa is suggested as a better
5
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template for modeling SERT, relative to GIpT and LacY, because of its 
corresponding dependence on sodium ions for transport of substrate. However, 
no refined SERT protein models, that utilize LeuTAa as a design template, have 
yet come forward in the literature.
Developing a cogent understanding of the three-dimensional structure of 
SERT will provide insight into functional aspects of the protein and also provide a 
tool for the design and synthesis of new SERT ligands.
1.3 The Serotonin Transporter and Disease
Serotonin 1 has been well documented as having a key role in the 
pathology of certain CNS related disorders.23, 24 It has been suggested that the 
amount (density) of cell-surface expressed SERT may serve as an indicator of 
the overall integrity of serotonergic terminals in the CNS.25 The distribution of 
SERT in the CNS in healthy human brains has been determined from 
postmortem studies26-29 and a summary of relative (high, medium, low) SERT 
distributions in different brain regions is given in Table 1.2. The role of SERT in 
neuropsychiatric disorders (depression, dependence, bipolar disorder, obsessive 
compulsive disorder, among others) and neurological disease (Parkinsons’s 
disease, Wilson’s disease, Stroke, Tourette’s syndrome, among others) is still 
poorly understood. Studies in postmortem and living brain have demonstrated 
significant changes in SERT density (increases and decreases) for these 
diseased states, relative to healthy controls.
6
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Table 1.2: Relative SERT densities in discrete brain regions.
Relative amount 
of cell surface 
expressed SERT Brain Regions
High MIDBRAIN AND DIENCEPHALON: Medial and
dorsal raphe, thalamus, hypothalamus, striatum
Medium LIMBIC SYSTEM: Hippocampus, parahippocampal
gyrus, amygdala and cingulate cortex
Low Neopallium and cerebellum
Additionally, regional cerebral changes in SERT density have been noted 
for age differences (decreased availability with increasing age) and seasonal 
variation (decreased in autumn and winter) in healthy patients. Detailed 
summaries of these studies have recently been reported.23, 24 The results from 
these studies have provided conflicting correlations. For example, in two 
separate studies of depression, children and adolescents have shown increased 
(p < 0.02) SERT in the midbrain regions relative to controls30 while adults 
demonstrate significant (p = 0.02) decreases in SERT within the same region.31 
Similar conflicting correlations for other diseased states have been 
documented.23,24 Clearly there are discrepancies observed in the current body 
of research that has been devoted to understanding the role of SERT in 
neuropsychiatric disorders and neurological disease. It is suggested that an 
enhanced understanding of the SERT role in these disorders will be assisted by 
the development of better in vivo pharmacological tools, such as new positron 
emission tomography (PET) and/or single photon emission computed 
tomography (SPECT) imaging agents 23
7
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Of the conditions mentioned above, depression, anxiety and OCD have 
seen significant therapeutic benefit from serotonin reuptake inhibitors. These 
drugs bind to SERT and competitively inhibit (block) the uptake of 5-HT. It is 
hypothesized that a resultant increase of 5-HT in the synaptic cleft affords 
increased transmission of signal and an amelioration of symptoms.32
The earliest SERT inhibitors, introduced in the 1950’s, were the tricyclic 
antidepressants (for example 4 and 5, Figure 1.3). Although these had a 
profound effect at reducing depressive conditions, they also promoted adverse 
side effects such as cardiotoxicity, sedation and weight gain.1 A new generation 
of a SERT inhibitors, the selective serotonin reuptake inhibitors (SSRI’s, for 
example 6 - 9 ,  Figure 1.3), were introduced in the late 1970’s. The most prolific 
and well known SSRI, Fluoxetine (Prozac, 6), was the first to receive Food and 
Drug Administration (FDA) approval for the treatment of depression in 1987.1, 33 
The SSRI’s interact selectively with SERT to provide their therapeutic effect and 
have demonstrated a reduction in adverse side effects relative to the tricyclic 
antidepressant counterparts.1
8
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NH
4 Imipramine 5 Amoxapine 6 Fluoxetine (Prozac)
Cl O
7 Sertraline (Zoloft)
CF3
8 Fluvoxamine (Avoxin) 9 Paroxetine (Paxil)
Figure 1.3: A collection of known SERT ligands; the tricyclic antidepressants (4 and 5) and the 
modern selective serotonin reuptake inhibitors (SSRI's, 6 -  9).
1.4 Positron Emission Tomography Imaging
Positron Emission Tomography (PET) is a medical imaging technique that 
utilizes radioactive probes (tracers, radioligands) to visualize and quantitate 
biochemical processes within living tissues. These tracers possess positron 
emitting radionuclides that undergo decay in vivo, thereby providing the 
necessary signal for quantifying the biochemical process of interest.34 The most 
commonly utilized radionuclides are fluorine-18, carbon-11, nitrogen-13 and 
oxygen-15.35 Another radionuclide that is often used with CNS ligand tracers, is 
bromine-76.36 These positron radionuclides undergo beta plus (p+) decay and 
emit a positron that travels a few millimeters or less before colliding with an 
electron. The annihilation event produces two high-energy photons that are
9
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emitted 180° apart along a line of decay response. Using precision detection 
instrumentation, the origin of the photons in three-dimensional (3D) space can be 
determined thereby providing the in vivo location of the decay event. Resultant 
3D maps of radionuclide decay can be created that allow for the quantitative 
measurement of radiotracer accumulation and/or localization in the tissue or 
region of interest. Anatomical correlation of the 3D PET decay images with high- 
resolution nuclear magnetic resonance images (MRI) allows for the discrete 
identification of target tissues and the anatomical volume associated with tracer 
accumulation.37 Provided that the radiotracers are selective for their in vivo 
target, PET imaging allows for the non-invasive measurement of the associated 
biochemical processes.34 A sample PET image is shown in Figure 1.4.
Figure 1.4: Sample PET images (bottom) from a study in baboon, displaying the accumulation of 
SERT tracer [11C]AFM 14 in the midbrain and thalamus. The corresponding MRI image of the 
brain is displayed above the PET images. (Image from ref. 51).
10
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To afford efficacious PET imaging agents for the CNS, prospective PET 
ligands must meet certain criteria. These criteria have been recently detailed38"41 
and are summarized below.
-Synthetic Criteria -  Radioligand planning and synthesis -  The position of 
radionuclide introduction into a prospective ligand can have profound implications 
on tracer development. The modification of a parent compound to accommodate 
a radionuclide may grossly change the ligands properties (lipophilicity, binding 
affinity for target, metabolic fate), relative to the parent, and affect the tracers 
performance. Target agents should be rigorously characterized, in non­
radioactive form, for the appropriate in vitro characteristics (see below). 
Radiochemical syntheses are desired where the yield of target ligand at the end 
of synthesis (e.g. incorporation of radionuclide, removal of protecting groups, 
purification and preparation of injectate) is usually greater than 1 0 %. 
Furthermore, the radiosynthesis should afford the target tracer with specific 
activity (amount of radioactivity per mole or gram of ligand) that is sufficient for 
adequate PET data acquisition (usually >500 Ci/mmol). Additionally, 
radiosynthesis time needs to be minimized so PET experiments can be 
completed in the useable lifetime of the radionuclide (usually 4-5 half-lives). For 
certain radionuclides, especially carbon-11 (ti/2 = 20.3 min), this criterion is of 
timely importance.
-In vitro pharmacological profiles -  The competitive binding affinity (Kj) of the 
tracer for its target protein in the CNS should typically be at low nanomolar 
concentrations or below, so that the target can be adequately quantitated given
11
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the low doses (< 1 mg) of ligand typically administered for PET imaging studies. 
The radioligand should display at least a 100 fold preference for its target over 
other sites that it may interact with. This selectivity helps minimize complications 
that arise from non-specific (non-target) binding interactions during the in vivo 
PET experiments. To achieve adequate brain penetration by passage through 
the blood-brain barrier (BBB) the lipophilicity of the compounds (partition 
coefficient, logP) needs to be considered. More lipophilic (logP > 3.5) qualities 
can sometimes lead to increased nonspecific binding in vivo40 and management 
of the tracer lipophilic qualities should be considered as additional synthetic 
criteria.
-In vivo pharmacological profiles -  The uptake of the radioligand into the brain 
should occur quickly following injection. The nonspecific binding interactions 
should washout of the tissues rapidly, so target specific binding can be quantified 
on a timescale appropriate for the radionuclide. The target specific binding 
interactions should be reversible on the experiment time scale so kinetic tracer 
analyses can be performed. Radioligands should show minimal metabolic 
activity in the CNS since radiolabeled metabolites may have distinct in vivo 
properties that could complicate the tracer target evaluation.
-Additional considerations -  Ligand toxicity is of minimal concern since the 
injected mass of radioligand is well below a therapeutic dose; that is usually less 
than 10 pg. The dose of radiation administered in an experiment is also a 
concern, yet is minimal based on the low tracer dose as a function of radioligand 
specific activity.
12
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Other specific tracer considerations can be made based on the needs of 
the system under study. Additional criteria for the in vivo imaging of the SERT 
target within the CNS are provided in the next section.
1.5 Imaging of the Serotonin Transporter with SPECT and PET
Studies toward efficacious imaging agents for SERT have been ongoing 
now for approximately fifteen years. The first successful imaging agent 
developed for SERT was the cocaine analog (single photon emission computed 
tomography (SPECT) agent [123l]p-CIT 10 (Figure 1.5) .42
Figure 1.5: First generation SPECT imaging agent for SERT.
Ligand 10 however, is not selective for SERT, and has also found use as 
an imaging agent for the dopamine transporter (DAT). The inability of 10 to 
quantify SERT in regions where DAT was coexpressed proved to be a significant 
limitation to the efficacy of this tracer, and has limited it’s use in imaging medium 
to low density SERT regions.43 The synthesis of novel ligands that are selective 
for SERT, relative to the other biogenic amine transporters (DAT and NET), 
remains a ongoing challenge in the development of new SERT imaging agents.
10 [123 l]pCIT
13
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Next generation SERT PET imaging agents have largely been derived 
from two structural classes (Figure 1.6, with references); the pyrroloisoquinolines 
(11 and 12) derived from (+)-McN5652 26 and the diaryl sulfides (13 -  15).
Cmpd R ref
11 11CH3 44
12 CH218F 48
NH2 14[11C]AFM 11CH3 CH2F 47 
15[18F]AFM CH3 CH218F 52
13DASB 11CH3 CN 47
Cmpd R-, R2 ref
Figure 1.6: Next generation PET imaging agents for SERT.
The first tracer to find use as a selective in vivo imaging agent for human 
SERT was 11.44 Although 11 has been utilized successfully in human studies of 
depression45 and drug abuse,46 it has been shown to be an inferior tracer to 
ligands from the diarylsulfide series (particularly 13 and 14, Figure 1.6) .47 The 
fluorine-18, fluoromethyl analog 1 2  has demonstrated superior in vivo properties 
(40% higher specific binding, reduced metabolism, faster kinetics) relative to 
carbon-11 variant 11.48 Additionally, the longer-lived fluorine-18 radionuclide 
provides an opportunity for off-site imaging applications. However, the 
successful imaging of brain tissues with low SERT density may fail as a result of 
high NSB in non-target regions (i.e. cerebellum) .49
Of the diaryl sulfides that have been developed, DASB 13 and [11C]AFM 
14 have emerged as lead SERT imaging agents (Figure 1.6) .47 Although 13 has 
been one of the most widely used ligands for the in vivo imaging of SERT in 
humans,46, 50 it still does not allow for a reliable quantification of low-density
14
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SERT regions.43 It has been suggested that the use of [11C]AFM 14 (with greater 
target to non-target ratios) may allow for the quantification of low-density SERT 
regions.43,47,51 A recently developed fluorine-18 ligand, [18F]AFM 15, shares the 
high specific binding qualities of carbon-11 analog 14 as demonstrated in rat.52 
Given the longer lifetime of the fluorine-18 radionuclide, and the possibility for off- 
site imaging applications, 15 may emerge as a superior ligand to both 13 and 14. 
Studies of ligand 15 in non-human primates, to substantiate the early rodent 
findings have yet to be put forward. To date, diaryl sulfide ligands 13 and 14 
have been established as the most efficacious ligands for the in vivo imaging of 
SERT.43, 47, 53 However, there still exists a need for ligands that can quantify 
SERT in brain regions displaying low-density expression of the receptor.43
Six 6 -nitroquipazine analogs have been advanced as plausible SERT 
tracers since the early 1990’s (Figure 1.7, with references). These tracers have 
all largely failed to provide the in vivo qualities necessary for efficacious SERT 
imaging agents. Compound 16 suffers from metabolic defluorination and an 
apparent lack of selectivity for SERT in blocking studies.54
Cmpd R-| R2 ref
16 H -(CH2)318F 54
17 11CH3 H 55
18 123l H 57
NH 19 76Br H 36
20 18F H 56
F igure 1.7: SERT imaging agents derived from 6-nitroquipazine.
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Compounds 17, 19 and 20 all showed poor thalamus to cerebellum (high to low 
SERT density; target to non-target) ratios.36, 55, 56 Compound 17 also displayed 
slow binding kinetics (equilibrium not reached at 90 min) that was not amenable 
to the lifetime of the carbon-11 radionuclide. SPECT agent 18 has demonstrated 
good target to non-target ratios (> 2 ) in primate brain but the use of this 
compound has been limited due to metabolic dehalogenation generating free 
iodine-123 that obscures experimental images.55' 57 PET agent 21 has recently 
been described.58 However, in a comparison study with DASB 13, 21 was shown 
to be an inferior PET ligand.59 Collectively, these 6 -nitroquipazine agents have 
not proven as efficacious at imaging SERT as diaryl sulfides 13 and 14.
1.6 6-Nitroquipazine Analogs: Previous Work from Our Lab and Others
Our group has been interested in the development of novel SERT tracers 
derived from the known SERT inhibitor 6 -nitroquipazine (6 -NQP, 22) (Figure 1.8 ).
Figure 1.8: 6-Nitroquipazine and a description of ring numbering in the quipazine series.
The IUPAC name for 22 is 6-nitro-2-(piperazin-1-yl)quinoline. However, 
the term ‘quipazine’ is typically used when referring to compounds in this series. 
The parent compound, quipazine 23, is also shown in Figure 1.8 and the 
numbering scheme for the rings is indicated. Substituents on the piperazine ring
4
3'
22 23
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are indicated with a ‘prime’ after the position number to differentiate them from 
substituents on the quinoline ring.
Compound 22 was first described in the early 1980’s under the trade 
name DU 24565 and its selectivity for SERT over the other biogenic amine 
transporters (NET and DAT) was high (103 fold) .60 A tritiated ([3H]) variant of 22 
was generated61 and the in vitro and in vivo characterization of [3H]22 further 
demonstrated the potency and selectivity of 22 for SERT .62,63
Our group performed a structure activity relationship (SAR) study to 
evaluate the effects of methyl group introduction to quipazine 22 at the 2’- and 3’- 
positions (Figure 1 .Q) .64
Figure 1.9: Investigational compounds from our initial SAR study.64
We observed a marked increase in SERT affinity with 2’-methyl agent 24 
(K j = 0.08 nM) relative to 22 (K j = 0.16 nM) and a competitive binding decrease 
with the 3’-methyl analog 25 (K j = 4.56 nM). The selectivity of these compounds 
for SERT has not yet been evaluated through comparison biding studies at NET 
and DAT. However, it is conjectured to be high, based on the selectivity of 
parent compound 2 2 .
Concurrent with this SAR study, our group was generating an inhibitor- 
based pharmacophore of the SERT binding site using SERT inhibitors of known
17
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efficacy.65,66 The training set ligands used in this computational study are shown 
in Figure 1.10 with their key structural similarities identified.
Figure 1.10: Training set ligands utilized in the generation of our SERT pharmacophore.
These computational studies used rigorous conformational searching and 
scoring functions to identify conformations of each molecule (7, 26 -  28) that are 
most like each other in three-dimensional (3D) space relative to their key 
structural similarities. The key points of similarity, the terminal amine group, both 
aromatic rings (Ar1, distal to amine group; Ar2 proximal to amine group) and the 
X group (Shown in Figure 1.10) were used as points of comparison in this study. 
The resultant pharmacophore model is shown in Figure 1.11 as a superposition 
overlay of select conformations of the training set ligands. The similarities in the 
alignments of the key structural elements are detailed in Figure 1.11 where the 
regions are indicated with arrows.
When 2’-methyl quipazine analog 24 was fit into the pharmacophore, it 
was observed that the methyl group provided a contact into the Ar2 region of the 
model. It is thought that this simple alkyl group may be a suitable replacement
Amine
Central
Carbon
Terminal
NH2
Central
Carbon
Terminal
Amine
N.
\
\
Terminal
Amine
7 Sertraline 26 (+)-MCN5652 27 Indatraline 28 (S)-Citalopram
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for the Ar2 moiety. The 3’-methyl analog 25 fit less optimally into this region, 
placing the methyl group into a region of the 3D model that was undefined. The 
decreased affinity of 25 might result from steric interactions that occur within this 
undefined region of our model.
Figure 1.11: Our derived SERT pharmacophore model, illustrated as a superposition overlay of 
select conformations of training set ligands. (Image from ref. 6 6 ).
With quipazine 24 identified as a new lead agent, subsequent studies 
sought to refine the SAR of this initial lead. Our computational efforts 
corroborated our initial SAR findings and suggested the abandonment of the 3’- 
substituted-6 -nitroquipazine analogs (like 25). Former group member Mark 
Walker initiated these studies with his synthesis of 2’-methoxymethyl-6- 
nitroquipazine (MOM-NQP, 35, Figure 1.12) .67 Briefly, the Walker synthesis 
began from known dibenzylpiperzine ester 2968 that was reduced to alcohol 30
Het
Terminal 
Amine A h-ax is  
\  View
Connecting
CarbonX Group Terminal 
’ Amine
(1 S,4S)-(+)-c/s-Sertraline 
(1 R3S)-(+)-fra/?s-lndatraline 
(1 S)-(+)-Citalopram
Top View Het |  (6S,10bR)-(+)-McN-5652
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with UAIH4 in ether. Alkylation of 30 with NaH and CH3I in THF, followed by 
dihydrochloride formation gave 31. Hydrogenolysis of the benzyl groups with Pd- 
C in ethanol gave piperazine 32 that was protected with trityl chloride in DCM to 
give 33.
Figure 1.12: Walker's synthesis of 2'-methoxymethyl-6-nitroquipazine (MOM-NQP).67
Compound 33 was coupled to 2-chloroquinoline using the method of 
Gilman69 to provide quipazine 34 following deprotection. Nitration of 34 provided 
the target, MOM-NQP 35 .67
Compound 35 displayed very high binding affinity for SERT, and is one of 
the most potent SERT inhibitors known to date.70 It displayed a 65-fold increase 
in potency over parent compound 22 and a 32-fold increase over our initial lead 
agent 24. The MOM-NQP ligand 35, like the 2’-methyl analog 24, still needs to 
be evaluated for its SERT selectivity relative to DAT and NET. A summary of the 
initial SAR data is detailed in Table 1.3, in comparison to parent compound 6 - 
NQP 22. The radioligand displacement binding assay used to acquire the SERT 
binding data is detailed in Chapter 5.
Et02C '4 %/NBn ether 
H
BnN/ N 'i  L1AIH4
29
Rondu, 1997
30 31 32
2-CI-quinoline
Et3N H
33
NH
H
34 35
H
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Table 1.3: Preliminary SAR data from the Gerdes laboratory.
Compound Structure Binding affinity (Kj± sd) nM
22m 0.163 ±0.053
N 0.0025 ± 0.0003
0.081±0.061
4.56 ± 2.4
H
Other structure activity studies of 6 -NQP analogs at SERT have been 
ongoing by other researchers and their work has focused primarily on quinoline 
ring substituted analogs.54,71'73 A few representative targets from their work are 
shown in Figure 1.13. Many of the compounds produced by Chi and coworkers 
have displayed good SERT affinity in the low to sub-nanomolar concentration 
range (i.e. compounds 36, 38 and 40 and others). Additionally, they have 
successfully demonstrated that groups of moderate size are well tolerated at the 
3- and 4- positions of the quinoline ring (i.e. 37, 38 and 40).
21
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N N' ^ 1
k^NH
Cl
N
l^ N H
F
3672
SERT K = 0.03 +/- 0.01 nM
3772
SERT Ki = 5.23 +/- 0.53 nM
l^ N H
38s4
SERT K| = 0.31 +/- 0.01 nM
Cl Cl
N N ^ i N N'''X | 
k^NH k^NH
4171
SERT Ki = 12.62+/-1.44 nM
Br
3973
SERT K = 17.28 +/- 2.33 nM
4073
SERT K, = 2.70 +/- 0.32 nM
Figure 1.13: Example ligands from the SAR studies performed by Chi et al. The Kj values are 
determined with rat brain homogenate2  and fHlcitalopram.
The addition of a methyl group to the terminal amine was not well 
tolerated, and a 570 fold decrease in SERT affinity was demonstrated for the 
conversion of 36 to 39.
To date, compound 38 is the only ligand from Chi and co-workers that has 
been advanced as a PET imaging tracer. This agent however displayed 
significant in vivo metabolic defluorination as evidenced by the accumulation of 
radioactivity in bone. Additionally, the in vivo challenge of [18F]38 with selective 
SERT blocking agents (fluoxetine and paroxetine) only reduced the binding of 
[18F]39 by 11-31% in the frontal cortex signifying that in vivo nonspecific binding 
of this tracer is high.54 These results suggest that [18F]38 may not be a suitable 
tracer for imaging SERT.
22
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1.7 Focus of the Investigation
Following the successes of our initial SAR investigations, attention was 
turned toward the development of 6 -nitroquipazine analogs as new SERT PET 
imaging agents. As discussed earlier, recent reports of new PET agents for 
SERT have suggested that a need still exists for tracers that can quantitatively 
measure SERT in brain regions with medium to low SERT density.43,47 A tracer 
that can meet these demands must demonstrate the in vivo properties that 
promote accurate in vivo SERT measurements; including, the disappearance of 
nonspecific binding within a timeframe that is within four half-lives of the 
radionuclide and appropriate signal-to-noise ratios that permit reproducible 
quantification of moderate to low SERT density regions. Given the very high 
affinity of our new 2’-substituted-6-nitroquipazine analogs (compounds 24 and 
35, as per Table 1.3) and the known SERT selectivity of 6 -nitroquipazine 22,60 
we felt that select analogs may offer significant improvements in tracer 
performance relative to the established 6 -NQP SERT imaging agents (Figure
1.7).
With the new goal of obtaining novel PET imaging agents that could 
reproducibly image brain regions with moderate and low densities of SERT, we 
set out to establish synthetic protocols for obtaining these agents from our initial 
lead agents MOM-NQP 35 and 2’-methyl-NQP 24. The investigation described 
within, details our discovery of new SERT PET imaging agents, with an emphasis 
on the synthetic methods utilized to obtain our targets in non-racemic form.
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Chapter Two of this dissertation discusses the initial racemic syntheses of 
our new targets and the preliminary radiochemical studies that produced our 
target fluorine-18 and carbon-11 SERT PET tracers. The asymmetric synthetic 
methods developed to obtain our non-racemic targets will be discussed in 
Chapter Three. The discussion of the asymmetric method is extended in 
Chapter Four, as it is applied to the synthesis of novel 2’-aryl-6-nitroquipazine 
analogs. The biological evaluation of our new SERT ligands is provided in 
chapter five, and a summary of the study closes out this work in chapter six. 
Finally, full experimental details are afforded in Chapter Seven.
24
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
CHAPTER 2
SYNTHESIS OF RACEMIC TARGETS
2.1 Introduction
Preliminary studies from our laboratory aimed at acquiring a SERT PET 
imaging agent have been focused on the generation of a fluorinated target ligand 
derived from the initial lead agent 2’-methyl-6-nitroquipazine 24. The fluorinated 
target ligand 42 was never synthesized, even in non-radioactive ‘cold’ form and 
efforts to acquire it were abandoned (Figure 2.1).
Figure 2.1: Attempted route toward the generation of 2 ’-fluoromethyl-6-nitroquipazine.
These synthetic failures resulted largely from the instability of the fluorine 
atom to the alkyllithium coupling conditions (discussed later) used to form 42 
from piperazine 45 and 2-chloroquinoline. A control reaction confirmed that the 
fluorine atom was undergoing elimination (HF) since an analysis of the product 
mixture by GC/MS showed a decrease in mass (m/z A20) of the trityl protected
Failed
BnN ''i PAST  BnN""''N| H2, Pd/C
l2CI2 FH2c 4 — NBn EtOH
H N '^  Trityl-CI
H° ^ 4 ^ NBn CH2Cl2 FH2C.
H
Et3N FH2C
ch2ci2
30 43 44 45
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material 45 consistent with the loss of HF. This was unfortunate since piperazine 
45 could be synthesized easily from the dibenzyl alcohol substituted 30 (Figure 
2.1). Additionally, attempts at generating a tosylate leaving group from the 
alcohol 30 and another alcohol intermediate 58 (HOM-BOC, shown later) failed. 
Thus, a radiochemical precursor could not be generated. The introductions of 
other sulfonate leaving groups (mesylate, triflate) were never attempted since our 
radiochemical collaborators preferred to have the tosylate leaving group 
chromophore as an experimental tool for observing its displacement by 
radioactive [18F]fluoride ion.
Given these failures at generating fluoromethyl agent 42, our group next 
sought to extend the piperazine side chain to 3-fluoropropyl in the hope that a 
fluorinated agent might be generated. These efforts were successful, and the 
formation of compound 50 was partially the focus of another research group 
member, Brian Kusche.74 The synthesis of target ProF-NQP 50 is briefly 
summarized below (Figure 2.2).
Figure 2.2: Summary of the route used by Kusche74 to obtain ProF-NQP. For 49, the protecting 
group (PG) was N-formyl or N-ferf-butoxycarbonyl (N-Boc).
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The side chain extension was accomplished through a Swern- 
oxidation/Horner-Emmons homologation sequence using alcohol 30, to afford 
unsaturated ester 46. The conversion of 46 to protected piperazine 47 was 
accomplished in five steps and the coupling of 47 to 2-chloroquinoline afforded 
2’-(3-methoxy-1-propyl)-6-nitroquipazine (PrOM-NQP) 48 following deprotection 
and nitration. With the extended side chain, the introduction of the tosylate 
leaving group proceeded smoothly and precursor 49 for radiolabelling was 
generated in 3 steps from 48. Depending on the method of synthesis, an U-tert- 
butoxycarbonyl (N-Boc) or N-Formyl protecting group (PG) was utilized. The 
conversion of 49 to 2’-(3-fluoro-1-propyl)-6-nitroquipazine (ProF-NQP) 50 was 
accomplished using nucleophilic fluoride ion from tetrabutylammonium fluoride 
(TBAF) in THF. Radiochemical studies with the compound are ongoing and an 
optimization of the synthesis to obtain a fluorine-18 radiotracer is forthcoming.74
The synthetic studies described herein detail the efforts to generate SERT 
PET agents from our refined lead agent MOM-NQP 35.
2.2 Generation of N-Boc-2’-Hydroxymethyl-6-Nitroquipazine
To afford plausible radiotracers, the synthetic plans must meet certain 
criteria. Mainly, because of the short half-life of the carbon-11 and fluorine-18 
atoms, the radionuclide group must be introduced very late in the synthesis, 
ideally as a last step. This is a necessary criterion since the short half-lives of 
the radionuclides ([18F] tm = 1 1 0  min; [11C] tm = 20.4 min) require that the 
formation of the radioactive atom, synthesis of the radiochemical tracer and PET
27
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
experiment all be accomplished in a short period of time ( 4 - 5  half-lives of the 
respective radionuclide). The subsequent removal of any protecting groups 
should also be fast and the purifications uncomplicated so reaction times can be 
minimized. To fulfill these criteria, an alkylation strategy was considered 
whereby a [11C]-methyl group could be introduced on the side chain using routine 
synthetic protocols, followed by removal of an appropriate nitrogen protecting 
group (PG) to afford the desired radiotracer [11C]35 (Figure 2.3).
°2Nv V \  o2nlI T ]  [11C]CH3-X deprotection
H3-0 0 _ 4 J nH
H  11 H  51 [11C]35
Figure 2.3: Synthetic strategy devised for the synthesis of [11C]MOM-NQP.
Initial studies from our laboratory aimed at generating a protected 
hydroxymethyl-nitroquinoline 51 met with only mediocre success. For example, 
attempts at generating ethyl 2’-carboxylate-6-nitroquipazine 53 that could be 
reduced to alcohol 51 were unsuccessful (Figure 2.4, unpublished results). 
Thus, alternate methods were investigated that began from lead compound 35 
and necessitated O-dealkylation technologies.
~xx .~!'ccx
Trit Et02C‘̂ v ^ ' NH 2. protection H0^ ^ ^ N' PG
52 53 51
Figure 2.4: Failed, previously attempted route for acquiring an alcohol intermediate.
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Trimethylsilyl iodide (TMS-I) is a reagent well characterized in its ability to 
afford O-dealkylation under generally mild conditions.75 ,76 TM S-I is commercial­
ly available, but it can also be generated in situ through the reaction of TMS-CI 
with Nal in toluene.77 In our hands however, this reagent gave unsatisfactory 
results (yields < 20%) with unnitrated quipazine 34 yielding only a poor yield of 
alcohol 54 (Figure 2.5) . 67 In hindsight, the poor yields may have resulted from 
the lack of a protecting group on the secondary nitrogen. However, this notion 
has yet to be fully investigated and alternate methods have been considered.
Figure 2.5: TMS-I promoted dealkylation reaction attempted by Walker.67
Boron tribromide (BBr3) is another common O-dealkylation reagent and it 
is most commonly utilized for the demethylation of phenols.78 ,79 However, there 
are reports in the literature of BBr3 use for the demethylation of aliphatic ethers, 
which provided good yields of target alcohols.80 A BBr3 dealkylation was 
attempted with MOM-NQP 35 using 400 mol% of BBr3 (1 M in CH2CI2) in CH2CI2 
(DCM) at -78 °C. Excess BBr3 was used so that coordination of the reagent to 
the other electron donors would not inhibit reactivity with the methyl ether.78
Toluene
34 54
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BBf3, CH2CI2
N N ^ j
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55 H xHCI
-78 °C
60%
Scheme 2.1: Boron tribromide mediated demethylation of MOM-NQP.
These conditions resulted in good conversion to alcohol 55 and the 
product was isolated as a hydrochloride salt through a forced crystallization from 
EtOH/HCI(g) with ether. Product identity was assigned based on the 
disappearance of the methyl singlet and a TLC profile that showed a more polar 
material (as the free base) relative to starting material (Rf of 0.04 vs. 0.15; 
MeOH:DCM, 1:9). With the alcohol in hand, it was now necessary to choose a 
nitrogen protecting group that could easily be removed and would withstand the 
conditions necessary for O-alkylation (base and electrophile, CH3-X).
The triphenylmethyl (trityl) protecting group was chosen initially because it 
met these general criteria and was a reagent with which we were familiar from 
previous work in our lab (e.g. Figure 1.12) .67 The nitrogen protection was 
attempted using the method of Rondu68 which employed trityl chloride in DCM 
with triethylamine at 0 °C. These reaction conditions provided a poor yield of the 
desired N-trityl protected alcohol 56 because of a competing reaction with the 
primary alcohol to provide di-protected product 57 (Scheme 2.2). Products 56 
and 57 were easily separated (column chromatography) and their 1H NMR 
spectra clearly indicated the presence of a single protecting group and two 
protecting groups, respectively.
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NH 2. Trityl chloride
55 0 ° C  56 31%  57 24%
-78 °C  50%  20%
Scheme 2.2: Formation of N-trityl protected alcohol.
An attempt to minimize the alcohol reactivity by lowering the temperature 
to -78 °C only improved the yield of desired product slightly, providing milligram 
quantities of 56 in 50% yield.
With N-trityl alcohol 56 generated, it was time to attempt our cold 
radiosynthetic strategy (Figure 2.3) to reintroduce the methyl group and remove 
the trityl protecting group. The alkylation of 56 was first attempted in 
tetrahydrofuran (THF) with NaH as the base followed by the addition of methyl 
iodide at 35 °C. Although conversion to the methyl ether occurred, the reaction 
was slow and required an overnight stir to reach completion. Another attempt 
was made using DMF as a solvent with excess NaH (3000 mol%) and methyl 
iodide (800 mol%) (Scheme 2.3) . 81
Scheme 2.3: 'Cold' radiochemical synthesis of MOM-NQP from the N-trityl protected alcohol.
65%
NH
31
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Following the addition of reagents, the reaction was heated (35 °C) briefly 
and a check by TLC after five minutes showed that the starting material had been 
consumed, and the alkylated product had formed. After work-up, the crude 
reaction mixture was immediately subjected to deprotection conditions (EtOH, 
HCI, 10 min) to remove the trityl group. Work-up and chromatography provided 
lead agent MOM-NQP 35 in 65% yield (Scheme 2.3). The 1H NMR spectrum of 
35 was identical to that produced according to Walker as described in Chapter 
1 67
This synthesis validated our radiosynthetic strategy for the generation of 
[11C]35. Furthermore, the transformations were accomplished quickly, with 
reaction times being less than ten minutes. However, we were still 
disadvantaged by the lack of regioselectivity in our N-trityl protection that 
provided only a modest chemical yield of protected target 56. At this time other 
efforts within our laboratory demonstrated the usefulness of the tert- 
butylcarbamate (Boc) group for the protection of the secondary amine 
functionality in our quipazine compounds. The introduction of this group 
proceeded smoothly using di-ferf-butyldicarbonate (B0 C2O) in DCM followed by 
concentration of the reaction mixture and chromatography of the residue.82 This 
was an attractive alternative sequence to the trityl synthesis since Boc groups 
are well known for their tolerance of aqueous environments83 and they could 
likely be introduced in the workup of the boron tribromide demethylation reaction. 
Additionally, the Boc deprotection products (CO2 and isobutylene) are gaseous
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and easily removed from the reaction mixture, simplifying the purification process 
for target 35.
The initial attempt of this reaction sequence using 500 mol% BBr3 (1 M 
solution in DCM) and 180 mol% of di-fe/f-butyldicarbonate provided a modest 
yield of N-Boc protected product 58 (Scheme 2.4).
Scheme 2.4: Synthesis of key intermediate 58, HOM-BOC-NQP.
Pure, free-base form, amino alcohol 55 can be isolated by deprotection of 
the Boc group with 4 M sulfuric acid in THF. The identity of 58 was confirmed 
primarily from LC/TOF-MS data, which provided a molecular weight of 388, that 
was consistent target molecule 58. Analysis by 1H NMR was problematic since 
the incorporation of the tert-butylcarbamate protecting group had a profound 
broadening effect on the piperazine hydrogen signals, and to a lesser extent on 
the aromatic signals. However, the absence of a methyl singlet (expected at 3.2 
-  3.7 ppm) and the presence of the tert-butyl group singlet (~1.5 ppm) 
accompanied with all of the quinoline resonances was enough for us to proceed 
with confidence that compound 58 had been formed.
The 1H NMR spectra of 58 in comparison to the deprotected amino 
alcohol 55 are shown in Figure 2.6, where line broadening of the Boc- 
intermediate (upper panel) is shown.
NBoc
H 2. Aq. NaHCOo
35
H
55 58
H
H2S04, THF, 73%
33
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
___ PJ U
_______   1__ i ___1_____ i
o2n
HO. NH
H
55
X
Figure 2.6: 1H NMR spectra of N-Boc protected alcohol 58 (top) and amino alcohol 55 (bottom) 
demonstrating the line broadening observed as a result of the introduction of the N-Boc protecting 
group. The scale is in 5 ppm.
The differences in the resolution of the piperazine protons is clearly 
observed and this broadening has been consistent across all Boc protected 
compounds in the quipazine series. This broadening effect is also transferred to 
the carbon atoms and a similar comparison can be made with the 13C NMR 
spectra of the same compounds (Figure 2.7).
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Figure 2.7: 13C NMR spectra of N-Boc protected alcohol 58 (top) and amino alcohol 55 (bottom) 
demonstrating the line broadening observed as a result of the introduction of the N-Boc protecting 
group. The scale is in 5 ppm.
Ultimately, the confirmation of product identity came from the independent 
synthesis of the methyl ether to form 35 using the same strategy that was 
employed for the N-trityl protected alcohol 56. A clean conversion to the methyl 
ether was accomplished using 250 mol% NaH, and ~600 mol% CH3-I in DMF
H
55
* * * * *
35
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(reduced quantities vs. N-Trityl reaction). The crude Boc protected intermediate 
(not shown) was treated with trifluoroacetic acid (TFA in DCM, 111)84 at ambient 
temperature until complete conversion to the secondary amine (more polar) was 
observed by TLC (~1 h). A basic workup provided the crude material that was 
unambiguously identified as desired target 35 by 1H NMR (Scheme 2.5).
Scheme 2.5: 'Cold' radiosynthesis of MOM-NQP using the N-Boc protected alcohol.
This experiment was evidence enough that we had developed a 
methodology that could be adapted to the synthesis of [11C]35. Adequate 
quantities of radiolabelling precursor 58 could be generated so that 
radiochemical experiments by collaborators at the Lawrence Berkeley National 
Laboratory (LBNL) could commence. These experiments are detailed in Section 
2.7.
2.3 Synthesis of (rac)-MeProF and a Tosylate Precursor for the 
Radiosynthesis of [ 8F](rac)-MeProF
Other concurrent efforts within our laboratory were focused on the 
synthesis of the fluorine-18 agent [18F]2’-(3-fluoropropyl)-6-nitroquipazine [18F]50 
([18F]ProF-NQP, shown in Figure 2.8a) as per Figure 2.2. However, preliminary 
results from our radiochemical collaborators at LBNL indicated some
2. TFA:CH2CI2NBoc NH
H 35
H
58 120% Crude
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decomposition and side reaction complications during the radiosynthesis.74
Consequently, avenues toward other fluorine-18 ligands were considered.
We decided to append a fluroroalkyl side chain onto the primary alcohol of 
our N-Boc intermediate 58. In this way we had the opportunity to gain multiple 
agents 59 -  61 from a common intermediate (Figure 2.8b).
Figure 2.8: a) [18F]ProF-NQP; b) Alkylation strategy to afford fluoroalkyl ethers.
Thus far, these routes have proven quite unsuccessful. The Boc 
protected fluoromethyl ether (n = 1, 62) was readily formed in a reaction of 58 
with FCH2CI in DMF with NaH as the base. However, the ether side chain did 
not survive the Boc deprotection step under a number of different conditions 
(Figure 2.9).
Figure 2.9: Attempted Boc deprotection conditions for the formation of fluoromethyl target 59.
a. b.
NBoc
59 n = 1 H
60 n = 2
61 n = 3
NH
H
[18F]50 common
intermediate
4 M H2S04
NBocNBoc NH
H H H
62 58 55Phenol/
TMS-CI
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The conditions included; 4 M H2S 04 in THF at 50 °C and 0 °C, SnCI4 in 
EtOAc 85 and TMS-CI/Phenol 86. Under all of these conditions, the fluoromethyl 
ether cleaved in preference to removal of the Boc group to give intermediate 58 
and/or amino alcohol 55. With these results, we abandoned our efforts at 
generating fluoromethyl ether 59. Attempts to alkylate the N-trityl protected 
alcohol 56 with bromofluoroethane (n =2) under DMF/NaH and THF/NaH 
conditions failed for unknown reasons, resulting with the generation of multiple 
side products as observed by TLC. Since these reactions were attempted on a 
small scale (< 1 0  mg), characterizations of the reaction products were not 
attempted. Efforts to alkylate Boc alcohol 58 with bromofluoroethane to generate 
compound 60 are currently underway at LBNL with our collaborator Dr. Andy 
Gibbs. The reaction of 58 with bromofluoropropane in DMF with NaH failed to 
produce the Boc protected fluoropropyl ether (structure not shown), and only 
recovered starting material was obtained. Although it was never investigated in 
detail, it is suspected that lack of conversion to the propyl ether resulted from the 
alkoxide acting as a base rather than a nucleophile.
Since these alkylation attempts were not efficacious, a new synthetic 
strategy was devised which would afford the fluoropropyl target, 2’-(3- 
fluoropropoxymethyl)-6-nitroquipazine (MeProF-NQP, 61). Key to this new 
approach was the use of allyl bromide in the alkylation step which reduced the 
possibility of elimination reactions competing with substitution. Importantly, this 
synthesis generated Boc-Tosylate 65 that later served as the precursor for 
radiofluorination and the generation of [18F]MeProF-NQP [18F]61 (Scheme 2.6).
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Alkylation of Boc alcohol 58 with allyl bromide provided allyl ether 63 in good to 
almost quantitative yields following chromatography.
Scheme 2.6: Synthesis of racemic MeProF-NQP.
Hydroboration of the terminal alkene with 9-borabicyclo[3.3.1]nonane (9- 
BBN),87 followed by alkaline peroxide oxidation provided primary alcohol 64. 
Conversion of 64 to tosylate 65 was accomplished with tosyl chloride and 
pyridine in DCM in good yield. Displacement of the tosylate with nucleophilic 
fluoride ion was accomplished with 150 mol% of tetrabutyiammonium fluoride 
(TBAF) in THF at 60 °C.88 After chromatography, the Boc protected fluoroalkyl 
intermediate (structure not shown) was deprotected to provide target compound 
61 in 70% yield. Incorporation of the fluorine atom was very efficient, and no 
detectible traces of alkene were observed (1H NMR) as a result of fluoride 
promoted elimination which has been characterized as a common side reaction 
in nucleophilic fluoride transformations.89 Side chain identity was confirmed 
based on the 1H NMR spectrum of 61 which shows doublet of triplet and doublet 
of pentet hydrogen signals that were split by the fluorine for the geminal and
NBoc
H73 - 97% 63 H 68 - 78 % 64
CH2CI2, Pyridine
Tosyl-CI
NBoc
2. cold H2S04
1. THF, TBAF
NH
75 - 80% H 70% H65 61
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vicinal (relative to fluorine) hydrogens, respectively, indicating that the fluorine 
atom was at the end of the propyl chain (Figure 2.10).
o2n.
NH
Figure 2.10: 1H NMR of MeProF-NQP 61, with the fluorine-coupled hydrogen resonances 
indicated. The scale is in 5 ppm.
For this new synthetic approach, our target ligand MeProF-NQP 61 was 
synthesized in five steps from intermediate Boc alcohol 58. The yield for this 
process on average was 32%. However, given optimal yields for each step, this 
yield can be as high as 45%,
Other alkylation methodologies were attempted to short-cut the approach 
of Scheme 2.6 by synthesizing propyl alcohol 64 or tosylate 65 directly from 
protected alcohol 58. As shown in Scheme 2.7, tetrahydropyranyl (THP) 
protected 3-bromopropanol 66 and 1,3-propanediol di-p-tosylate 67 were used as 
alkylating agents in these reactions. Unfortunately, these attempts provided the 
same poor results that were observed with bromofluoropropane (as per Figure
2.8), with no significant product formation seen. To test our hypothesis that we 
were seeing a lack of substitution due to competing alkoxide elimination
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reactions, control reactions were performed with the more nucleophilic alkoxide, 
methoxide ion.
NBoc
V o ^ B r
2. cat. H+ MeOH
1. NaH, DMF
C X  66
X
NBoc
: H
! CH2CI2, Pyridine 
♦ Tosyl-CI
NaH, DMF
TsO-(CH2)3-OTs
67 NBoc
H
65
Scheme 2.7: Attempted 'short-cut' alkylations to obtain intermediates in the synthesis of MeProF- 
NQP.
The electrophiles 66 and 67 were added to NaOCH3 in DMF in an 
identical manner to the alkylation strategies employed for 58 (as per Scheme 2.7) 
and the crude reaction mixtures were analyzed by 1H NMR (Scheme 2.8).
Scheme 2.8: Control reactions to evaluate the ability of methoxide ion to evoke SN2 substitution 
on our 'short-cut' electrophiles.
In both cases, the predominate product formed was the alkene (68 or 70) 
and little substitution product (69 or 71) was observed, as evidenced by a lack of 
a strong singlet at 3.0 -  3.5 ppm in the 1H NMR spectra of the crude reaction 
mixtures. Based on these results, our original synthetic plan (Scheme 2.6) was
Br NaOCH
66 68
major products
69
not observed
TsO-(CH2)3-OTs
NaOCH3 70 71
41
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
maintained to produce our target, MeProF-NQP 61. Additionally, intermediate 
tosylate 65 proved to be an excellent radiochemical precursor for the 
radiofluorination reactions performed at LBNL. The successes in forming 
[18F]MeProF as well as its preliminary in vivo performance in rat will be detailed in 
Section 2.7 and Chapter 5, respectively.
2.4 Synthesis of 2’-(2-Methoxyethyl)-6-nitroquipazine: EtOMe-NQP
The synthesis of the methoxyethyl side-chain analog of 6-nitroquipazine 
was desired as an alternative route to additional PET imaging agents. However, 
ethyl analog 78 was also desired as a part of a larger structure activity 
relationship (SAR) study to explore the size of the Ar2 SERT binding region (as 
per Figure 1.11). The Ar2 region is presumed to accommodate our piperazine 
side chains (Figure 2.11).74
Figure 2.11: Methyl, ethyl and propyl side chain quipazines to study the Ar2 region SAR.
Since the Ar2 region of the SERT pharmacophore is represented by 
aromatic ring groups in a majority of commercial and non-commercial ligands (as 
per discussions in Chapter 1), we had hoped to better understand the limits of 
the Ar2 binding region as our alkyl side chains extend beyond the volume 
occupied by the more common, aromatic side chains. Additionally, we sought to
35 78 48
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better understand the role of the side chain oxygen heteroatom for modulating 
the binding affinity of our ligands at SERT. The ethyl side chain compound 78 
would place the oxygen one atom further away from the piperazine headgroup 
relative to 35 and may provide us with insight into the subtle SERT binding 
characteristics of this ligand region.
The synthesis of 78 was modeled on the chemistry utilized to synthesize 
lead compound 35, with only minimal changes made to the previous procedure 
(Scheme 2.9).67
1.(CICO)2 ,DMSO,
B n N ^ |  EtgN, -78 °C » BnN^  1. THF, 9-BBN^
H° v ^ NBn 2  H,C=PPh, * ^ 4 ^ N B n  2. H20 2>-OH H0 ^ ^ ^ NBn
H ' 2 3 H H
30 76% 72 8 6 % 73
1 CH3Fi NaH BnN ^  MeOH' Pd/C’ H N ^  CH2Ci2, Et3N;
2. HCI, Et20  - 0 ^ - NBn H2 Trityl chloride
68% -2HCI 9 7 % "  '2HCI quant.f "I i 9
H N ^ |  2-CI-quinoline
2 . HCI - q ^ 4 - NH
76 92% 77 H
N N* ''i
Scheme 2.9: Synthesis of EtOMe-NQP that was modeled after W alker’s67 synthesis of 
M O M -N Q P 35 (Figure 1.12).
An intermediate in the synthesis of 35, 1,4-dibenzyl-2-
hydroxymethylpiperazine 30,90 was the chosen starting material for this 
sequence, and the addition of a carbon to the side chain was accomplished 
through an oxidation-homologation sequence. Compound 30 was subjected to
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Swern oxidation conditions, according to Kusche,74 to generate the intermediate 
aldehyde (not shown). Following the workup and evaporation of the extraction 
solvent, the crude aldehyde material was pumped under high vacuum for ~10 
minutes then immediately used in a Wittig reaction with 200 mol% of ylide to give 
alkene 72 in a 76% combined yield. The alkene 72 underwent hydroboration 
with 9-BBN, and oxidation with alkaline hydrogen peroxide afforded primary 
alcohol 73 in excellent yield. From here forward, the synthesis parallels the 
methods used by Walker to form lead agent 35.67 The alkylation of alcohol 73 to 
provide methyl ether 74 was performed with DMF as a solvent rather than THF 
as had been utilized previously for the synthesis of 35. The more polar DMF 
solvent greatly increased the reaction rate (1 h vs. 16 h) and simplified the work­
up. DMF could easily be removed by flooding with two volumes each of water 
and saturated NaHC0 3 , then and extracting the product with ether. Following 
chromatography, free base form 74 was dissolved in ether and the solution 
saturated with HCI(g) to produce dihydrochloride 74.
The benzyl groups were removed by catalytic hydrogenolysis using 5% 
Pd/C in MeOH, with balloon pressure of hydrogen to afford 75. The trityl group 
was selectively introduced to the 4-position of the piperazine to provide 76 by the 
reaction of trityl chloride in DCM with Et3N.68 In general, the crude material from 
the tritylation reactions was usually of sufficient purity for the subsequent 
quinoline coupling step. However, should these intermediates require 
purification, the stationary phase must be something other than silica gel, or 
deprotection of the trityl group will result. Our lab has discovered that using basic
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alumina as a stationary phase, with mixtures of chloroform and ethyl acetate as 
eluent is a suitable replacement, and provides efficient separations of N-trityl 
protected piperazines.
The coupling of compound 76 to 2-chloroquinoline was performed 
according to the method of Gilman, who in the 1940’s, described an efficient 
coupling of simple lithium di-alkylamides to 2-chloroquinoline.69 A detailed 
discussion of this reaction follows (Section 2.5). Briefly, a solution of 2- 
chloroquinoline (100 mol%) in ether was added to an etheral solution of 150 
mol% each of piperazine 76 and n-butyllithium at 0 °C. Following the work-up, 
chromatography, and removal of the trityl protecting group, compound 77 was 
isolated in 92 % yield. Nitration of this material provided the target quipazine 
EtOMe-NQP 78 in excellent yield. The overall synthesis of 78 was accomplished 
in eight steps with an overall yield of 38%.
The protocol used for the removal of the trityl group to form 77 was 
significantly improved relative to earlier work in our laboratory.67 The previous 
procedure utilized 6 M HCI in ethanol, followed by a base quench and extraction 
to give the crude product that contained trityl left-overs and required column 
chromatography for purification. This method worked well, providing yields 
around 80%. However, the polarity of the deprotected secondary amine made 
normal phase purification of desired product 77 difficult. Very polar MeOH:DCM 
solvent mixtures were required to elute the product and excessive tailing of 
material 77 was observed. The improved procedure used 6 M HCI (6 ml_) added 
to a solution of trityl protected quipazine (structure not shown) in a minimal
45
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
amount of acetone ( 3 - 4  mL). The mixture was swirled or stirred for only a few 
minutes, then diluted with 20 -  30 mL of 1 M HCI. Washing the acidic, aqueous 
mixture with DCM removed all traces of the trityl side products and upon 
returning the aqueous layer to basic pH with 4 N NaOH and saturated NaHCC>3, 
the pure, deprotected quipazine 77 could be extracted with DCM.
With the synthesis of our ethyl homolog 78 complete, we turned our 
attention again to the preparation of potential radiolabelling precursors that might 
afford us new fluorine-18 or carbon-11 PET agents. Compound 78 was 
converted to the Boc-protected alcohol 79 using the same dealkylation strategy 
developed for key intermediate 58 and the demethylation reaction with BBr3 
provided an efficient conversion of ether 78 to the primary alcohol (Scheme
2 .10).
Scheme 2.10: Synthesis of N-Boc protected ethyl alcohol.
However, unlike the formation of methyl alcohol 58, the N-Boc protection 
of the crude ethyl alcohol (structure not shown) was not regioselective for the 
nitrogen and, in addition to desired target 79, a di-Boc protected product 80 was 
also formed. This reactivity is also observed for longer alkyl chains (3 carbons 
and more).74 Presumably the ethyl side chain provides reduced steric influences 
that hinder attack for the methyl alcohol side chain and limit the formation of a di-
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Boc derivative. Both Boc protected compounds (79 and 80) were collected 
together following chromatography and treated with excess K2 CO 3  in MeOH at 
60 °C. These conditions resulted in the selective deprotection of the carbonate 
after ~3 h and provided 79 in 63% yield.
The alkylation of 79 to generate parent methyl ether 78 using the non­
radioactive (cold) methods described in Scheme 2.5 has not yet been attempted. 
Furthermore, no radiochemical studies have been planned with this material to 
generate a carbon-11 agent. Interestingly, two separate experiments to convert 
the alcohol into a tosylate-leaving group for fluorination attempts have failed, 
using the same conditions that readily formed tosylate 65. No product was ever 
identified and the starting material was not recovered in any significant quantity. 
This curious reactivity is still under investigation within our laboratory, and 
opportunities for undesired intramolecular reactivities are being considered.
2.5 Gilman Quinoline Coupling Mechanistic Considerations
Earlier work in our laboratory67 has demonstrated that the Gilman coupling 
reaction69 is highly sensitive to the ratios of reactants. Deviations from the 
reported ratios (150 mol% each of amine and n-BuLi to 100 mol% 2- 
chloroquinoline 81) significantly reduced the yield of coupled product. A 
mechanism was suggested that sought to explain this sensitivity, that also 
incorporated the formation of a reactive, aryne intermediate specie (Figure 
2 .12)67
47
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Figure 2.12: The elimination-addition Gilman coupling mechanism proposed by Walker,67 
demonstrated with a general N-trityl protected piperazine.
The proposed mechanism begins with the removal of the 3-position 
hydrogen of 81 by lithium amide 82 to eliminate the chlorine atom and form aryne 
intermediate 83. Intermediate 83 then undergoes protonation from amine 84 to 
form charged intermediates 82 and 85 that combine to form the coupled product 
86. Although the mechanism seems plausible, there is nothing to suggest the 
need for an extra 50 mol% of lithium amide 82 to afford efficient conversion to 86 
(as suggested by the strict adherence to reagent ratios). Additionally, it is 
believed that nucleophilic attack on arynes (like 83) precedes the protonation 
step in elimination-addition type mechanisms.91
An alternate mechanistic explanation (Figure 2.13) addresses these 
concerns by suggesting a need for excess amide 82 to act as a proton transfer 
agent in the reaction. Furthermore, the mechanism also provides for a 
nucleophilic attack on aryne 83 by amide 82.
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Proton Transfer 
, ProcessExtra 
50 mol%
82
Figure 2.13: Alternate mechanistic explanation for the extra 50 mol% of lithium amide.
For this mechanism, excess amide 82 (extra 50 mol%, top-center) serves 
as a proton acceptor-donor, initially generating aryne 83, then protonating (as 
conjugate acid 84, step 2) the 3-position of the quinoline ring following 
nucleophilic attack of amide 82 at the 2-position (step 1). The proposed proton 
transfer process ensures that a nucleophilic specie will attack aryne 83 and also 
suggests an explanation for the need of excess 82.
Although the above mechanism may provide a better explanation than 
Walker’s67 for the sensitivity of the Gilman coupling to the stoichiometry of the 
reactants, it does not account for the explicit regioselectivity for substitution at the
2-position of quinoline 81. It is known that nucleophilic attacks on arynes 
typically produce two or more regioisomeric products as a result of reactivity at 
both ends of the triple bond.92 This was in fact how the benzyne intermediate 
was discovered, when attempts at doing nucleophilic substitution reactions on 
aromatic halides produced multiple regioisomeric products.93 Furthermore, it has
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been shown that substituent effects can influence the preferred side of 
nucleophilic attack. However, the regioselectivity is rarely shown to be high.94
Connon and Hagarty have suggested that 2,3-pyridynes 87 may 
experience bond polarization as the result of the electron withdrawing effect of 
the ring nitrogen to generate the dipolar specie 87a (Figure 2.14).95 Provided this 
opportunity, it is reasonable to suggest that a nucleophilic attack on 83 would 
favor substitution at the 2-position as a result of the dipolar character of 83a 
(Figure 2.14). However, the degree to which this may be favored is not clear.
Figure 2.14: Proposed dipolar character of 2,3-pyridynes as an explantion for Gilman coupling 
regioselectivity for substitution at the 2-position of quinoline.
Another, recent observation from our laboratory was the conversion of 1- 
chloroisoquinoline 88 and lithium amide 89 to coupled material 90 in excellent 
yield using the same Gilman conditions as described above (Scheme 2.11).
Trit
Scheme 2.11: Another coupling, facilitated by the Gilman conditions, that is unable to proceed 
under benzyne-type conditions.
87 87a 83 83a 82
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Since 88 cannot react in a benzyne-type mechanism, a different 
mechanism must be operating. Simple nucleophilic aromatic substitution (SnAr) 
may be the mechanism operating, and this is also a very plausible mechanism 
for our Gilman coupling using quinoline 81 (Figure 2.15).
F igure 2.15: Nucleophilic aromatic substitution (SnAr) mechanism for the Gilman coupling 
reaction.
However, the SNAr mechanism still does not explain why the Gilman 
coupling is highly sensitive to reactant stoichiometry. Clearly, more detailed 
experiments aimed at discovering the actual mechanistic details are required. 
Benzynes are known to undergo [4 + 2] cycloadditions92, 95 and trapping 
experiments with furan or other dienes could be performed to detect the 
formation of aryne intermediate 83.
2.6 The Boron Tribromide Dealkylation: Reaction Complications and 
Inconsistencies
The boron tribromide dealkylation reaction (Scheme 2.4 and Scheme
2.10) has led to frustration on a number of occasions because the reaction 
outcome is not consistent. The conversion has been attempted with a methoxy 
methyl side chain a total of eighteen times with an average yield of 48% for Boc 
alcohol 58. However, across all of these synthetic attempts the range of yields
R
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extends from 0 -  70%. The conditions for this reaction had 500 -  600 mol% of 
BBr3 added to a -7 8  °C solution of ether 35 in DCM. The mixture was 
maintained at -7 8  °C for 3 -  4 h then warmed to ambient temperature and stirred 
overnight. The reaction was quenched with saturated NH4CI solution and made 
basic with 4 M NaOH. The alcohol was extracted and the Boc group installed to 
provide 58 (as per Scheme 2.4). This methodology was utilized on eight 
instances with an average yield of 46% (range, 34 -  58%). Then, for still 
unknown reasons, yields dropped in two attempts to 0% and 11%. The same 
trend was observed by another group member, who had similar poor results 
(yields < 30%) with similar reactions on propyl side chain quipazine analogs.74
At this time the reaction quench was changed to saturated NaHC0 3  so 
that any acid generated as a result of BBr3 reacting with water would be 
neutralized. Following this change, product yields increased to the mid 60% 
range. Ultimately, the most consistent results were observed when the ether 
starting materials (e.g. 35 or 48) were purified prior to use using a Biotage 
purification system with amine-based silica gel. The amine silica allowed for 
mixtures of EtOAc:Hexanes to be used as eluent rather than the very polar 
MeOH:DCM or MeOHiCHCh mixtures that had been employed previously. 
When the Biotage purification method was used in combination with a NaHCC>3 
quench, Boc protected product 58 was obtained in an average yield of 60% (49 -  
70%, n = 5). The average yield for all uses of NaHCOs in the quench was 58% 
(31 -  70%, n = 8), and this is marked improvement over the 38% (0 -  58%, n = 
10) average yield for all NH4CI quenched reactions. It is recommended that the
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Biotage Purification-NaHC03 quench conditions be utilized until a more 
promising set of conditions emerges.
2.7 Radiochemical synthesis of [11C]MOM-NQP and [18F]MeProF-NQP
The radiochemical syntheses of our PET ligands was accomplished at 
LBNL in collaboration with scientists specializing in radiopharmaceutical 
development. Dr. James P. O’Neil is the lead radiochemist in charge of the 
Cyclotron facility and has been our key liaison for these studies. The Biomedical 
Isotope Facility at LBNL houses a CTI RDS-111 cyclotron that is used to 
generate the positron emitting radionuclides.
The synthesis of [11C](rac)-MOM-NQP [11C]35 followed the general 
alkylation approach described earlier for the cold radiochemical synthesis of 35 
(Scheme 2.5). Carbon-11 methy liodide is synthesized from [11C]C02 in a gas 
phase procedure adapted from published methods.96,97 Briefly, carbon-11 CO2 
is generated through the 14N(p,a)11C nuclear reaction using a 10 MeV proton 
beam. The [11C]C02 is then transferred to a flow reactor where it is reduced to 
[11C]CH4 then subjected to a thermal free-radical halogenation reaction with 
gaseous iodine (I2) to generate [11C]CH3-I that is cryogenically (-78 °C) trapped 
for subsequent reactions.
The two-step alkylation sequence begins with the deprotonation of N-Boc 
precursor 58 with NaH in DMF (Scheme 2.12). The mixture was cooled to -5  °C 
and gaseous [11C]CH3-I was bubbled into the solution. The mixture was then 
heated at 100 °C for 2-3 min and cooled. The crude reaction mixture was loaded
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onto a C-18 Sep-Pak cartridge and the crude intermediate (structure not shown) 
eluted with DCM. Trifluoroacetic acid (TFA) was added in a 1:9 ratio and the 
solvent was concentrated at 100 °C to provide the crude product [11C]35 that was 
purified by reversed phase HPLC (radioactivity detection) to afford the target 
radioligand [11C]35 in 9 -  16% (n = 4) decay corrected (dc) end-of-bombardment 
(EOB) yield.
Scheme 2.12: Radiochemical synthesis of [11C](rac)-MOM-NQP.
Recent literature evidence55 has demonstrated that the in vivo 
equilibration point of binding of 6-NQP derived SERT PET lignds is not achieved 
until 2-3 hours. Consequently, we have not pursued any in vivo studies with this 
ligand since the experiments could not be performed in the useable lifetime (4 -  
5 half-lives) of the radionuclide ([11C] ti/2 = 20.4 min). However, radioligand 
[11C]35 may be of use for examining SERT density in cerebral slice preparations 
employing in vitro autoradiographic techniques.98
The synthesis of [18F]MeProF-NQP [18F]61 followed the general procedure 
developed for the cold synthesis of 61 (Scheme 2.6) but with modifications 
necessary for radiochemical synthesis (Scheme 2.13).
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NBoc 2. H2SO4  20 °C, 10 min; NaOH
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Scheme 2.13: Radiochemical synthesis of [18F](rac)-MeProF-NQP.
Briefly, radioactive fluoride ion was generated by irradiating oxygen-18 
enriched water (> 94%) with a 10 MeV proton beam in a silver coated target 
chamber. Following irradiation, the water (containing Ag[18F]F, 175 pL) and dry 
acetonitrile (ACN, 300 pL) were added to 2 pL of tetra-n-butyl-ammonium 
hydroxide (TBAOH) in a siliconized vacutainer. The water was removed through 
azeotropic evaporation of the water/ACN mixture at 100 °C (3 cycles) to afford 
[18F]TBAF in > 90% radiochemical yield (rcy). The [18F]TBAF was then 
transferred with ACN to a reaction vial containing tosylate 65. The vial was 
sealed and heated at 100 °C for 10 min. The crude mixture was pushed through 
a silica gel cartridge with ACN and evaporation of the solvent at 100 °C provided 
the crude Boc-protected fluoride (structure not shown) in > 50% dc RCY. The 
crude material was treated with conc. H2SO4 for 10 min at 20 °C to remove the 
Boc group. After diluting with 0.1 N NaOH, the solution was loaded onto a C-18 
Sep-Pak cartridge and rinsed with water. The crude target radiotracer [18F]61 
was eluted by flushing the cartridge with MeOH. The methanol solution was 
diluted with water (1 mL) and purified by semi-preparative HPLC (radioactivity 
detection), and the product fraction was diluted with water and loaded onto a C- 
18 Sep-Pak cartridge. The purified, [18F](rac)-MeProF [18F]61 was obtained in 
17.8% dc radiochemical yield by eluting with ethanol. The radiochemical
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synthesis takes 90 minutes to complete. Tracer [i8F]61 has undergone initial 
vivo evaluations in rat and these studies will be discussed further in Chapter 5.
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CHAPTER 3
ASYMMETRIC SYNTHESES
3.1 Introduction
The enantiomers of a wide range of chemical compounds are well known 
to elicit different biological responses. The enantiomers of the terpene carvone 
(Figure 3.1) have very distinct fragrances and flavors and are the major 
components of the essential oils from common spices and herbs.
('S>(+)-Carvone ('Rj-(-)-Carvone fSJ-Thalidomide ('flj-Thalidomide
Caraway smell Spearmint smell Teratogen Sedative
Figure 3.1: Examples of enantiomers that elicit different biological responses.
For carvone, the olfactory receptors in our bodies are able to distinguish 
between the stereoisomers and the biological effect is a different ‘smell’ signal 
that is transmitted to our brains." Another well-known example is Thalidomide 
(Figure 3.1). The racemic mixture of this compound was utilized in the 1960’s as 
a sleep-aid and anti-nausea medication for pregnant women. Thalidomides’s 
teratogenic effects at that time were unknown, and unfortunately, around 15,000 
pregnancies were affected by the drugs use. The birth defects that resulted left 
the children deformed and often lead to death in the first years of life. Later, it 
was found that only the (S)-stereoisomer provided these teratogenic effects and
the (Rj-antipode was shown to be an effective sedative. Unfortunately, even if
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the ‘safe’ (RJ-isomer is administered, the compound is metabolically racemized in 
vivo and the teratogenic qualities will still be afforded.100
The naturally occuring benzomorphan compounds that exert strong pain- 
relieving qualities through interactions with the opioid receptors (e.g. morphine) 
are all the levorotatory form. The dextrorotatory isomers (e.g. dextromethorphan) 
do not show activity at the opioid receptors and often possess activities at other 
CNS receptors such as NMDA.101 The differences in biological activity are a 
result of optically active compounds interacting with the optically active bio­
molecules.
This relationship can be explained simply, although somewhat crudely, as 
shown in Figure 3.2 for a hypothetical ligand-receptor interaction involving the 
enantiomers of 35. The general receptor biding site is shown (panel a.) and 
consists of amine, aromatic and side chain binding regions. The side chain 
binding region extends above the other two regions (as indicated by the 
darkened lines). When (R)-Z5 is bound to the receptor, the molecule contacts 
these point nicely with the methoxymethyl side chain extending up into the 
appropriate side chain binding region (panel b.). However, when (S)-35 is 
bound with the side chain in the correct ‘up-position’ it is on the wrong side of the 
piperazine ring to reach into the side chain binding region (panel c.). If the 
piperazine ring is rotated 180° around the quinoline bond to move the substituent 
into the correct position, it will not be extending up into the binding region (panel 
d.). Instead, it will be positioned significantly below that region, and provide a 
different binding profile relative to the (R)-isomer.
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Figure 3.2: Hypothetical ligand-receptor model to demonstrate a plausible enantiomeric 
discrimination of a ligand. The general receptor binding site consists of amine, aromatic and side 
chain binding regions (panel a). When (RJ-MOM-NQP binds to the receptor (panel b), ligand 
contact with each receptor binding region is made. When (SJ-MOM-NQP binds (panels c and d), 
ligand contact with each binding region cannot be made since the side chain is positioned far 
from the binding region (panel c) or extends well below that region (panel d).
Given this hypothetical example, the enantiomeric binding differential 
could result in a variety of biological outcomes. These include: 1) The (S)- 
enantiomer may show no activity at this receptor at all; 2) The molecule may 
have a reduction in activity as a result of less optimal binding and 3) The 
molecule may show an inverse in activity relative to the (R)-isomer (i.e. its 
antagonist-agonist properties).
The inherent chirality of bio-macromolecules enables the stereochemical 
discrimination of stereoisomers, and pharmaceutical researchers are trying to 
take advantage of these differences in their drug design strategies. The use of 
stereochemically pure pharmaceuticals can improve the therapeutic effect of an
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active ingredient, enhancing product marketability. Furthermore, researchers 
may find that they can extend the profit-life of a molecule by patenting a pure 
stereoisomer for a ‘new’ inventive use.102
Given the diverse differences that exist between enantiomers within some 
biological systems, it was desirable for us to isolate and biologically characterize 
each enantiomer of our final synthetic targets. Additionally, we desired to acquire 
the radiolabeiling precursors so we could also evaluate the enantiomers of our 
PET agents in vivo. The differences in biological activity for the enantiomers of 
our 6-NQP analogs could result in the identification of a non-racemic radioligand 
with increased in vivo efficacy relative to the racemate, providing a more 
efficacious candidate PET tracer.
Our laboratory performed an initial SAR study with the enantiomers of 2’- 
methyl quipazine 24.103 The synthesis of the (RJ-enantiomer (R)-24 is shown in 
Figure 3.3.
Hn -^ N  Trityl-CI n n ^ N  2 ’ ’
I 1 FtQN i I 2-CI-quinoline
bX3lV  H'J^NTrit ---------------- -
h3C CHoCU HgC 2. HCI
3. HN03, H2S04
(R)-92 (R)-93
Figure 3.3: Synthesis of (R)-2'-methyl-6-nitroquipazine. The (Sj-isomer is similarly prepared.
The synthesis was accomplished in four steps from commercially available 
(R)- and fSj-methylpiperazines, according to the method of Walker.67 
Unfortunately, when the enantiomers were individually evaluated for their binding 
affinity at SERT, a significant difference in the affinities was not observed.103 We
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cautiously attribute the lack of difference to the relatively short methyl side chain, 
which may not be large enough to evoke stereochemical differences in SERT 
binding affinity (additional discussion can be found in Chapter 5).
Unfortunately, for our more complex piperazine side chains (for example, 
with MOM-NQP 35 and MeProF-NQP 61), commercially available, 
stereochemically pure piperazine starting materials are either too costly or 
unavailable. Thus, our initial strategy was to resolve the stereoisomers from 
racemic intermediates.
Traditional attempts of resolving the stereoisomers through diastereomeric 
salt formation and fractional crystallization were unsuccessful mainly because 
crystals never formed.74 This methodology was attempted on the two racemic 
compounds 31 and 32 in their free base forms (Figure 3.4).
Figure 3.4: Failed resolution strategy attempted by Kusche to isolate stereochemically pure 
piperazine intermediates.
Compounds 31 and 32 can be easily synthesized in quantities (gram 
scale) amenable to the resolution technique (as per Figure 1.12, Walker, 2001). 
Multiple attempts to form crystals from tartaric and benzoyl tartaric acid using 
different solvents and solvent mixtures all resulted in the formation of oils. 
Additionally, semi-preparative chiral HPLC columns were used in an attempt to
tartaric /  fractjonal 
mid salts V crystalization
(Sy 35 and 61
(R)- 35 and 61
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isolate final compounds in quantities sufficient for bio-assay ( 1 - 2  mg). These 
attempts also failed to generate satisfactory results. Rather than belaboring the 
resolution methods, alternate chiral synthetic approaches were investigated.
Because of their widespread use in biologically active molecules, 
piperazine rings have received significant attention in medicinal chemistry 
literature. The modification of the nitrogen atoms is relatively straightforward, 
since general amine chemistry is typically employed. However, the 
functionalization of the ring carbon atoms is more synthetically challenging. The 
most common way to accomplish this is through synthesis from a-amino acids. 
Recently, routes that utilize direct alkylating methods have been developed.35 
There is also a considerable quantity of literature devoted to the isolation and 
synthesis of non-racemic piperazine compounds. These syntheses encompass 
a wide range of methods including enzymatic kinetic resolution,104 traditional 
fractional crystallization105 and a myriad of synthetic strategies.106"110 Of the 
literature we reviewed, the work of Naylor111 caught our attention because of the 
ease of synthesis of alcohol (S)-9A (Figure 3.5).
Figure 3.5: Key intermediate alcohol described by Naylor as a precursor for the enantiomers of 
MOM-NQP and MeProF-NQP.
The features of this intermediate that appealed to us were, 1) the 
hydroxymethyl side chain that provided a direct handle for the synthesis of non
(SH* 1
H (sy35 H
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racemic MOM-NQP 35 and MeProF-NQP 61; 2) the benzyl group was installed 
as a protecting group, in the correct position for us to accomplish our Gilman 
quinoline coupling reaction and 3) the chiral center seemed stable to most 
chemical transformations and did not easily racemize. Indeed, the authors 
elaborated (S)-9A in five additional synthetic steps and the final product still 
showed an enantiomeric excess (ee) of >99% (HPLC). The transformations 
included a Swern oxidation that introduced an aldehyde on the side chain, and 
this afforded an acidic a-hydrogen on the chiral carbon. It was critical to use N- 
methylmorpholine as the base, in place of the usual E^N, which resulted in 
preservation of the stereochemical center. The convenience of this method, 
coupled with the apparent robustness of the chiral center, encouraged us to 
abandon our efforts to achieve resolution through the more tedious crystallization 
or chromatographic techniques and proceed with our asymmetric synthesis.
Note: for all of the schemes shown in this chapter, only one stereoisomer is 
indicated. However, bear in mind that these routes were usually run in parallel, 
employing both enantiomers. The results for the stereoisomer not shown were 
usually consistent with the results provided for the other. The range of yields 
reported below the synthetic steps are the range observed for both 
stereoisomers.
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3.2 Synthesis of the Enantiomers of MOM-NQP
Since the method described by Naylor111 suited our needs we adapted the 
method directly toward our synthetic goals (Scheme 3.1).
BocI
Bn''"v i EDC.HCI, PFP HCI H 
O^OH
GO2M©
H,n4 v ^
Bn
Boci
.N
1. MeOH 
SOCI2
Bn
N. -O
CH2CI2
95
Et3N, CH2CI2 
> 90% (65%)
>  C02Me SOCI2 T  f  
2. NH4OH
UAIH4 H N ^
H O ^ k . N . Bn
THF EDC.HCL
91% (91%) (5>94
> 80% (6 6 %)
H H 
(R}G 7
OH
V HCI fy V F
= V  PFP= M
Scheme 3.1: Our synthesis of key amino alcohol (S>94 using D-serine. Naylor’s reported yields 
are in parentheses.
The carboxyl group of protected, N-Boc-N-Bn glycine 95 was activated by 
the conversion to the pentafluorophenolic ester with 1-[3-(dimethylamino)propyl]-
3-ethylcarbodiimide hydrochloride (EDC.HCI) and pentafluorophenol (PFP). The 
activated ester (structure not shown) was then coupled to D-serine methyl ester 
hydrochloride in CH2CI2 (DCM) to provide dipeptide (R)-96. Naylor and co­
workers reported only modest (~65%) yields for this transformation but in our 
hands the coupling provided excellent results with yields consistently in the mid 
nineties. We also found that the coupling reaction could be run in reagent grade 
DCM, without concern for maintaining dry conditions, with no change in chemical 
yield.
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The piperazinedione (R)-97 was generated in a two-step process. The 
Boc protecting group was removed in the first step using thionyl chloride in 
MeOH to form the secondary amine hydrochloride salt (not shown). The isolated 
intermediate was then dissolved in methanol and treated with ammonium 
hydroxide to generate the amine free-base that cyclized with the ester to form 
(R)-97. Naylor’s workup involved the removal of all volatile components followed 
by column chromatography with the very polar mixture of DCM:MeOH:NH4OH 
(75:10:2). We found this to be tedious and problematic since the crude material 
included NH4CI that was not soluble in the organic solvent and therefore made 
loading a column difficult. We found that a simple aqueous work-up (saturated 
NaHC0 3 ; extracting with 4:1 CHCh.isopropyl alcohol) following the evaporation 
(in vacuo) of the methanol provided (R)-97 with the same purity and with 
increased yield. The reduction of diamide (R)-97 proceeded smoothly with 
UAIH4 in THF to give the benzyl protected aminoalcohol fSJ-94 in excellent yield.
The di-protected glycine 95 was synthesized according to literature 
procedures that detailed the formation of monobenzylglycine hydrochloride 
100112 and the final product 9583 (Scheme 3.2).
Bn H .HCI N
Bocr\ I I
HOAc
MeOH, HCI
H2, Pd/C
H20:Dioxane Bn'
NaOH, Boc20
N
98 80% 99 96% 100 76% 95
Scheme 3.2: Synthesis of N-Boc-N-Benzyl glycine.
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Briefly, dibenzyl glycine 99 was generated through the base promoted 
alkylation of 98 with benzyl bromide. Catalytic hydrogenolysis with Pd/C in 
MeOH with 150 mol% of HCI provided an excellent yield of 100, that was readily 
converted to product 95 with B0 C2O in watendioxane. This sequence was easily 
accomplished, and 95 was typically produced in 15-18 g batches.
With benzyl protected alcohol intermediate (S>94, it was necessary to 
convert the alcohol to a methyl ether so that the Gilman coupling to the quinoline 
could be accomplished. To eliminate reactivity of the amine, our initial strategy 
was to protect it with a Boc group and perform our usual alkylation with DMF, 
NaH and CH3-I (Scheme 3.3).
NaH, DMF 71%
. O | q  |  Not Observed
CH2CI2 NaH, DMrF B o c N ^
H0\ , 4 v /N .b BocaO H0 \ . 4 v /N  CH3-I X" ’i ^ N'Bn
H H H H
(R).94 93% (R)-101 (R)-102 <7?>103
Scheme 3.3: Attempted O-methylation sequence using N-Boc as the protecting group.
The preliminary chemistry was performed with the (R)-enantiomer and the 
protection of the amine (R)-94 went smoothly, with the B0 C2O in DCM producing 
(iRJ-101 in excellent yield. However, when the alkylation was attempted to form 
ether (7?)-103, the crude 1H NMR did not show an -O CH 3 singlet, indicating the 
alkylation failed. The NM R also did not show a f-butyl singlet from the Boc 
protecting group, indicating that this group had reacted. Our assumption was the 
alkoxide reacted intramolecularly with the carbamate to displace the f-butoxy 
group and form the five-membered cyclic carbamate (R)-102. A control reaction,
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in the absence of CH3I, produced the same result and cyclized product (R)-102 
was isolated. Product identity was confirmed by NMR and GC/MS.
Another method needed to be identified to introduce the methyl group. 
We hoped initially that a selective O-alkylation (in the presence of an amide -NH) 
of diamide (S)-97 would afford ether (S)-104 that could then be reduced with 
LiAlhU to provide our desired piperazine (Scheme 3.4).
Bn Bn Bn
rNY° NaH- dmf r ny° rNr°
H H ^  CHg-l " 0  H Y ^ ° ' C H 3 0 ^ n 4 - ° H
c h 3
fS>97 fS>104 1 : 3 5  fS>105
Scheme 3.4: Failed attempt to selectively introduce a methyl group to the alcohol.
Unfortunately, the pKa differential between the amide -NH and the alcohol 
(both ~16 -  17) afforded a majority of the undesired N-alkylated product (SJ-105 
in a ratio of 3.5:1 relative to the desired methyl ether fSJ-104. This determination 
was made by integrating the methyl singlets in the crude 1H NMR spectrum (- 
NCH3 at 2.96 ppm; -OCH3 at 3.30 ppm). Another attempt at selective O-alkylation 
involved the use of Ag30  and CH3-I in acetonitrile according to the method of 
Andurkar.113 This method was extremely slow (4 day reaction time), did not 
produce satisfactory yields of (SJ-104 and required large amounts (> 1000 mol%) 
of CH3-I. With the poor results of these two attempts, we decided to abandon 
selective alkylation in favor of alternate protecting group strategies.
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We decided to try another protection-alkylation sequence from 
intermediate (S>94, employing N-formamide as the protecting group (Scheme 
3.5).
0 o
HCQ2H h ^ N ^ ,  NaH, DMF HaSOf
H O ^ X ^ N B n  AcaO H° ^ k ^ NBn CH3-I ^ O ^ J ^ N B n  THF
H H
fS>94 8 7 0 /0  fS>106 8 3 0 /0  (S)-107 84%
Scheme 3.5: Successful alkylation strategy using N-formamide as a protecting
Since DMF (an N-formamide) as the reaction solvent does not interfere 
with O-alkylation, we figured the N-formyl protecting group would be a good 
alternative to N-Boc. Working on a 45 mg scale, the formamide group was
introduced with acetic anhydride in formic acid according to Sheehan114 providing
an excellent yield of N-formyl alcohol (^-106. The product was subsequently 
alkylated under our standard conditions (DMF, NaH and CH3-I) to afford methy 
ether (SJ-107 in 83% yield. Deprotection of the formyl group with H2SO4 in THF 
at 60 °C afforded the sought after amine-ether (SJ-108 that was ready for Gilman 
coupling.
Given the success of this method on small scale we adapted it to our 
normal quantities (> 600 mg) of aminoalcohol (SJ-94 and found that the amine- 
ether fS>108 could be generated with comparable yields. At this point it seemed 
that the conversion to our targets, (R)- and (SJ-MOM-NQP 35, would be 
straightforward. The Gilman coupling was effective, giving good to excellent 
yields of the coupled benzyl protected quipazine (SJ-109 (Scheme 3.6).
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H N ^  Et20 , n-BuLi;
(S>109
Problematic
 -----------  _  -  -te- IN N ^ |
H
(sy34
2-CI-quinoline
70 - 98%
Scheme 3.6: Formation of N-Bn-MOM-quipazine with the Gilman coupling.
However, the removal of the benzyl group, initially thought to be a trivial 
step, proved to be a challenge. The initial de-benzylation attempt with fS>109 
using 5% Pd/C (15% by weight) and H2 in MeOH with 300 mol% HCI went very 
well. The conversion to product was clean, although very slow, requiring an 
overnight reaction time. During the course of the reaction, an additional 
equivalent of acid was added to protonate the quinoline ring, thinking that it may 
be poisoning the catalyst and slowing the reaction. Additional catalyst (25% by 
weight) was also added and the reaction allowed to proceed and additional 4 h. 
Following work-up, (SJ-34 was isolated in 96% yield with a minimal amount of 
impurities. The 1H NMR was a match to a sample prepared according to our 
racemic strategy 67 validating our asymmetric synthetic methodology.
When this reaction was attempted on (R)-109 however, a very different 
result was obtained. Under virtually identical conditions and after stirring 
overnight, two products were formed as observed by TLC and 1H NMR. The 
product mixture was nitrated and the compounds protected with a Boc group to 
facilitate a more straightforward chromatographic separation. Following 
chromatography, the compounds were immediately deprotected. Interestingly, 
the proportion of side product (determined by 1H NMR) was greatly reduced upon 
nitration, possibly as a result of its degradation in the strong acid. One of the
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products was our target (R)-MOM-NQP (R)-ZS. The other product was a 
compound showing only three aromatic proton signals in the 1H NMR, indicating 
that quinoline ring reduction had occurred, possibly giving (R)-110 (Scheme 3.7). 
Reductions of the quinoline ring are known under these conditions and reduction 
usually occurs on the nitrogen containing ring.115
Scheme 3.7: Debenzylation reaction giving side product formation from ring-reduction.
Concurrent with this study, the synthesis of (R)- and (S)- MeProF 61 
(discussed later) was encountering the same benzyl group removal problems. In 
this series, Rainey-Ni was used as a catalyst and provided similar poor results. 
In this case, the removal would not go to completion (3 days, 40 psi of Ffe) and 
side products were again forming as observed by TLC. Based on the lack of 
consistency for the debenzylation transformation, and the possibility that side 
products could be formed in significant quantities, catalytic hydrogenolysis of the 
benzyl groups was abandoned.
We next considered the use of 1-chloroethyl chloroformate (ACE-CI, 111) 
for the debenzylation transformation.116 This reagent is well known for its ability 
to dealkylate tertiary amines to provide good yields of secondary amine products. 
When cyclic amines are reacted with this reagent, there also occurs a preference 
towards the dealkylation of the noncyclic alkyl group. The use of this reagent for
Pd/C, H2 
MeOH Product
mixture
<7?>109 (Ry35 (Ry 1 1 0
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the removal of benzyl groups from cyclic tertiary amines (piperazines, 
piperadines) is well documented.117,118
The mechanism of the dealkylation is shown in Figure 3.6 for the 
debenzylation of N-benzylmorpholine 112. The amine is heated with 111 in 
refluxing dichloroethane (DCE) to afford the dealkylated chloroethyl carbamate 
intermediate 113 and benzyl chloride 114. To complete the transformation all 
volatiles are removed (in vacuo) and the residue is treated with methanol and 
heated at 50 -  60 °C. The methanol reacts with the chloroethyl side chain to give 
intermediate 115 that decomposes to dimethylacetal 116 and N-morpholine 
carboxylic acid 117 that further decomposes to CO2 and the product morpholine 
118; the later picks up the HCI generated in the reaction.
MeOH A
118 116
115 © C l
Figure 3.6: The mechanism of ACE-CI dealkylation.
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The first attempts at effecting this transformation provided confusing 
results. The reported conditions (~100 mol% ACE-CI in DCE, reflux 1 h; then 
MeOH hydrolysis at 50 -  60 °C, 1 h) seemed to provide a complete conversion of 
the benzyl amine to the secondary amine product based on TLC analysis 
(product Rf = ~0.15 vs. starting material Rf = 0.70 MeOH:DCM 1:9); where the 
analysis showed no starting material and a large product spot. However, when 
the crude reaction mixture was analyzed the next day by 1H NMR it appeared 
there were three products present and the benzyl group still appeared to be 
partially intact.
After considering this result, a follow-up TLC analysis was performed and 
this distinctly showed the presence of the N-Benzyl starting material (Rf = 0.70; 
MeOH:DCM 1:9). We figured that this had just been missed on the previous 
analysis and thought initially that the reaction had not gone to completion. 
Consequently, our next attempts at dealkylation utilized increased amounts of 
ACE-CI reagent (400 mol%) and increased reaction times (reflux 4-5 h; then 
MeOH hydrolysis). Following this sequence, the material was chromatographed 
immediately and product yields in the 75 -  80 % range were afforded. Given 
these improved yields with the more rigorous conditions, we attempted a larger 
scale reaction for our coupled tertiary amine (SJ-109. The conditions of this 
reaction were exactly as described immediately above. However, the crude 
material was not chromatographed immediately following the work-up and was 
kept under high vacuum overnight. The crude weight the next morning was very 
high (150%) and a TLC showed that a significant quantity of starting material
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remained. Following chromatography, we obtained product (S)-34 and starting 
material (SJ-109 in yields of 51% and 43% respectively (Scheme 3.8).
1. ACE-CI (200 mol%) DCE, A 2.5 h
^  / S ,  L / W I - ,  K 7 I I U A ,  xJ  I I
N N^^| --------------------- -
/ ° v ^ k ^ N B n  2. MeOH, 60 °C, 2 h 
H Basic work-up
1. ACE-CI (400 mol%) 
DCE reflux 5 h
N"^|
^ O ^ k ^ N H
2. MeOH, 60 °C, 1 h 
Acidic work-up 
^  ~90%
N N " ^ |  
/O ^ k ^ N B n
H
(S>34 51%
H
(S>109 43%Pumped overnight
Scheme 3.8: Refinement of the ACE-CI mediated debenzylation reaction.
Since the yields of products from immediate chromatography (75 -  80%) 
varied greatly from the materials that pumped overnight (-50% ) we concluded 
that something was reacting within the crude material as it sat on the pump. It 
became obvious after considering the literature117, 118 and the reaction 
mechanism (discussed above) that we were simply alkylating our amine with the 
benzyl chloride 114 that was formed as a reaction side product (See mechanism, 
Figure 3.5). Our work-up conditions after the methanol hydrolysis, were to 
evaporate the reaction solvent then dilute the residue with saturated NaHC0 3  
and DCM. The basic (pH ~9) aqueous layer was extracted with DCM to afford 
the crude product. Unfortunately, this also extracted 114 and any ACE-CI 
reagent 111 that wasn’t destroyed in the workup. When these reagents were 
concentrated and allowed to sit for 16 h overnight, the alkylation reaction took 
place.
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The recovered benzyl amine fSJ-109 was subjected again to the 
debenzylation reaction conditions (Scheme 3.8). This time less rigorous 
conditions were used (ACE-CI 200 mol%, reflux 2.5 h), and the work-up was 
changed. Following the hydrolysis step with methanol, the crude residue was 
dissolved in 1 N HCI and washed with a few portions of DCM. A check of these 
washes by TLC showed that a UV active non-polar material had been removed 
(probably benzyl chloride). The aqueous phase was then made basic and 
extracted with DCM to afford (S)-34 in ~90% yield. This material did not show 
reactivity once it had been concentrated and allowed to stand for extended 
periods of time. Furthermore, the purity of the isolated product was high enough 
so that column chromatography was not required. For the last transformation, the 
nitration of (S)-34 was achieved in > 90% yield in all cases to afford the final 
target (S)-35.
The complete synthesis for (S)-35 is shown above and the yields below 
each step represents the range obtained for both isomers (Scheme 3.9). The 
asymmetric syntheses of the enantiomers of MOM-NQP were accomplished in 
nine steps from inexpensive amino acid starting materials. Given the typical 
yields for each of these transformations, the final compounds are routinely be 
obtained in ~40% overall yield. Given optimal yields for each step, this overall 
yield could go as high as 60%.
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Scheme 3.9: The complete synthesis of fSJ-MOM-NQP; the (R)- stereoisomer was similarly 
prepared.
3.3 Synthesis of the Enantiomers of MeProF-NQP
The synthesis of (R)- and (S)- MeProF-NQP 61 utilized the same 
asymmetric peptide 96 that was used in the synthesis of (R)- and (S)- MOM-NQP 
35. However, there were two criteria that we wanted to meet so that we could 
avoid synthetic complications. Firstly, we wanted to avoid performing the 
synthesis of (R)- and (S)- 61 from 35 as was done for (rac)-61, so the BBr3 
demethylation step could be avoided (see Chapter 2, Scheme 2.6). Secondly, 
we understood that we could not have a fluorinated side chain present during the
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Gilman coupling step since the halogen lacked stability under the alkyllithium 
coupling conditions (as per Chapter 2, Figure 2.1). Consequently, we desired to 
discover a protecting group for the alcohol of diamide 97 that could withstand the 
transformations (diamide reduction and Gilman69 coupling) to the coupled 
quipazine and then be easily removed. This strategy would allow us the 
convenience of obtaining the alcohol side chain without the need for the 
inconsistent BBr3 demethylation reaction. Furthermore, it would allow us to use 
the same side chain extension chemistry that we had developed for (rac)- 
MeProF 61 (as per Scheme 2.6).
Because of its stability to basic reaction conditions and the ease with 
which it is introduced and removed 79, our first choice of a new alcohol protecting 
group was the tetrahydropyranyl ether (-OTHP). Given the general lack of 
nucleophilicity of amides we felt that a selective protection of the alcohol (R)-96 
could be accomplished in the presence of the secondary amide. Our choice of 
the THP protecting group happened to be a correct one, as demonstrated by the 
facile synthesis of the benzyl protected quipazine alcohol (S)-122 shown below 
(Scheme 3.10). The introduction of the THP group was accomplished according 
to the method of Bernady119 and utilized excess dihydropyran (460 mol%) in 
DCM with p-toluenesulfonic acid as the catalyst ( 3 - 5  mol%). The reaction was 
complete after 30 min, and following chromatography, an excellent yield of (R)- 
119 was obtained as a ~6:4 mixture of diastereomers (C-2 of the THP ring). The 
reduction of (R)-M 9  went easily with UAIH4 in refluxing THF to give protected 
piperazine fSJ-120 in excellent yields.
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Scheme 3.10: Facile production of benzyl protected quipazine alcohol fSJ-122 using the OTHP 
group for alcohol protection.
Compound fSJ-120 underwent Gilman69 quinoline coupling to provide (S)- 
121, however, the yields were inconsistent. The best yield (93%) was obtained 
with a piperazine that had not been column purified following the UAIH4 
reduction. As such, this is explained simply as a lingering anomaly. The removal 
of the THP group was consistent, giving excellent yields of (S)-122. Conversion 
to alcohol fS>122 was accomplished very cleanly, in high yield by stirring in 
MeOH with 220 mol% of HCI overnight.
Given the ease of synthesis of alcohol (S)-122, it is worthwhile to discuss 
the option of abandoning the previously described synthesis of (R)- and (S)- 
MOM-NQP (Scheme 3.9) in favor of adopting the new THP protected 
methodology (Figure 3.7). Simply alkylating (S) -122 with DMF, NaH and CH3-I 
would provide M O M -N Q P intermediate fSJ-109 in an equal number of steps 
(seven) from the amino acid starting materials. For future studies, if large 
quantities of the enantiomers of MOM and MeProF are required, it may be
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desirable to generate bulk quantities of (R)- and (S) - 122 so two synthetic routes 
will not be required to acquire all of the targets.
OoN
N
fS>35
N N ^ i N N
HCX^-v^NBn
(S>122
Figure 3.7: Intermediate benzyl alcohol fSJ-122 to generate both asymmetric targets.
The conversion of the alcohol side chain of (SJ-122 to the fluorinated 
propyl side chain followed the same basic methodology (as per Scheme 2.6) that 
was utilized for the conversion of N-Boc alcohol 58 to (rac)-MeProF 61 (Scheme 
3.11).
| I I NaH, DMF [I 'I ' I  1.THF, 9-BBN [I
H O ^ J ^ N B n  ^ / Br ^ v ^ O ^ ^ J s ^ N B n  2 ‘ H z ° z ' ' 0 H  H O ^ - ^ O ^ l ^ N B n  
H „co/ H89- 95%
fS>122
CHoCIo, Pyridine
N N ^ |
fS>123
Tosyl-CI 
40 - 52%
TBAF
THF
73 - 95 %
(sy124
ch 2ci2
DAST
NBn ' '"  FN 
39 - 89%
'O-s^k^NBn
58-62%
Scheme 3.11: Synthesis of the fluoropropyl side chain from the key alcohol intermediate fSj-122 
using two distinct fluorination stragies.
The reaction conditions were identical in all cases, with the exception of 
the alkylation step ((SJ-122 -*■ (S>123) where care was taken to use s 5 mol% 
excess of allyl bromide to avoid quaternization of the tertiary amine. This change
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in concentration did not effect the conversion to ether (S J -1 2 3  and excellent 
yields of product were obtained. The hydroboration-oxidation sequence went 
smoothly producing alcohol (S J -1 2 4  in high yield. Interestingly, the conversion of 
(S)-1 2 4  to tosylate (S J-1 2 5  could only be achieved in modest yields of 40-52% 
(yields with the Boc protecting group were consistently > 70%). This range of 
tosylate yields was maintained with 100, 200, and 400 mol% of tosyl chloride. 
This conversion was not investigated in detail. However it is suggested that 
future attempts utilize dimethylaminopyridine (DMAP) as a catalyst with only 100 
-  150 mol% of tosyl chloride. The formation of very polar material was observed 
with reactions involving 400 mol% of tosyl chloride and it may result from amine 
quaternization. Fluorination of (S J -1 2 5  using 150 mol% of TBAF in THF initially 
gave very poor results with yields of (S J -1 2 6  being < 50%. Later attempts, using 
1500 mol% of TBAF, afforded yields > 80% and (S )-1 2 6  was easily separated 
from the remaining TBAF with column chromatography. The combined yield for 
the tosylation-fluorination sequence was, at best, 47 %.
An alternate fluorination method was investigated to enhance the chemical 
yield of the fluorinated product (S )-1 2 6 . Diethyl aminosulfurtrifluoride (DAST) is 
well known for its ability to convert alcohols to alkyl fluorides.120 The DAST 
reagent was effectively used in DCM at -78 °C to convert alcohol (S)A2A directly 
to the fluoride (S )-1 2 6  in yields of ~60%. Although not a large improvement from 
the two-step process, this alternative synthetic transformation does provide a 
modest increase in yield and shorten synthetic time. Benzyl tosylate (S )-1 2 5 , is 
not an appropriate radiochemical precursor since two lengthy chemical
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transformations would be required following the fluorination to generate the target 
tracer. Consequently, it is not necessary to generate this intermediate, and the 
DAST route can be routinely used.
The final conversion of the benzyl protected fluoride (SJ-126 to MeProF 
product fSJ-61 follows the same ACE-CI and nitration sequence that was used 
for (R)- and (S)- MOM-NQP. The ACE-CI promoted debenzylation reactions 
provided consistent good results since the crude material was always 
chromatographed immediately following the work-up so that subsequent 
alkylation was avoided. The acidic work up has not yet been utilized in this 
series, however, it is recommended that it be the standard method for obtaining 
the crude products from ACE-CI reactions. The usual nitration of (SJ-127 to 
provide target material (S)-61 completed the synthesis.
The complete synthetic scheme for the formation of (R)- and (S)- MeProF 
61 is shown below and is completed in 11 -  12 steps from the amino acid starting 
materials with the best overall yield being 32% (Scheme 3.12).
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Scheme 3.12: The complete synthesis of (SJ-MeProF-NQP; the (R)- stereoisomer was similarly 
prepared.
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3.4 The Synthesis of Enantiomeric Radiolabelling Precursors
The precursors for radiochemical synthesis studies were synthesized 
initially in an identical manner to the racemic targets (Scheme 3.13). The 
enantiomers of 35 were treated with boron tribromide to remove the methyl group 
and the Boc group was introduced to generate the key N-Boc protected alcohol 
(SJ-58. This radiochemical precursor for (R)- and (S)- [11C]35 has not yet been 
utilized in any radiosyntheses based on the presumed poor in vivo properties 
(e.g. long equilibration time), discussed earlier in Chapter 2 (Sandell, 2002), that 
would not afford a useful carbon-11 imaging agent.
The MeProF tosylate precursor (S)-65 was again synthesized from Boc 
intermediate (S)-58 in an identical manner to the racemic variant. These 
approaches are summarized again below and the radiochemical precursors are 
boxed (Scheme 3.13).
1 ■ BBr3, 
(R)-or(S)- CH2CI2
MOM-NQP 2. Boc20
Scheme 3.9
35 0 - 70%
1. THF, 9-BBN
2. H20 2> -OH
62 - 78 %
NaH, DMF ° 2N
N N N
O ^J^NBocHO^Jx^NBoe
73 - 97%
CH2CI2, Pyridine
N
Tosyl-CI 
75 - 82%
OoN
Scheme 3.13: Synthesis of enantiomeric radiolabelling precursors (boxed). Only the (S)- 
intermediates are shown.
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Since this pathway involves the inconsistent BBr3 demethylation reaction, 
an alternate synthesis was desired, particularly one that began from the key 
asymmetric intermediate, N-benzyl alcohol (S)-122. It has been shown already 
how this compound can afford both cold asymmetric agents (35 and 61), and an 
efficient conversion of (SJ-122 to Boc alcohol (S)-58 would provide a GRAND 
UNIFICATION of the asymmetric pathway by affording all targets, from a 
common intermediate (Figure 3.8).
0?N
N N '^ 'j N N N N
ACCOMPLISHED ?? CAN TH S BE
N N
H0^ T ^ ' NBoc
N NXVs|
3 H
[11CtfS>35
O ^ v ^ N H  
H
[18F]rS>61
Figure 3.8: Intermediate N-benzyl alcohol fS>122 as a plausible precursor for all assymetric 
targets.
To achieve this transformation a relatively simple synthetic strategy hs 
been developed using only the ('RJ-stereoisomer, (R)-122 (Scheme 3.14). A key 
feature of this synthesis was the need for an acid stable protecting group for the 
alcohol so the nitration could be accomplished.
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Scheme 3.14: Synthesis of Boc alcohol radiochemical precursor (R)-58 from the key intermediate 
N-benzyl alcohol fRj-122.
When the alcohol is subjected to cold H2SO4 and HNO3 a reaction occurs 
(perhaps an oxidation) to form a water soluble product that does not extract into 
organic solvents under basic (pH 9) conditions. This result suggests that a 
carboxylate anion may be present. The acetate group was chosen as the alcohol 
protecting group since it shows a general stability to rather acidic conditions.79 
The introduction of the acetate protecting group was accomplished using typical 
conditions (AC2O, Pyr, cat. DMAP in DCM) to afford acetate (R) -128 in 95% yield. 
In one experiment, this material was nitrated with 300 mol% HNO3 to afford 
dinitro product (iRJ-131 that surprisingly would not debenzylate under our usual 
ACE-CI reaction conditions (Scheme 3.15).
2. MeOH
1. ACE-CI 
DCE
H
(fl>132
H
(R)-131
Scheme 3.15: Attempted debenzylation of the nitrobenzyl intermediate.
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The alternate approach performed the debenzylation first to afford (R)-129 
in a yield of 95% (Scheme 3.14). In the work-up, care was taken to ensure that 
the aqueous layer did not become to basic and cause acetate hydrolysis by using 
only saturated NaHC0 3  to bring the mixture to basic pH. The secondary amine 
acetate (R)A29 was then nitrated under our standard conditions and protected 
with B0 C2 O in the work-up to afford the crude intermediate N-Boc acetate (R)- 
130. Following the evaporation of the extraction solvent, selective hydrolysis of 
the acetate was accomplished using K2 CO 3  in methanol at room temperature to 
afford the key radiolabelling precursor intermediate (R)-58 in an overall yield of 
45% from N-Benzyl alcohol (R)A22.
This synthetic route has demonstrated that the conversion of (R) -122 to 
key Boc intermediate (R)-58 is a reality, and can be accomplished with moderate 
yields. The low yield of the final nitration step likely occurred because of 
conditions that caused acetate deprotection and subsequent reactivity of the 
alcohol to form the water-soluble product mentioned above. Less acidic nitration 
conditions may be employed that will minimize this side-reactivity and 
subsequent reduction in chemical yield.121 This synthesis of (R)-58 
demonstrates the ability of N-Benzyl alcohol (R)A22 to act as a key intermediate 
for the generation of all asymmetric targets detailed in this chapter.
The pairs of enantiomers that were generated from this work all 
demonstrated equal and opposite optical rotations in polarimetry experiments. 
The differences in the optical rotations for a pair of enantiomers was typically less 
than 5%. More quantitative determinations of optical purity (enantiomeric
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excess, ee) need to be established, and experiments to provide these 
determinations are being planned. We hope to utilize gas chromatography with a 
chiral stationary phase to quantity the enantiomeric excess of our final 
compounds. Should these chromatographic separations fail to adequately 
resolve the enantiomers, the %ee determinations will be made using the NMR 
method of Mosher.122
Mosher’s method reacts an enantiomerically pure acid chloride (R)-133 
with an optically active molecule (for example (S)-61) to form a compound with 2 
or more stereocenters 134 (Figure 3.9). The trifluoromethyl group (circled) will 
be diastereotopic as a result of the (S)- and (R)- configurations at the other chiral 
center. An analysis of product 134 with 19F NMR allows for the determination of 
enantiomeric excess by the integration of trifluoromethyl signals.
(S)- and (R)-
Figure 3.9: Reaction of (SJ-MeProF with Mosher's reagent. The trifluoromethyl group can be 
analyzed by 19F NMR to quantify enantiomeric excess.
(S>«1 (R)-133 134 ffl>only
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CHAPTER 4
OTHER ASYMMETRIC-LIKE SYNTHESES
4.1 Introduction for the 2’-Aryl-6-Nitroquipazines
Given the success of the asymmetric synthesis for generating the 
enantiomers of 35 and 61, we thought that this technology might be useful for 
generating other 2’-substituted-6-nitroquipazine analogs using different amino 
acids.
Of particular interest was the generation of 2’-aryl-6-nitroquipazine 
analogs containing phenyl and benzyl substituents (135 and 136, Figure 4.1). 
These ligands will someday serve as test agents for the hypothesis that 6-NQP 
analogs containing dual aromatic ring motifs (quinoline ring and pheny or benzyl 
substituent) may allosterically modulate ligand transport and binding at the 
substrate (5-HT) binding site of SERT because of their prospective steroid like 
qualities.
NH
136
OoN
NH
135
Figure 4.1: Our 2'-aryl target ligands: 2'-phenyl- and 2 '-benzyl-6 -nitroquipazine.
This hypothesis was developed from a collection of evidence from several 
researchers, that indicates certain steroids and steroid-like molecules, as well as
commercial SSRI’s, can allosterically influence the binding characteristics and
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transport properties of ligands at the substrate (endogenous 5-HT) binding site of 
SERT. A common structural motif to these ligands (steroids excluded) is the 
presence of two aromatic ring functional groups. We hypothesize that this ligand 
structural feature may promote select influences on SERT function.
Plenge demonstrated that the dissociation rates of [3H]imipramine 4 and 
[3H]paroxetine 9 from SERT could be modulated in a dose-dependent manner by 
the addition of micromolar concentrations of non-radiolabelled paroxetine 9 or 
citalopram 28 (Figure 4.2 for structures).
Figure 4.2: Compound structures from the study of Plenge, 1985, 1991.123,124
The addition of 28 caused a decrease in the rate of dissociation from 
SERT for both radioligands (increased affinity). Compound 9 caused an increase 
in the dissociation rate for [3H]4 (decreased affinity) and a decrease in 
dissociation for [3H]9 (increased affinity). Since these experiments were run 
under non-competitive conditions ([3H]4 was diluted ~50 fold at the time of 9 or 
28 addition), the modulatory effect had to arise from a ligand-protein interaction 
at a different or allosteric binding site on SERT.123,124 Recent affinity modulation 
(Af-M) studies on SERT mutants have provided additional evidence that the 
allosteric site is independent from the reuptake inhibitor binding site.14
4 Imipramine 9 Paroxetine 28 Citalopram
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Interestingly, the SSRI sertraline 7 has shown Af-M properties at the 
norepinephrine transporter (NET) by decreasing the dissociation rate of the NET 
selective ligand, [3H]nisoxetine 137. The results suggest that the allosteric 
binding site may be a common feature of the biogenic amine transporters (Figure
Figure 4.3: Compound structures from the study of Plenge, 1997.125
What was most intriguing from the work of Plenge, were the results of an 
experiment that evaluated the Af-M properties of around 10 SSRI’s under the 
same assay conditions.125 The experiments demonstrated that SSRI’s 
possessing two aromatic rings in their structure show enhanced ability to 
allosterically modulate ligand affinity at the substrate binding site of SERT. The 
study showed that the SSRI’s Fluvoxamine 8, Clovoxamine 138 and Indalpine 
139 (Figure 4.3), that do not have two aromatic rings, were the least potent Af-M 
ligands. This subtle structural observation is key for the development of our 
hypothesis, that may also involve Af-M ligand confomational flexabilty. In that, 
ligands that have decreased structural rigidity seem to demonstrate diminished 
Af-M activity.
ci
7 Sertraline
NH
137 Nisoxetine 8  Fluvoxamine X = CF3 
138 Clovoxamine X = CI
139 Indalpine
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Chang demonstrated a similar Af-M phenomenon at SERT when 
examining transport velocities of [3H]5-HT 1 and the binding characteristics of the 
cocaine analaog [3H]CFT 140. The observations were made using the steroids 
p-estradiol 141 and estriol 142 and the steroid analog tamoxifen 143 (Figure
Figure 4.4: Compound structures from the study of Chang, 1999.126
Similar to Plenge, Chang observed a dose-dependent decrease in [3H]1 
uptake, and also observed a decrease in [3H]140 dissociation from the SERT 
substrate site, in the presence of micromolar concentrations of 141. Drugs 142 
and 143 also displayed the ability to inhibit [3H]1 uptake, but with decreased 
potency. The similarities of the results to the work of Plenge are notable and 
they may suggest a relationship between steroid qualities, dual aromatic ring 
structural motifs, ligand flexibility and affinity modulation properties.
Our laboratory has identified two flavonoids, 144 and 145, that 
demonstrate Af-M properties towards the dissociation rate of [3H]paroxetine 9 
from the reuptake site on SERT.127 These flavonoid compounds also possess 
dual aromatic ring motifs and are conformationally limited (Figure 4.5).
COOCH;
140 CFT 141 p-estradiol R = H
142 estratriol R = OH
143 Tamoxifen
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OH
HO OH O
.OH
144 Genistein 145
Figure 4.5: Compound structures from the study of Weller, 2 0 0 2 .127
Furthermore, flavonoids have been shown to possess steroidal qualities128 
and our experiments provide additional evidence that rigid, steroid-like molecules 
demonstrate affinity modulation properties at SERT.
Other evidence that may further link steroids and SSRI’s possessing two 
aromatic functional groups comes from the work of Griffin (Figure 4.6).129
F igure 4.6: Compound structures from the study of Griffin, 1999.129
Griffin demonstrated that the SSRI’s fluoxetine 6, sertraline 7 and 
paroxetine 9 (all with two aromatic rings) interact with neurosteroid enzymes 
within the CNS, and affect the oxidative and reductive pathways of their 
respective steroid enzymatic substrates. The results present additional evidence 
that SSRI’s having two aromatic rings may posses some “steroid-like” qualities 
that afford these overlapped properties with steroids and steroid analogs.
6  Fluoxetine 7 Sertraline 9 Paroxetine
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Yet another possible correlation exists with the sexual dysfunction (SD) 
that results from SSRI therapy.130 Many patients (occurrence may be as high as 
80%) experience SD as a result of SSRI administration and this effect is thought 
to be highly dose-dependent.131 Although the exact mechanisms of SSRI 
induced SD remain less clear, correlations of SD to low levels of estradiol 141 in 
females have been observed.132 Studies have demonstrated that in some 
instances switching to a different SSRI medication can ameliorate these side 
effects. Interestingly, two medications that have shown decreased incidence of 
SD side effects both possess only a single aromatic ring; Bupropion 146133 and 
Fluvoxamine 8 (Figure 4.7).134
Figure 4.7: Two pharmaceutical agents with reduced incidence of sexual dysfunction side effects.
The reductions in SD for 146 have been observed in double blind studies 
where direct comparisons to SSRI’s with two aromatic functional groups were 
made, and a statistically significant difference was noted.135 Provided that 
SSRI’s have been shown to interact with steroid enzymes,129and that changes in 
endogenous hormone levels can lead to sexual dysfunction,132 it is reasonable to 
hypothesize that SSRI’s induce SD side effects though interactions with various 
sites associated with the neuroendocrine system. By switching to medications
146 Bupropion 8  Fluvoxamine
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that have only one aromatic functional group (rather than two, like 6, 7, 9, and 
28), one could eliminate the interactions with steroid receptors since the single 
aromatic moiety compounds structurally less like steroids. Hence, we suggest 
that SSRI’s that have two aromatic ring moieties provide the binding affinity 
modulation and promote sexual dysfunction qualities as a result of their steroid 
mimic qualities.
Given the potential use of our 6-NQP analogs in SSRI therapies, we 
focused to minimize these potential sexual side effects by designing ligands 
devoid of the two aromatic functional group structural motif. Towards the 
generation of novel PET imaging agents and to provide a handle for radionuclide 
introduction, our ligand design strategy has utilized an alkyl side chain 
replacement for one of the aromatic rings (similar to fluvoxamine 8). Preliminary 
biochemical studies in our lab, following the techniques of Plenge,125 have shown 
that MOM-NQP 35 does not display affinity modulation properties at SERT.127 
To an extent, this supports our initial hypothesis that ligands devoid of two 
aromatic moieties are with minimal Af-M qualities. To further test the dual 
aromatic functional group -  steroid mimic hypothesis, we sought to purposely 
alter our 6-NQP analogs by introducing the dual aromatic ring structural motif 
through the synthesis of quipazine analogs Phen-NQP 135 and Ben-NQP 136 
(Figure 4.8).
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o2n o 2n o 2n
NH
H
35 MOM-NQP 135 Phen-NQP 136 Ben-NQP
Figure 4.8: Refined lead agent MOM-NQP, and new dual aromatic ring ligands Phen-NQP and 
Ben-NQP.
With ligands 135 and 136, we would now be able to test our hypothesis 
that 6-NQP analogs containing dual aromatic functional groups may allosterically 
modulate ligand transport and binding at SERT because of their steroid qualities. 
Doing so, would allow us to compare, within the same chemical family, changes 
in the affinity modulation properties as a result of the introduction of a second 
aromatic group. The ligands could be further tested at steroid receptors to truly 
evaluate their steroid qualities. With this goal in mind we began our syntheses of 
the 2’-aryl-6-nitroqupazines 135 and 136.
4.2 Synthesis of 2’-Aryl-6-nitroquipazines
The first attempts at generating a 2’-aryl agent focused on the synthesis of 
a 2-phenyl substituted piperazine. There are several literature accounts of 
piperazine syntheses related to our target and many of them begin from ethyl 
bromophenyl acetate 147 or a similar alpha bromo ester.136,137 Roderick utilized 
147 in a reaction with ethylene diamine to generate 2-phenyl piperazineone 148 
and we hoped to utilize a similar procedure, with N,N-dibenzylethylene diamine
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(DBEDA) as the nucleophile, in an analogous manner to Rondu’s method for the 
generation of piperazine ester 150 (Figure 4.9) .68
Figure 4.9: Various strategies for piperazine synthesis and our design for obtaining a phenyl 
piperazine.
Our first attempts to generate 151 from bromo ester 147138 and DBEDA 
utilized conditions analogous to those of Rondu, with —1:1 ratio of 147 and 
DBEDA with 110 mol% EtaN in toluene at 80 °C. A TLC (EtOAc:Hexanes, 2:3) 
showed a non-polar (Rf = 0.63) ninhydrin active and UV active spot that 
appeared to be the desired target. However, following chromatography, a 1H 
NMR spectrum clearly showed that this material was not desired product 151. 
However, while sitting for two days, the chromatography column had leaked and 
an oil had been deposited on the counter top. This material was analyzed by
Br (H2NCH2)2 HN"^
OEt NH Roderick, 1966136
147 148
Et02C'x̂ /B r  toluene, Et3l
Br (BnNHCH2) 2
N Et02u
Rondu, 199768
149 150
(BnNHCH2) 2
Our design
147 151
(BnNHCH2) 2
O
153
Naylor, 1993111
152
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TLC (EtOAc:Hexanes, 2:3) and was considerably more polar (Rf = 0.29), showed 
minimal UV activity and was only very slightly active to ninhydrin staining (faint 
pink). This material however, was very clearly product 151 by 1H NMR. The 
column fractions were analyzed again and a 58% yield of 151 was obtained. We 
were pleased with this result but given the side products that were generated via 
this route, we felt that alternate synthetic conditions could be found to increase 
the product yield.
Naylor had cyclized diethyl bromomalonate 152 with 200 mol% DBEDA in 
refluxing acetonitrile and obtained good yields of piperazinone 153 (Figure 
4.9) . 111 Attempting this strategy with bromo ester 147 resulted in a good 
conversion to product 151 with a yield of 77%. Satisfied with this result we 
proceeded further with our synthesis (Scheme 4.1).
MeOH, Pd/C,(BnNHCH2)2
1. Et20 , n-BuLi, 
2-CI-quinoline
Trityl chloride
153 154 155
Scheme 4.1: Initial synthesis of 2'-phenylquipiazine.
The cyclized material 151 was reduced to piperazine 152 with LiAIFU in 
THF and removal of the benzyl groups by catalytic hydrogenolysis provided 153 
in excellent yields. The less hindered amine was protected with a trityl group and
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protected piperazine 154 was coupled to 2-chloroquinoline. Following 
deprotection, 2’-phenylquipazine 155 was obtained in 90% yield.
Unfortunately, we naively thought that a regioselective nitration of the 
quinoline ring might be possible since it was activated by the piperazine nitrogen. 
However, this was not the case. Using 400 mol% of HNO3, a mixture of 
dinitrated products was formed. Reducing the HNO3 to 100 mol% provided a 
mixture of unnitrated starting material 155, dinitrated mixture 156 and what 
appeared to be desired product 135 (Scheme 4.2).
OoN
155 NH NH
156 135
N N '^ ' j
NH
155
Schem e 4.2: Nitration attempt with 100 mol% of nitric acid form ing a complex product 
mixture.
Attempts to isolate 135 through various protection-purification- 
deprotection cycles with N-Boc and N-formyl protecting groups all failed to 
generate a pure sample of 135 so an alternate synthetic route was pursued.
The obvious solution was to avoid the nitration step altogether, by 
coupling protected piperazine 154 to an already nitrated quinoline ring. A 
literature search demonstrated that the strategy could be accomplished, in that 
researchers working with quipazines had already established the utility of 2 - 
chloro-6 -nitroquinoline 159 for these purposes (as per Figure 4.10) . 139 The
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nitroquinoline can could be synthesized easily from commercially available 
hydrocarbostyril 157 in two steps (Scheme 4.3).
N O  H2 S 0 4 
H H
DDQ, POCI3  ° 2 N
Cl
158 98% 159
Scheme 4.3: Synthesis of 2-chloro-6-nitroquinoline.
Nitration of 157 provided a mixture of 6 - and 8 -nitrostyrils. The 6 -nitro 
regioisomer 158 could easily be isolated through recrystallization from EtOAc or 
rinsing the crude solids with cold EtOAc. Chloro nitroquinoline 159 was 
generated through a one-pot, chlorination-oxidation reaction of amide 158 with 
2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) and POCI3.
With nitrated quinoline 159 in hand, Gilman coupling reactions (similar to 
those described previously) with trityl protected methylpiperazine 89 were 
attempted and these all proved unsuccessful (Scheme 4.4).
Et20 , n-BuLi;
no product observed
159, Et20
THF, n-BuLi;
159, THF
no product observed
159 89
Et20 ,  n-BuLi;
159, DMF
160
Scheme 4.4: Gilman coupling attempts with 2-chloro-6-nitroquinoline.
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Quinoline 159 was exceptionally insoluble in ether, relative to the 2- 
chloroquinoline, and the usual Gilman conditions did not lead to product 
formation. The more polar etheral solvent, THF was utilized and this resulted in 
similar poor results. Using DMF as the solvent for 159, provided a small amount 
of a product-like (yellow colored) material by TLC. However, after isolation, the 
material was shown to be 2 -dimethylamino-6 -nitroquinoline 160, that was formed 
upon displacement of the dimethylamide ion from the DMF solvent.
Although discouraged by these results, we were encouraged by literature 
accounts detailing piperazine couplings to 159, and related quinolines, using 
excess amine in DMF at elevated temperatures (as shown in Figure 4.10).54,72,73, 
139 We proceeded to study the thermal coupling reaction with benzyl and phenyl 
piperazines, using three different nitrogen protecting groups; N-trityl, N-formyl 
and N-benzyl. The protected piperazines were coupled to 159 under a variety of 
conditions (solvent, temperature, concentrations, ratios) and the discussion of 
these coupling attempts follows below. First, we’ll discuss the application of the 
asymmetric synthesis to acquire our aryl piperazines and then the synthetic 
transformations necessary for the introduction of our protecting groups
The peptide coupling was performed according to the method of Naylor,111 
using phenylglycine or phenylalanine methyl ester hydrochlorides 161 and 165, 
respectively. The starting materials were synthesized from the commercially 
available amino acids using SOCI2 in MeOH .140 Both couplings went smoothly, 
providing excellent yields of dipeptides 162 and 166 that were routinely cyclized 
to the piperazindiones 163 and 167 (Scheme 4.5).
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Bn
BocI
X EDC.HCI, PFP Et3N, CH2CI20  OH CH2CI2 
95
LiAIH,
THF
C02Me
hq r
H2N X^Ar H
161 Ar = Ph 
165 Ar= Bn
Boci
Bn'N>  C02Me
O ^ N ^ A r  
H H
96% 162 Ar = Ph 
96% 166 Ar = Bn
1. MeOH 
SOCI2
Bn
N ^ O
  X T
2. NH„OH O f j X * '
90% 163 Ar = Ph 
93% 167 Ar = Bn
Ar
H N ^
^v^,NBn EDC.HCL =
H
" V 'hci R
■ S./-' PFP= f
OH 
F. F
74% 164 Ar = Ph 
77% 168 Ar = Bn
Scheme 4.5: Synthesis of the N-benzyl aryl piperazines using the 'assymetric' methodology 
described in Chapter 3.
The reduction of the diamides with LiAlhU in THF provided our N-benzyl 
protected aryl piperazines 164 and 168 in good yields. The synthesis of these 
piperazines, again, demonstrated the ease to which the non-racemic compounds 
could be generated from the commercially available D or L amino acid starting 
materials.
The N-formyl protected piperazines 170 and 171 were selectively formed 
from dihydrochlorides 153 and 169 using methyl formate in DCM or DME with 
Et3N as a base (Scheme 4.6) . 141
H N ^
Ar̂ ^N B n
H
164 Ar= Ph 
168 Ar= Bn
MeOH, Pd/C, 
HCI, H2
H N ^ ,
A r X - NH
H .2HCI
99% 153 Ar = Ph 
94% 169 Ar = Bn
CH2CI2, Et3N 
Methyl formate
DME, Et3N 
Methyl formate
H N ^
a , X - nohoH
62% 170 Ar= Ph
HN' ''j
A r X " " 0
76% 171 Ar = Bn
Scheme 4.6: Synthesis of N-formyl protected aryl piperazines.
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Since these reactions were run under heterogenous conditions, it was 
important at the outset that the hydrochlorides be fine powders to ensure 
adequate mixing. The piperazine hydrochlorides 1 5 3  and 1 6 9  were easily 
formed from 1 6 4  and 1 6 8  using standard hydrogenolysis conditions. The phenyl 
dihydrochloride 1 5 3  was also generated from dibenzyl piperazine 1 5 2  under the 
same catalytic conditions, according to Scheme 4.1 above.
The synthesis of the trityl protected phenylpiperazine 1 5 4  was described 
above (Scheme 4.1). The benzyl analog 1 7 2  was synthesized in an identical 
manner from 171 in excellent yield (Scheme 4.7).
Scheme 4.7: Synthesis of N-benzyi protected benzyl piperazine.
Our thermal coupling studies were adapted from those of Lee139 who 
utilized 500 mol% of N-formyl piperazine 1 7 3  with 1 5 9  in DMF to generate 6 - 
nitroquipazine 2 2  in 95% yield following deprotection (Figure 4.10).
Figure 4.10: Lee's reported thermal coupling to form 6 -nitroquipazine.
However, we decided to use a maximum of 200 mol% of amine since our 
piperazine fragments were synthetically valuable to us, in contrast to the
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CH2CI2, Et3N;
Trityl chloride
H .2HCI 
171 98%
H
172
H N ^
+ ^ ny °
H
173 500 mol%159 100 mol% 95% 22
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inexpensive and commercially available 173 . Our thermal synthesis trials (Table 
4.1) began with the N-trityl protected phenyl and benzyl piperazines (1 5 4  and 
172 , respectively, Entry 1 and 2). These fragments were reacted with 1 5 9  in 
DMF at 110 °C and we were pleased that the coupling reaction occured as 
observed by the formation of a non-polar spot by TLC (R f = >0.55, 
EtOAc:Hexanes, 2:3) that had the distinctive yellow nitroquipazine color. The 
new spots were distinct from the 2-dimethyl-aminoquinoline 1 6 0  (R f = 0.29, 
EtOAc:Hexanes, 2:3) observed with the Gilman coupling attempts in DMF. Thus, 
we were confident that the desired transformation was occuring. However, when 
the products were isolated and the trityl groups removed, very poor yields of the 
products (1 3 5  and 1 3 6 ) were obtained (< 20%) in both cases.
Interestingly, there was also a very polar (R f  = 0.0, EtOAc:Hexanes, 2:3; 
R f = ~0.4, MeOH:CH2Cl2, 1:9) material observed by TLC that had the same 
distinctive yellow color as the product. We suspected that the material was 
coupled product that had deprotected under the conditions of the coupling 
reaction and we investigated this further for the phenyl case (Entry 1). After 
flushing the material from a column we attempted to isolate it from the rest of the 
polar side products by treating the mixture with excess B0 C2O in DCM.
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T ab le  4.1: Summary of the thermal coupling experiments. For the amine substrate, A r denotes 
the side chain aromatic functionality and PG  denotes the nitrogen protecting group used for that 
entry. Mol% indicates amount of amine substrate relative to quinoline 159 (100 mol%). For trityl 
and formyl protecting groups, standard acidic deprotection conditions were used as described 
earlier in Chapters 2 and 3.
Solvent, Heat ° 2N
N Cl X  N I-,'Pf; Deprotection i J,
1 5 9  (CHO, Trit) A r " ^ N'H/Bn
Entry #
A m ine  
A r PG Mol°/o
C onditions  
Solvent T em p Tim e(h)
O utcom e  
Product Y ie ld
1 1 5 4 Ph trityl 200 DMF 110 °C 20 1 3 5 15%
2 1 7 2 Bn trityl 200 DMF 110 °C 6 1 3 6 18%
3 1 7 0 Ph formyl 200 DMF 130 °C 20 1 3 5 54%
4 171 Bn formyl 200 DMF 120 °C 44 1 3 6 46%
5 1 68 Bn Bn 200 DMF 155 °C 24 1 7 5 37% a
6 1 6 8 Bn Bn 200 Cl-Ben 155 °C 44 1 7 5 43%
7 1 64 Ph Bn 200 Cl-Ben 130 °C 40 1 74 29% a
8 171 Bn formyl 200 Cl-Ben 135 °C 39 1 3 6 <25% b
9 1 68 Bn Bn 200 DMSO 120 °C 20 1 75 74%
10 171 Bn formyl 200 DMSO 120 °C 44 1 3 6 45%
11 1 64 Ph Bn 200 DMSO 120 °C 24 1 7 4 76%
12 1 64 Ph Bn 200 DMSO 80 °C 44 1 7 4 63%
13 1 68 Bn Bn 
w / Hunig's Base
100
200
DMSO 120 °C 20 1 75 46%
14 1 6 4 Ph Bn 
w / 2,4,6-collidine
100
200
DMSO 
(.35 M)
120 °C 29 1 7 4 59%
15 1 64 Ph Bn 
w / 2,4,6-collidine
100
200
DMSO 
(.91 M)
115 °C 40 1 7 4 53%
0 2N
174 175^ ~ / 1 H/  ^ NBn
XX
N N ^ I  N ^ I  \
135 ^  ^ |^ N H  136/ —\  Ht X 'N H
H \ — /  Hunig's Base
CH;3
J-L <Xi I —  I L  H3C ^ N ^  CH3
2,4,6-collidine
a) yield off the column in question, other material present; b) estimated, not isolated
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The yellow spot showed a distinct change in polarity (Rf = 0.29, 
EtOAc:Hexanes, 2:3) suggesting that the Boc protecting group had been 
introduced. After isolating the product 176 by column chromatography and 
removing the protecting group we found that we had isolated the 3’-phenyl 
isomer 177 of our desired product 135 (Scheme 4.8).
Scheme 4.8: Isolation of 3'-phenyl-6-nitroquipazine.
The yield of 177 (29%) was nearly double the yield of the target 135 
(15%). The results clearly suggested that N-trityl was not a good protecting 
group for this transformation. It also suggested that the 3’-isomer 177 is readily 
formed. An observation that is not surprising, since the phenyl substituent 
provides steric hindrance towards the formation of the 2 ’-isomer.
Following these initial encouraging results, our attention turned to the use 
of the formamide and benzyl protected piperazine coupling fragments. The 
reactions involving the N-formyl protected phenyl and benzyl piperazines (170 
and 171 respectively, Entries 3 and 4) gave improved yields (54% and 46%, 
respectively) of their respective products and this is attributed to the increased 
stability of the N-formyl protecting group. A side product observed in these 
transformations was 2-dimethylamino-6-nitroquinoline 160. Clearly, the DMF 
solvent is again contributing to the formation of 160, by a displacement of the
Polar column CH2CI2
fraction from --------- •
Entry 1 (Table 4.1) Boc20 N ^ PhL^NBoc
176 177
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dimethylamine group under the coupling reaction conditions. Compound 160 
was also a side product from a Gilman coupling attempt using DMF as per 
Scheme 4.4. It should also be noted that doubling the reaction time (Entry 4 vs. 
3) did not improve the overall yield of the reaction. In all attampts involving DMF 
as a solvent, the reactions never went to completion, as 159 was still clearly 
visible by TLC.
Our next experiments utilized N-benzyl protected benzyl piperazine 168 
with DMF and chlorobenzene (Cl-Ben) as reaction solvents (Entries 5 and 6 ). 
Again, using DMF, we observed the same formation of 160 as a result of solvent 
participation in the reaction. The N-benzyl product 175 was formed with 
decreased yield and the purity of 175 isolated from column purification was low 
because a range of unidentifiable side products coeluted with the product. The 
use of chlorobenzene as the reaction solvent inhibited the reaction, as observed 
(TLC) by the slow disappearance of quinoline 159. However, the formation of 
side product 160 was eliminated and the product 175 isolated from the column 
was of much higher purity than that from the DMF reaction. Interestingly, when 
the benzyl protected phenyl piperazine 164 was reacted under similar conditions 
in chlorobenzene (Entry 7), poor conversion to the product 174 was observed 
and the product isolated from the column was contaminated with unidentifiable 
side products. The use of N-formyl benzyl piperazine 171 in chlorobenzene was 
remarkably slow (Entry 8 ). After 39 h very little product formation was observed 
by TLC and no attempt to isolate the product was made.
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Of the experiments that had been completed (Entries 1 - 8 ) ,  the best 
coupling results were demonstrated with N-formyl piperazines and DMF as the 
reaction solvent. However, these conditions were hampered by the unwanted 
formation of 160 as a result of solvent participation in the reaction. Additionally, 
with the poor results observed in chlorobenzene, we were compelled to believe 
that the polarity of DMF played an important role in assisting the transformation; 
very likely through the stabilization of charged intermediates and/or transition 
states. Consequently, we decided to try DMSO as a reaction solvent and entries 
9 - 1 5  summarize these transformations.
For the first time, we observed the consumption of our quinoline starting 
material 159 by TLC. The initial trial (Entry 9) produced an excellent 74% yield of 
175 from our benzyl protected benzyl piperazine 168 at a relatively low 
temperature (120 °C) in 20 h. Although DMSO if often difficult to remove 
following a reaction, the crude coupled product can easily be isolated by flooding 
the reaction contents with water and extracting the aqueous mixture twice with 
ether. The combined extracts are then washed with five portions of water and 
two portions of brine to provide the crude material that is virtually free from 
DMSO and can be chromatographed immediately. The Entry 9 transformation 
was also much cleaner than the all reactions performed in DMF. The reduced 
formation of unidentifiable side products resulted in simpler chromatographic 
separation and increased product purity.
Another intriguing observation was the general lack of reactivity of the N- 
formyl protected benzyl piperazine 171 to the DMSO conditions. The reaction
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was exceptionally slow and after 2 days only a 45% conversion to product was 
observed (Entry 10). This decreased reactivity could be explained by a reduction 
in the nucleophilicity of the amine lone pair of electrons as a result of the electron 
withdrawing influence of the formamide protecting group. The inductive effect 
resulting from the formal positive charge in resonance structures 179 and 180 is 
thought to lessen the availability of the lone-pair electrons for nucleophilic attack 
(Figure 4.11).
178 °  179 180
Figure 4.11: Reduction in amine nucleophilicity as a result of inductive effects from the formyl 
protecting group.
Given the poor DMSO coupling result with the N-formyl piperazine 171 we 
returned our attention to N-benzyl protected phenyl piperazine 164. When 164 
was coupled to 158 in DMSO, coupling results were obtained that were similar to 
those for 168 (Entry 11). A clean reaction and a good conversion to product 
afforded 174 in yield of 76%. This reaction was repeated at a lower temperature 
(80 °C, Entry 12) and although slower (reaction time of 44 h, 159 was not 
consumed), a good yield of 174 was still obtained. We felt that we had finally 
established reaction conditions that provided consistent, satisfactory results with 
both piperazine substrates. What was even more pleasing was the ability to 
achieve yields > 70% with only 200 mol% of our piperazine fragments.
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Pragmatically, we were still throwing away half of our amine starting 
material in every coupling reaction, and the yields based on our piperazine 
starting materials were only -38%. In an attempt to reduce our amine starting 
material utilization, we experimented with some non-nucleophilic amine bases as 
additives to act as a sponge for the HCI that is generated in the coupling reaction 
(Entries 13-15). The amine bases we chose were Hunig’s base (diisopropylethyl 
amine) and 2,4,6-collidine (Table 4.1). The bases were utilized as 200 mmol% 
additives in a 1:1 mixture of 159 and benzyl protected piperazine (164 or 168). 
When Hunig’s base was utilized with piperazine 168 (Entry 13), the overall 
conversion was low and it was evident by TLC that additional side products were 
forming. Still, the yield of product relative to the piperazine (46%) showed a 
-10%  increase over the prior DMSO conditions that utilized 200 mol% of amine 
(e.g. Entry 12 vs. Entry 13). Collidine was used twice with two different amounts 
of solvent and provided a marked improvement over the Hunig’s base conditions, 
giving a much cleaner conversion and yields that approached 60%. The yields 
relative to the piperazine were now - 2 0 % greater than those observed with 2 0 0 % 
mol% of piperazine and no additive base (e.g. Entry 12 vs. Entry 14). Increasing 
the concentration of the reactants by reducing the amount of solvent didn’t seem 
to have much of an effect on the overall transformation (Entry 15).
We had now established a simple and relatively efficient method of 
generating our 2 ’-aryl-6 -nitroquipazine agents with the thermal coupling 
methodology. Furthermore, the reactions are simple to perform: place the 
starting materials in an 8  ml_ vial, add stirbar and solvent, seal under argon and
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place in an oil bath at a temperature of 120 °C. The reaction workup and 
chromatography are straightforward giving products with high purity. 
Additionally, the best results were obtained with the N-benzyl protected 
piperazines (164 and 168) that could easily be generated using the ‘asymmetric’ 
methodology adapted from Naylor (Scheme 4.5). We had earlier established 
good benzyl deprotection conditions using ACE-CI, so the final products (135 and 
136) can be obtained in good overall yields.
The complete syntheses of our 2’-aryl-6-nitroquipazine analogs are 
detailed in Scheme 4.9 and are accomplished in five steps with > 40% yields 
from the amino acid starting materials 161 and 165. The nitroquinoline coupling 
fragment 159, is easily synthesized from a commercially available starting 
material 157 in 8 6 % yield.
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Scheme 4.9: Complete, optimized synthesis of the 2'-aryl-6-nitroquipazine targets. The thermal 
coupling step was optimized as detailed in Table 4.1.
4.3 The Alternate Assymetric-Like synthesis of 2’-EtOMe-NQP
Given the potential need for the enantiomers of the ethyl side chain analog 
78, it was undertaken to see if Naylor’s synthesis111 could be applied to these 
targets. The obvious choice for an amino acid building block was aspartic acid 
since the R group contained a 2-carbon ester that could be reduced to the 
alcohol and afford the methoxyethyl ether.
The racemic acid 181 was utilized since proof of concept was all that was 
desired and the aspartate dimethyl ester hydrochloride 182 was generated with
110
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
excess SOCb in refluxing methanol.140 Diester 182 underwent the Naylor 
peptide coupling under the reported conditions to provide dipeptide 183 in 
excellent yields (Scheme 4.10).
Bn
1. 95, EDC.HCL 
H2N ^ .C 0 2Me PFP, CH2CI2 Boc"
I
H2N C02H SOCI2I c r vNx^ ' ' C° 2Me>  C02MeC02H MeOH 
181 93%
H H 
183182 > 90%
Scheme 4.10: Synthesis of the racemic aspartyl dipeptide.
When considering the cyclization step though, we realized that we may 
encounter a problem. Our dipeptide 183 presented two opportunities for ring- 
closing amide formation 1 ) with the amino-acid ester and 2 ) with the side chain 
ester (Figure 4.12) to provide six and seven membered ring products 184 and 
185, respectively. Given the relative stabilities of the ring sizes, we were 
concerned about the formation of isomeric product mixtures. Indeed, these ring 
closures, being 6 -exo-trig and 7-exo-trig, are both ‘favored’ according to 
Baldwin92 so a mixture of cyclized products was expected.
I l l
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BocI
Bn'N>  C02Me I.MeOH, SOCI2
0 ^ N^ C° 2Me 2. MeOH, NH4OH 
H 4
183
Figure 4.12: The peptide cyclization step showing the opportunities for two isomeric products.
Interestingly, when the crude reaction product was analyzed by 1H and 13C 
NMR it was clearly shown to contain a single, major isomeric product. More 
careful inspection of the 1H NMR spectra indicated the presence of another 
product, but this made up < 2% of the total material. The major product was later 
proven to be the desired 6-membered piperazine dione 184, once the synthesis 
had been carried through to product 78. The selectivity for this single product is 
curious since both ring sizes are known to be relatively stable.
With the fortunate formation of a single major cyclized product, we 
proceeded with our synthesis (Scheme 4.11) and reduction of dione 184 with 
LiAIH4 in THF provided the crude piperazine alcohol 186 in 97% yield. Since this 
alcohol is a homolog of the alcohol 94 from the asymmetric MOM-NQP synthesis 
(Scheme 3.9, Chapter 3) we used the same synthetic strategy to generate target 
quipazine 78.
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Scheme 4.11: Complete synthesis of 2'-methoxyethyl-6-nitroquipazine using dimethyl aspartate 
amenable for asymmetric preparations.
The crude alcohol 186 was converted to N-formyl alcohol 187 that was 
alkylated with CH3-I to provide 188. After removal of the formyl group, 189 was 
coupled to 2-chloroquinoline to provide benzyl-protected quipazine 190. The 
removal of the benzyl group with ACE-CI, followed by the acidic work-up, 
provided unnitrated quipazine 77 in an excellent 97% yield. The 1H NMR spectra 
of 77 was identical to the material generated via the previously described route 
(Chapter 2, Scheme 2.9) confirming that 6-membered ring dione 184 had been 
generated upon cyclization of peptide 183. The nitration of 77 provided target
EtOMe-NQP 78. The alternate synthesis of 78 established proof of concept for
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the future asymmetric synthesis of 78, provided that racemization does not occur 
at some point. The racemic EtOMe-NQP 78 generated via this route was 
synthesized in nine steps with a 40% overall yield from the amino acid starting 
materials.
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CHAPTER 5
BIOLOGICAL DATA
5.1 Serotonin Transporter Binding Affinity of Target Ligands
The initial evaluation of our new ligands is performed though a standard 
radioligand displacement binding assay. The method utilizes the procedure of 
Habert142 as described by Mathis143 and it is summarized below. The assay is 
used to determine the binding affinty (K i) of the ligands at SERT. Lower Kj values 
(more dillute concentrations) represent higher affinity ligands.
Tissue Preparation -  The cerebral cortex from commercially available (Pel- 
Freeze Biologicals, Inc.) frozen male rat brains is suspended in twenty volumes 
of 50 mM Tris-HCI buffer (pH 7.4 at ambient temperature) and homogenized. 
The brain mixture is centrifuged and the supernatant decanted. The tissue pellet 
was suspended in the same volume of Tris-HCI buffer and heated at 37 °C for 10 
min before centrifuging and decanting the supernatant. The final tissue 
suspension is generated by adding 50 mM Tris-HCI buffer (~ 1 mL for every 
milligram of wet tissue) containing 5 mM KCI and 120 mM NaCI to the pellet and 
mixing. The brain prep suspension is used immediately in the assay.
Radioligand Displacement Binding A ssay- To the tissue preparation suspension 
(0.8 mL) is added a solution of [3H]Paroxetine ([3H]Px) in Tris-HCI buffer (0.1 mL, 
2 - 3  nM, final concentration of 0.2 -  0.3 nM) followed by decreasing
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concentrations of challenge ligand (0.1 mL, 10'5 -  10'10 M; final concentrations of 
10"6 — 10"11 M) to give a total assay volume of 1.0 mL. Three assay solutions 
were prepared for each concentration of challenge ligand. Total binding (defined 
below) was determined by adding 0.1 mL of [3H]Px solution and 0.1 mL of Tris- 
HCI buffer (no challenge ligand) to 0.8 mL of tissue solution. Non-specific 
binding was determined by adding a solution of 6-Nitroquipazine 22 in Tris-HCI 
buffer (0.1 mL, 10 pM, final concentration 1 pM) to 0.1 mL of [3H]Px solution 0.8 
mL of tissue solution. The mixtures were incubated at 25 °C for 3 hours then 
diluted with 5 mL of cold (4 °C) Tris-HCI buffer. These solutions were rapidly 
filtered through Schleicher and Schuell #32 glass fiber filters (presoaked with 
0.5% polyethyleneamine solution) using a Brandel cell harvester (protein is 
collected on the filter, unbound [3H]Px is washed away). The filters were washed 
twice with 5 mL of cold Tris-HCI buffer, transferred to scintillation vials and 
scintillation fluid was added. The radioactivity remaining on the filters ([3H]Px still 
bound to protein) was determined using a Packard 1500 Tri-Carb liquid 
scintillation counter.
Data Analysis -  The total specific binding of [3H]Px to SERT is defined as the 
difference between total binding and nonspecific binding. Total binding is the 
total amount of [3H]Px that was bound to protein, including specific and 
nonspecific interactions. Nonspecific binding is determined using a high 
concentration (1 pM) of the non-radioactive, selective SERT ligand 6-NQP 22. 
Since the high concentration (4000 fold or greater) of 22 results in nearly all of 
the available SERT being bound by 22, the radioactivity present after filtration
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represents the [3H]Px that was bound to other macromolecules in the assay 
matrix.
The [3H]Px binding observed for test agent samples is reported as a 
percentage of the total specific binding. When this data is plotted, a binding 
curve like that shown in Figure 5.1 will result.
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Figure 5.1: Sample binding curve from a radioligand displacement binding assay. No error bars 
are indicated. The dotted lines demonstrate an estimation of the IC50 value.
For our experiments, each data point is an average of three 
determinations from the same assay. Since the figure above is an example, no 
error bars are indicated. Using GraphPad Prism software IC50, (inhibitor 
concentration that blocks 50% of [3H]Px binding) values were determined. On 
the above graph this value can be estimated as a concentration slightly less than 
10'8 M. The inhibition binding constant (Kj) is determined from the IC50 values 
using the following equation: Kj = IC50/(1 + [L]/Kd).144 Where [L] = concentration
117
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
of [3H]Px used in the assay (0.2 -  0.3 nM) and KD = 0.15 nM (known constant142). 
Final Kj values are reported as an average of at least three different assay 
determinations on different days. A standard ligand, 6-NQP 22 (known Kj = 0.16 
nM), was analyzed in each assay to evaluate assay performance.
Table 5.1: Comprehensive SERT binding affinity data for all racemic compounds from our lab that 
have been tested. The entries above the dotted line were also shown in Table 1.3.
0 2N
R acem ic T a rg e ts
r 2
Cm pd. R i r 2 K| (p M ) Ref.
22 H H 163 ±  53 64
24 c h 3 H 81 ±  61 64
25 H c h 3 4560 ±  2400 64
35 CH2OCH3 H 2.48 ±  0.28 70
55 CH2OH H 12.7 ±  3.0 a
61 c h 2o c h 2c h 2c h 2f H 3.96 ±  0.88 a
4 8 c h 2c h 2c h 2o c h 3 H 2.12 ±  1.13 74
50 c h 2c h 2c h 2f H 2.48 ±  0.19 74
191 c h 2c h 2c h 3 H 41.5  ±  19.9 74
1 92 c h 2c h 2c h 2c h 2c h 2f H 79.6  ±  21.2 74
aPresent study
A comprehensive summary of our SERT binding data for racemic targets 
is presented in Table 5.1 (Data above the dashed line was also shown in Table 
1.3). From our initial SAR studies, discussed in Chapter 1, we demonstrated a 
56 fold decrease in SERT binding affinity with the 3’-methyl positional isomer 25 
relative to the 2’-isomer 24. As a result, we maintained the alkyl substituents at 
the 2’-position for all of our quipazine targets. This ligand design strategy has 
proven successful, as all new racemic targets (55 and 61, present study; 48, 50,
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191, 192, Kusche, 2006) have demonstrated sub-nanomolar binding affinity at 
SERT that remains improved relative to parent ligand 6-NQP 22.
An interesting trend from the SAR data suggests an oxygen heteroatom in 
the side chain provides an enhancement SERT binding affinity. This trend can 
be observed by comparing side chains of similar length (excluding hydrogens). 
For example, MOM-NQP 35 and Prop-NQP 191 both have three atoms in the 
side chain (MOM, C-O-C; Prom, C-C-C) and 35 demonstrates a 17-fold increase 
in binding affinity relative to 191. A similar trend is observed with MeProF-NQP 
61 (C-O-C-C-C) and PentF-NQP 192 (C-C-C-C-C) where 61 demonstrates a 20- 
fold increase in binding affinity relative to 192. It is plausible that the oxygen 
atom enhances SERT binding affinity by acting as a hydrogen bond acceptor in 
the Ar2 binding domain at SERT or as an electronegative contact for positively 
charged amino acid residues or ions (salt-bridge interactions). Interestingly, the 
alcohol side chain ligand 55 shows a slight decrease in SERT binding affinity 
relative to the methyl ether side chain analogs (35 and 48). This decrease in 
affinity may result from the OH group being a hydrogen bond donor, rather than 
an acceptor (like the methyl ethers). Additionally, moving the oxygen atom 
further from the piperazine ring does not seem to alter the enhanced binding 
affinity observed with oxygenated side chains, as evidenced by the low binding 
affinity of propyl analog 48.
A fluorine atom might also provide a similar contact, as evidenced by a 
comparison of ProF-NQP 50 and Prop-NQP 191, where a fluorine-for-hydrogen 
replacement is made at the end of the side chain. The fluorinated variant 50,
119
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
displays a 17-fold increase in potency over 191, a difference identical to that 
observed between 35 and 191.
The non-racemic 6-NQP analogs that have been evaluated by our group 
are shown in Table 5.2.
Table 5.2: SERT binding data for the non-racemic ligands.
N on-R acem ic  T a rg e ts  N '^ j
RV" l ^ NH
r2
Cm pd. R i r 2 K, (p M ) Ref.
(R )2 4 H c h 3 91 ±  16 103
(S )2 4 c h 3 H 68 ±  21 103
(S )3 5 H CH2OCH3 1* a
(R )  35 CH2OCH3 H 4 7 * a
aPresent s tudy; *P re lim ina ry  value
The enantiomers of 2’-methyl-NQP 24 did not demonstrate significant 
differences in SERT binding affinity, as evidenced by the overlap of their error 
bars. It is plausible the methyl side chain may be too short for a significant 
change in biological activity to be observed, as a result of stereoselective 
interactions at SERT. The enantiomers of the longer side chain MOM-NQP 35, 
have demonstrated more pronounced differences in their biding affinities, but 
reliable values have yet to be confirmed. The preliminary results indicate that an 
approximate 47-fold difference in affinity exits between the isomers, with the (S)- 
isomer (S>35 being the more potent form. The increased binding affinity 
observed for (SJ-35, relative to the racemate may result from a more optimal
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contact of the methoxymethyl side chain with the Ar2 binding region (see 
pharmacophore model Chapter 1, Figure 1.11). Likewise, the converse 
argument can be made for the decreased affinity of (R)-35. Efforts to establish 
more accurate Kj values for these targets are presently underway and we hope to 
confirm these values through determinations at an independent laboratory.
To date, the only compound from our work that has been tested for SERT 
selectivity is [3H]Prop-NQP 191.74 Since [3H]191 was not significantly displaced 
by the NET and DAT selective ligands, Nisoxetine and GBR12935 respectively, 
the interaction of [3H]191 with NET and DAT is presumed to be minimal.145 
Although the selectivity of [3H]191 suggests that collectively our family of 2’- 
substituted quipazines may demonstrate significant SERT selectivity, these 
results can not serve as a definitive measure of SERT selectivity for all new 
target ligands.
The target compounds from this study that remain to be tested for their 
binding affinity (K j) at SERT are shown in Figure 1.2.
Figure 5.2: New ligands from this study that remain to be tested for activity at SERT. The 2'-aryl 
agents also need to be evaluated for affinity moduation properties.
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More rigorous biochemical studies with the 2’-aryl-6-nitroquipazine ligands 
135 and 136 will serve to evaluate their affinity modulation properties at SERT as 
per the discussions in Chapter 4. The methods utilized for these studies will 
mirror those of Plenge124 that have been adapted for experiments in our 
laboratory.127
5.2 Preliminary in vivo Evaluation of Racemic PET Agent [18F]MeProF-
NQP
The new SERT PET radioligand [18F]MeProF [18F]61 has undergone 
preliminary in vivo evaluation in rats to determine whole body organ tracer 
distribution. Within the brain, these studies were expanded to include the 
quantification of radioligand presence in discrete brain regions. This study also 
involved a preliminary evaluation of the in vivo metabolism of [18F]61 in blood 
plasma and brain. Our primary investigator, Dr. John Gerdes, performed these 
studies in collaboration with Dr’s Jim O’Neil, Scott Taylor and Jamie Eberling at 
the Lawrence Berkeley National Laboratory (LBNL). The scientists and facilities 
at this institution provide the necessary knowledge and resources for this study, 
including instrumentation dedicated to radiochemical experiments, a 
radiochemical synthesis lab and an on-site cyclotron for the preparation of the 
fluorine-18 tracer.
For all data collected in these studies, the following general procedure 
was used for the administration of tracer [18F]61 and sacrifice of the animals: 
Radiotracer [18F]61 was synthesized according to the synthetic protocols detailed
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in Chapter 2, Section 2.7. Male Sprague-Dawley rats were anesthetized and 
received a 35 -  50 pCi tail vein injection of radioligand [18F]61 in a saline matrix. 
Following a set period of time (15, 30, 60, 120 or 240 min), the animal was 
sacrificed with a large dose of anesthetic followed by exsanguination. The 
subsequent data collection protocols are summarized below.
Blood Metabolism -  Radioligand metabolism in blood was determined at 15 and 
60 minutes post injection. Blood was collected from the sacrificed animal and 
centrifuged. The supernatant blood plasma was decanted, extracted with MeOH 
and the mixture centrifuged to separate the layers. The methanolic extracts were 
first analyzed by UV/radioactive TLC and for both the 15 and 60 minute extracts 
the major radioactive product had an Rf that matched an unlabelled, standard 
sample of 61. The methanolic extract was further analyzed by reversed phase 
HPLC (UV and radioactivity detection) using a coinjection of unlabelled standard 
61. The major (> 95%) radioactive fraction had a retention time identical to that 
of unlabelled 61. These results were consistent at 15 and 60 minutes and 
suggest that tracer [18F]61 is relatively inert to metabolic degradation in the blood 
or the metabolites are not detected by this method.
Brain Metabolism -  Radioligand metabolism in the brain was determined at 60 
and 240 minutes post injection. Following sacrifice, the brain was carefully 
removed, placed in buffer and homogenized. The brain homogenate was 
extracted with methanol and the mixture centrifuged to separate the layers. The
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analysis of the brain extracts was identical to those from the blood, and again the 
major (> 95%) radioactive fractions for both time points (60 and 240 minutes) 
was parent radioligand [18F]61.
Whole Body Tracer Distribution -  Organ tracer distribution measurements were 
collected at 15, 30, 60, 120 and 240 minutes. Following sacrifice, the organs 
were carefully excised and the tissues analyzed for radioactivity (counted). The 
data for each time point represent an average of three replicate measurements 
from separate animals and the results are decay corrected. The whole body 
tracer distribution data is presented in Figure 5.3.
Figure 5.3: Whole body rat tracer distribution data with [18F]MeProF. Data is reported as an 
average of three measurements. The brain study (boxed) was expanded to include brain sub- 
regions (Figure 5.4)
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The distribution data demonstrate adequate brain penetration of the 
radioligand. The penetration was rapid (maximal radioactivity after 15 min) and 
tracer washout was observed over the experiment time course (gradual decline 
in radioactivity from 30 -  240 minutes). The gradual increase in radioactivity 
observed in bone (femur) suggests that ionic fluorine-18 is being generated as a 
result of some metabolic defluorination.
The tracer distribution study was extended to sub-regions of the brain to 
evaluate regional brain uptake as function of relative SERT distributions. 
Following animal sacrifice, the brains were carefully removed and the discrete 
brain regions were meticulously dissected and the radioactivity counted. The 
data for each time point represent an average of three replicate measurements 
and the results are decay corrected. The regional brain tracer distribution data is 
presented in Figure 5.4.
C e re b e l lu m  H y p o t h a la m u s  Cor t  m . H ip p o c a m p u s  B lo o d
Brain Tissues and Blood
Figure 5.4: Rat tracer distribution data for discrete brain regions. Data is reported as an average 
of three measurements.
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The greatest radiotracer uptake was observed in the SERT rich hypothalamus, 
and the moderate density cortex, and hippocampus. Radioligand uptake in the 
cerebellum, known to have low SERT densities, was reduced relative to the other 
regions and washout of the tracer was observed over the experiment time 
course. The radioactivity in the cerebellum after 240 minutes was almost 
equivalent to the amount in blood suggesting that minimal nonspecific binding is 
observed. At 240 minutes, the target (hypothalamus, cortex, hippocampus) to 
non-target (cerebellum) ratios of radiotracer accumulation were greater-than or 
equal to two. The preliminary results demonstrate that [18F]61 may provide 
quantitative determination of SERT densities within moderate and low density 
target regions. Furthermore, the metabolic analyses suggest that [18F]61 does 
not succumb to measureable metabolic degradation, with the exception of some 
in vivo defluorination as evidence by the accumulation of radioactivity in bone.
Additional studies to evaluate the performance of [18F]61 in rats and non­
human primates are underway at LBNL. Currently, a rat micro-PET study is 
being planned to compare racemic [18F]61 with both (R)- and (S)- forms of the 
tracer. Following this study, a non-racemic [18F]61 PET agent may be identified 
that possesses superior rodent in vivo qualities over its enantiomer and the 
racemate. Non-human primate studies in macaque monkeys with racemic 
[18F]61 have also begun. These studies will be invaluable for determining if 
[18F]61 possesses the necessary in vivo characteristics to advance it as PET 
agent for human imaging studies. The quantification of target to non-target 
binding ratios in primates is a critical determinant for ligand advancement.
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Additional primate study components will involve a more rigorous treatment of 
metabolite formation including the identification of metabolic products with 
tandem liquid chromatography-mass spectroscopy.
At the close of these studies, we hope to have identified a non-racemic 
[18F]61 lead agent that we will advance for imaging human SERT. Follow up 
studies will compare our lead agent to the current standard SERT PET agents 
[11C]DASB 13 and [11C]AFM 14. Following these studies, the efficacy of our 
tracer to target the SERT shall be established.
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CHAPTER 6
CONCLUSIONS AND FUTURE WORK
This study has successfully identified [18F](rac)-MeProF-NQP [18F]61 as a 
new candidate SERT PET imaging agent (Figure 6.1).
[18F]61 13 14
Figure 6.1: New SERT PET agent [18F](rac)-MeProF-NQP and current standard ligands DASB 15 
and [11C]AFM 16.
The in vivo properties, demonstrated thus far in rat, provide compelling 
evidence that [18F]61 may emerge as new standard SERT agent. What remains 
to be seen, is will [18F]61 meet the necessary in vivo performance requirements 
in non-human primates? Will [18F]61 or one of the non-racemic variants, provide 
the signal to noise ratios necessary for the reliable quantification of medium and 
low density SERT regions? Importantly, will [18F]61 outperform the current 
standard SERT PET agents DASB 13 and [11C]AFM 14 in comparison studies? 
The answers to these questions are currently being sought in collaboration with 
researchers at LBNL.
This dissertation has also demonstrated relatively simple routefs) to non- 
racemic 6-nitroquipazine analogs using an efficient asymmetric synthesis 
methodology adapted from the method of Naylor.111 For the syntheses of (R)-
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and (S)- MOM-NQP 35 and MeProF-NQP 61, a key intermediate 122 was 
identified that would provide all of the target compounds in the series (Figure 
6 .2).
N N '^  - N
H O ^L^N B n NH
H
(S )-35
H
(S)-122 (S)-61
H
N
HO' ^ \ ^ NBoc
H
(S )-58
H
[11C](S)-35 [18F](S)-61
Figure 6.2: Intermediate N-benzyl alcohol fS>122 as a precursor for all asymmetric targets.
Intermediate (S) -122 provides the unradiolabelled targets ((S)-35 and (S)- 
61) and the key radiolabelling precursor intermediate (S)-58 that affords both 
target radioligands [^CJfSj-SS and [18F](S>61.
We have also demonstrated that the method of Naylor can readily be 
adapted to other amino acids starting materials. Chapter Four of the present 
study was dedicated to a discussion of these efforts as they related to the 
synthesis of our 2’-aryl-6-nitroquipazine analogs 135 and 136 and an alternate 
synthesis of EtOMe-NQP 78 (Figure 6.3a). Brian Kusche has adapted Naylor’s 
method to perform asymmetric syntheses of 6-NQP analogs with three, four and
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five carbon side chains (48, 195 and 196), beginning with both isomers of 
glutamic acid 193 (Figure 6.3b). 74
a) Present study
O
H2Nv^ C 0 2Me H N ^ ^
161 Ar =  Ph 163 Ar =  Ph 135 Ar =  Ph
165 Ar =  Bn 1 6 7 A r  = Bn 1 3 6 A r  =  Bn
N
u
H2 N ^ C 0 2Me H N " N
HhrH\ C 0 2Me M e 0 2C ^ / ^  NBn O
182 184
NH
78
b) Kusche, 2006
H^^COaH 
’ H HN
NBn
194
N N
COgH Me° 20'  C H ,0 (C H 2)n' ^ ' NH
48 n =  3
193  195 n =  4
196 n =  5
Figure 6.3: Summary new SERT agents synthesized using the methodology of Naylor, with 
different amino acid starting materials, 
were synthesized in non-racemic form.
. Although not indicated, the compounds from Kusche74
We have now successfully utilized five different amino acid starting 
materials for the synthesis of novel 6-NQP analogs. The potential to discover 
additional SERT ligands using this methodology is obvious and the utilization of 
unnatural or synthetic a-amino acids provide endless opportunity for 
diversification at the 2’-position of quipazine. The incorporation of heteroatoms 
other than oxygen, particularly sulfur and nitrogen, would provide additional SAR
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data for the Ar2 biding region of SERT and also a handle for the introduction of 
radionuclides.
What is most lacking from this work is a complete set of biological data. 
Unfortunately, technical issues have limited the amount of SERT binding data 
that has been collected. The determinations of the Kj values for all of the ligands 
developed here are in progress. However, new compounds that have been 
rigorously tested have demonstrated very high affinity for SERT with Kj values in 
the low picomolar range (Figure 6.4).
Figure 6.4: New SERT ligands from this study and their determined SERT binding affinity.
The selectivity of new compounds for SERT relative to the other biogenic 
amine transporters, NET and DAT, still needs to be evaluated. Despite the 
promising preliminary in vivo PET data accumulated for [18F](rac)-MeProF-NQP, 
it is still possible that a lack of selectivity for SERT may limit its use as an 
effective SERT tracer.
H
55
K| =  12.7 +/- 3 .0 pM
H
61
Kj = 3.96 +/- 0 .88 pM
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CHAPTER 7
EXPERIMENTAL
7.1 General Methods
All reagents and solvents were purchased from commercial suppliers 
(Aldrich, Acros, Alfa Aesar, Fisher Scientific, VWR, Lancaster) and used without 
further purification unless otherwise stated. Anhydrous dichloromethane 
(CH2CI2, DCM) was distilled from calcium hydride (CaH2) or purchased from a 
chemical supplier. Anhydrous tetrahydrofuran (THF) and diethyl ether (ether, 
Et20) were distilled from Na/benzophenone or purchased from a chemical 
supplier. Anhydrous N,N-dimethylformamide (DMF), 1,2-dichloroethane (DCE), 
1,2-dimethoxyethane (DME), carbon tetrachloride (CCU), dimethylsulfoxide 
(DMSO), pyridine, triethylamine (TEA, EtaN), benzene and chlorobenzene (Cl- 
Ben) were purchased from commercial suppliers. Dihydropyran (DHP) was 
distilled prior to use. Recrystallization of p-toluenesulfonyl chloride (tosyl 
chloride, Ts-CI) was according to the method of Armarego.146 Solutions of n- 
butyllithium were titrated prior to use.147 Methyltriphenylphosphonium iodide was 
synthesized according to the method of McCortney.148
All non-aqueous reactions were carried out in oven-dried glassware and 
magnetically stirred unless otherwise stated. Reactions requiring anhydrous 
conditions were run under an atmosphere of argon. Brine, refers to a saturated 
aqueous solution of non-iodized salt, available at a grocery store. Water refers to
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deionized water. All aqueous solutions were prepared using deionized water. 
For all reactions, the dried (K2CO3, MgS(>4 or Na2SC>4 as indicated) organic 
phases were filtered (fluted filter paper or cotton plug) prior to evaporation. All 
solvent evaporations and/or extract concentrations were performed with a Buchii 
rotary evaporator under reduced pressure. Thin-layer chromatography was 
performed with EM Science, Silica gel 60 F254 aluminum-backed plates. 
Visualization of TLC plates was facilitated with UV light (254 and 365 nm) and/or 
ninhydrin-staining (11 mM in EtOH). Column chromatography was performed 
with EM Science, Silica gel 60 (230-400 mesh ASTM). Chromatography solvent 
mixtures are reported as volume:volume ratios.
Nuclear magnetic resonance (NMR) spectra were obtained on a Varian 
Unity Plus 400 spectrometer. Proton NMR (1H NMR) spectra were recorded at 
400 MHz and the chemical shifts are reported in parts per million (ppm, 5) 
relative to residual protonated solvent signal (CDCI3, 7.26 ppm; D20 , 4.63 ppm; 
DMSO-cfe, 2.49 ppm). Carbon NMR (13C NMR) spectra were recorded at 100 
MHz and the chemical shifts are reported in parts per million (ppm, 6) relative to 
solvent signal (CDCI3, 77 ppm; DMSO-cfe, 39.5 ppm) or with 1,4-dioxane as an 
internal standard (for D2O; 67.4 ppm). Proton NMR spectra are reported as 
follows: chemical shift (multiplicity, coupling constant^ in Hertz, number of 
protons). Optical rotations were obtained on a Perkin-Elmer 241 Polarimeter at 
ambient, room temperature using a 10 cm (1 dm) cell. The concentration of the 
solutions analyzed is reported as; c = (grams of solute)/(solution volume in mL). 
Optical rotations were calculated using the relationship [a]*5 = a/Lc; where a  is
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the instrument reading, L is the length of the sample cell (1 dm) and c is the 
concentration of solute (described immediately above). Gas 
chromatography/mass spectroscopy (GC/MS) data was collected on an Agilent 
Technologies electron impact (El) 5973Network mass selective detector 
connected to an Agilent Technologies 6890N Gas Chromatography system 
equipped with an Agilient HP-5MS crosslinked 5% PH ME Siloxane column (30m 
x 0.25 mm; 0.25 micron). High-resolution mass spectra (HRMS) were obtained 
with a Micromass LCT electrospray ionization (ESI) spectrometer connected to a 
Waters 2790 Separations Module. A chromatography column was not used in 
these analyses. Biotage purifications were run on a Biotage Horizon Flash 
Collector connected to a Biotage Horizon Pump and Horizon Detector.
7.2 Experimentals
The synthetic procedures detailed in this section are organized by 
compound number in ascending order.
N N
1. ACE-CI, DCE 
reflux
2. MeOH, A
H
(7?J-(+)-2-[2-(Methoxymethyl)piperazin-1-yl]quinoline (R)-Z4. To a 0 °C
solution of methyl ether (RJ-109 (0.119 g, 0.34 mmol) in dry dichloroethane (8 
ml_) under argon was added 1-chloroethyl chloroformate (0.093 g, 0.65 mmol). 
After stirring at 0 °C for 10 min the flask was heated at reflux for 2.5 h. The
134
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solution was cooled slightly and the volatile components were evaporated. The 
residue was dissolved in methanol (10 ml_), heated at 60 - 70 °C for 1 h, and 
then the solvent was evaporated. The residue was dissolved in 15 ml_ 1 M HCI 
and washed with CH2CI2 ( 4 x 1 5  mL). The aqueous phase was made basic with 
4 M NaOH, diluted with saturated NaHC0 3  (20 mL) and extracted with CH2Cl2 ( 4  
x 10 mL). The combined extracts were dried (K2CO3) and concentrated to give 
(R)-34 as a pale colored oil (0.081 g, 92%). TLC F?,0.1 (MeOH:CH2CI2, 1:9). 1H 
NMR (400 MHz, CDCI3): 5 1.93 (bs, NH, 1H), 2.87 (m, 1H), 2.98 (dd, J = 4.0 Hz 
and 12.5 Hz, 1H), 3.11-3.20 (m, 2H), 3.29-3.37 (m, 4H, overlapped singlet at 
3.36, OCH3), 3.48 (dd, J = 4.8 and 9.2 Hz, 1H), 3.86 (m, 1 H), 4.36 (bd, 1 H), 4.57 
(bm, 1H), 6.97 (d, J =  9.2 Hz, 1H), 7.21 (m, 1H), 7.52 (m, 1H), 7.59 (m, 1H), 7.68 
(d, J=  8 .8  Hz, 1H), 7.88 (d, J =  9.2 Hz, 1H); 13C NMR (100 MHz, CDCI3): 5 41.4,
46.0, 46.2, 50.7, 59.0, 69.7, 109.1, 122.1, 126.5, 127.1, 129.4, 137.3, 147.8, 
156.9; (R) - [ a f  +103.4 (c 0.0086, CHCI3); HRMS (ESI-TOF) m/z (M + H)+ 
calcd. for C15H20N3O 258.1606 found 258.1610.
(,S>)-(-)-2-[2-(Methoxymethyl)piperazin-1-yl]quinoline fS)-34. The title 
compound was similarly prepared and provided identical spectroscopic data. (S) 
- [a]“  -102.2 (c 0.0101, CHCI3).
H
135
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o 2n 1. DMF, NaH 
CH3-I, 35 °C
0 2N
^  U l 1 w
N N ]   :------
H O ^ ^ ^ N B o c  2. CH2CI2, TFA 
H H
2-[2-(Methoxymethyl)piperazin-1-yl]-6-nitroquinoline 35. To a solution of N- 
Boc alcohol 58 (0.0077 g, 0.02 mmol) in dry DMF (1 mL) under argon was added 
sodium hydride (0.012 g, 0.5 mmol) producing a dark red mixture, lodomethane 
( 8  pL, 0.13 mmol) was added and the reaction flask placed in an oil bath at 35 
°C. An immediate color change to orange occurred and a TLC confirmed that the 
starting material had been consumed. The excess hydride was destroyed with a 
few drops of methanol and the reaction contents were partitioned between water 
and ether (10 mL each). The organic phase was separated and the aqueous 
phase extracted with two additional portions of ether (15 mL). The combined 
extracts were dried (K2CO3) and concentrated to give the crude product. The 
residue was dissolved in CH2CI2 and trifluoroacetic acid (5 mL each). After 
stirring 1.5 h the solution was made basic with 1:5 K2C0 3 .water solution. The 
aqueous phase was extracted with two 20 mL portions of CH2CI2. The extracts 
were dried (K2CO3) and concentrated to afford 35 as a yellow film (0.007 g, 
120%). TLC Rf 0.14 (MeOH:CH2CI2, 1:9). The product’s 1H NMR spectrum was 
consistent to the known spectra.67 1H NMR (400 MHz, CDCI3): 8  1.77 (bs, 1H),
2.87 (td, J = 3.3, 11.7 Hz, 1H), 2.98 (dd, J = 4.4, 12.5 Hz, 1H), 3.15 -  3.28 (m, 
2H), 3.32 (m, 1H), 3.37 (s, 3H), 3.60 (dd, J= 5.5, 9.2, 1H), 3.85 (dd, J = 7.7, 9.2 
Hz, 1H), 4.50 (bm, 1H), 4.66 (bm, 1H), 7.08 (d, J = 9.2 Hz, 1H), 7.65 (d, J = 9.2 
Hz, 1H), 7.96 (d, J = 9.2 Hz, 1H), 8.29 (dd, J = 2.6, 9.2 Hz, 1H), 8.54 (d, J = 2.6
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Hz, 1H); 13C NMR (100 MHz, CDCI3): 5 45.9, 46.3, 50.9, 59.1, 70.2, 110.9,
121.0, 123.5, 124.2, 127.0, 138.5, 141.7, 151.4, 158.5; HRMS (ESI-TOF) m/z (M 
+ H)+ calcd. for C15H19N4O3 303.1457 found 303.1448.
N
h 2s o 4, h n o 3 N
H H
fiR)-(+)-2-[2-(Methoxymethyl)piperazin-1-yl]-6-nitroquinoline (R)-Z5. To a 0
°C solution of (R)-ZA (0.038 g, 0.15 mmol) in conc. H2SO4 (2 mL) was added 
HNO3 (15.4 M, 0.038 mL, 0.59 mmol). The reaction was stirred 17 min then 
quenched by pipetting onto ice. The solution was basified with 4 M NaOH then 
diluted with saturated NaHC0 3  (10 mL). The bright yellow aqueous mixture was 
extracted with CH2CI2 ( 3 x 1 0  mL) and the combined extracts dried (K2CO3) and 
concentrated to provide (R)-35 as a bright yellow-orange oily solid (0.040 g, 
91%). TLC R f 0.14 (MeOH:CH2Cl2, 1:9). The spectroscopic data for (R)-Z5 was 
identical to that for the racemic material. (R ) - [a]“  +138.8 (c 0.0016, CHCI3).
S)-(-)-2-[2-(Methoxymethyl)piperazin-1-yl]-6-nitroquinoline (S)-35. The title 
compound was similarly prepared and provided identical spectroscopic data. (S ) 
- [a]“  -137.8 (c 0.0023, CHCI3).
H
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o2n o2n
HOv, A - ' NH
2-[2-(Hydroxymethyl)piperzin-1-yl]-6-nitroquinoline 55. To 58 (0.035 g, 0.090 
mmol) dissolved in THF (2 mL) was added H2S 0 4 (4 M, 5 mL) and the solution 
stirred at ambient temperature until a TLC showed consumption of starting 
material (~2 h). The solution was pipetted into cold 4 M NaOH ( 8  mL) then 
diluted with saturated NaHC0 3  (10 mL). The aqueous mixture was extracted 
with CH2CI2 ( 4 x 8  mL) and the combined extracts were dried (K2CO3) and 
concentrated to provide 55 as an oily bright yellow solid (0.019 g, 73%). TLC Rf 
0.04 (MeOH:CH2CI2, 1:9). 1H NMR (400 MHz, CDCI3): 5 2.70 -  3.10 (bs, 2H) 
overlapped with 2.92 (td, J = 3.3, 11.7 Hz, 1H), 3.07 (dd, J = 4.0, 11.7 Hz, 1H),
3.21 (bd, J =  11 Hz, 1H), 3.36 (bd, J =  12.1 Hz, 1H), 3.56 (td, J = 3.3, 12.5 Hz, 
1H), 4.02 (dd, J = 4.4, 11 Hz, 1H), 4.15 (dd, J = 5.5, 11 Hz, 1H), 4.26 (bd, J =
12.5 Hz, 1H), 4.83 (bs, 1H), 7.08 (d, J = 9.5 Hz, 1H), 7.61 (d, J = 9.5, 1H), 7.96 
(d, J = 9.5 Hz, 1H), 8.28 (dd, J = 2.6, 9.5 Hz, 1H), 8.52 (d, J = 2.6 Hz, 1H); 13C 
NMR (100 MHz, CDCI3): 5 42.7, 46.0, 48.2, 52.0, 64.7, 111.2, 121.1, 123.7,
124.2, 127.0, 138.7 141.9, 151.1, 159.1; HRMS (ESI-TOF) m/z (M + H)+ calcd. 
for C14H17N4O3 289.1301 found 289.1304.
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o2n 1. BBr3, CH2 CI2 
-78 °C
0 2N
N ^ |
u  2. Boc20 , CH2CI2
M3O ^ H° ^ rrPk ^ N B°c
2-[4-(ferf-Butoxycarbonyl)-2-(hydroxymethyl)piperazin-1-yl]-6-nitroquinoline
58. To a -78 °C stirring solution of MOM-NQP 35 (0.143 g, 0.474 mmol) in dry 
CH2CI2 (75 mL) under argon was added (dropwise) borontribromide solution (1 M 
in CH2CI2, 2.37 mL, 2.37 mmol). The addition turned the mixture black initially 
and then faded to a turbid orange. The reaction was maintained at -78 °C for 3 
h then warmed to ambient temperature and stirred 18 h. The reaction was 
quenched with saturated NaHC0 3  (20 mL), transferred to a separatory funnel 
and shaken vigorously. The organic phase was separated and the aqueous 
layer extracted with CH2CI2 (30 mL) and CHCl3:isopropyl alcohol, 4:1 (3 x 30 
mL). The combined organic phases were dried (K2CO3), and concentrated to 
give a crude residue. The crude residue was dissolved in about 2 0  mL of CH2CI2 
and to this was added a solution of di-ferf-butyldicarbonate (0.124 g, 0.569 mmol) 
in CH2CI2 (5 mL). The solution was stirred for 5 min, concentrated and the 
residue purified by column chromatography (silica gel, EtOAc:Hexanes, 3:2) to 
afford 58 as a bright yellow foam (0.129 g, 70%). TLC Rf 0.11 (EtOAc:Hexanes, 
2:3). 1H NMR (400 MHz, CDCI3): 5 1.47 (s, 9H), 3.09 -  3.62 (bm, 4H), 3.66 -  
3.96 (bm, 2H), 3 .9 8 -4 .4 3  (bm, 3H), 4.82 (bm, 1H), 7.07 (d, J =  9.2 Hz, 1H), 7.61 
(d, J = 9.2 Hz, 1H), 7.97 (d, J = 9.2 Hz, 1H), 8.25 (dd, J = 2.6, 9.2 Hz, 1H), 8.47 
(d, J = 2.6 Hz, 1H); 13C NMR (100 MHz, CDCI3): 5 28.2, 40.2 (broad), 42.5 
(broad), 43.9 (broad), 53.9, 59.8 (broad), 61.2 (broad), 80.5, 111.0 (broad),
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121.1, 123.5, 124.0, 126.7, 138.7, 141.8, 150.6, 155.5 (broad), 158.8 (broad); 
HRMS (ESI-TOF) m/z (M + H)+ calcd. for Ci9H25N40 5 389.1825 found 389.1810.
o 2n
(R)-58
N ^ |
HO\ o' K ^ NBoc H O ^ jk ^ N B o c
-  H (S>58 H
(R)-{+)- and (rS)-(-)-2-[4-(fert-Butoxycarbonyl)-2-(hydroxymethyl)piperazin-1 - 
yl]-6-nitroquinoline (R)-5S and (S)-58. The title compounds were similarly 
prepared and provided identical spectroscopic data. (R)-58 - [a]“  +93.3 (c 0.012, 
CHCIs); (S)-58 - [ a ] * -91.4  (c 0.013, CHCI3).
(7?)-2-[4-(tert-butoxycarbonyl)-2-(Hydroxymethyl)piperazin-1-yl]-6- 
nitroquinoline (R)-58. To a 0 °C solution of acetate (R)-129 (0.108 g, 0.378 
mmol) in conc. H 2S O 4 (7 mL) was added (dropwise) H N O 3 (15.4 M, 0.1 mL, 1.54 
mmol). After stirring 15 min at 0 °C the reaction mixture was carefully pipetted 
into 200 mL of cold saturated N aH C C >3 in a separatory funnel containing ice. The 
bright yellow aqueous mixture was extracted with C H 2C I2 (3 x 40 mL) and the 
combined extracts were dried (K 2C O 3) and treated with di-fe/f-butyldicarbonate 
(0.20 g, 0.917 mmol). When a TLC showed that amine protection was complete, 
the solvent was decanted from the drying agent and evaporated. The residue 
was dissolved in methanol (10 mL) treated with K 2C O 3 and stirred at ambient
2. B oc20
3. K0 CO0 , MeOH
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temperature for ~ 1 h. A TLC showed consumption of starting material and the 
methanol was evaporated and the residue partitioned between 20 mL each of 
saturated NaHC0 3  and CH2CI2 . The organic phase was separated and the 
aqueous phase extracted with CH2CI2 ( 2 x 1 0  mL). The combined extracts were 
dried (K2CO3) and concentrated to provide the crude material that was purified by 
column chromatography (silica gel, EtOAc:Hexanes, 2:3 -  3:2) to provide (R)-58 
as a yellow foam (0.074 g, 50%). This product was spectroscopically identical to 
the 58 generated via the alternate BBr3 deprotection route.
2-[2-((3-Fluoropropoxy)methyl)piperazine-1-yl]-6-nitroquinoline 61. To a
solution of tosylate 65 (0.0238 g, 0.040 mmol) in dry THF (400 pL) was added a 
solution of TBAF in THF (1 M, 0.06 mL, 0.06 mmol). The reaction was sealed 
under argon and heated at 55 -  60 °C for 3 h. After cooling, the THF was 
evaporated and the residue was purified by column chromatography (silica gel, 
EtOAc:Hexanes, 1:3) to afford the N-Boc protected intermediate as a yellow film 
(0.0137 g, 77%). TLC Rf 0.27 (EtOAc:Hexanes, 2:3). To the intermediate N-Boc 
fluoride (0.0217 g, 0.048 mmol) in a flask at 0 °C was added cold (-10 °C) conc. 
H2SO4 (3 mL). Immediate bubbling was observed as the N-Boc group 
deprotected and the flask was swirled to clear the sides of material. After 5 min 
the contents were pipetted onto ice, made basic with 4 M NaOH and further 
diluted with saturated NaHCOs. The yellow aqueous mixture was extracted with
1. THF, TBAF
NBoc
H H
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CH2CI2 ( 3 x 1 0  mL) and the combined extracts dried (K2CO3) and concentrated to 
give the crude material that was purified by column chromatography (silica gel, 
MeOH:CH2Cl2, 1:39 -  1:19) to afford 61 as a yellow film (0.013 g, 80%). TLC Rf 
0.16 (MeOH:CH2CI2, 1:9). 1H NMR (400 MHz, CDCI3): 5 1.80 -  2.00 (m, 3H, 
overlapped bs of NH  and dp, Jf-h = 26.0 Hz, FCH2CH2-, Jh-h = 6.2 Hz), 2.87 (m, 
1H), 2.99 (m, 1H), 3 .1 2 -3 .3 6  (m, 3H), 3.58 (t, J = 6.2 Hz, 2H), 3.68 (dd, J =  5.5,
9.5 Hz, 1H), 3.88 (dd, J = 7.3, 9.5 Hz, 1 H), 4.44 (dt, JF.h = 47.2, FCH2-, Jh-h = 5.9 
Hz, 2H, overlapped with a bs at 4.50, 1H), 4.66 (bs, 1H), 7.08 (d, J =  9.2 Hz, 1H), 
7.63 (d, J = 9.2, 1H), 7.95 (d, J = 9.2, 1H), 8.28 (dd, J = 2.6, 9.2 Hz, 1H), 8.52 (d, 
J = 2.6, 1H); 13C NMR (100 mHz, CDCI3): 5 30.7 (JC-f =  19.8 Hz, FCH2CH2-), 
41.3, 45.9, 46.4, 50.0, 67.0 (JC-f = 6 .1  Hz, FCH2CH2CH2-), 68.5, 81.0 (JC-f = 
164.8 Hz, FCH2-), 111.1, 121.1, 123.6, 124.2, 127.1, 138.4, 141.8, 151.4, 158.7; 
HRMS (ESI-TOF) m/z (M + H)+ calcd. for C17H22N4O3F 349.1676 found 
349.1674.
(R)-(+)-2-[2-((3-Fluoropropoxy)methyl)piperazine-1-yl]-6-nitroquinoline (R)-
61. To a 0 °C solution of (R)-127 (0.065 g, 0.214 mmol) in conc. H2SO4 (6 mL) 
was added HNO3 (15.4 M, 0.028 mL, 0.431 mmol). The reaction was stirred for 
17 min then quenched by pipetting onto ice. The solution was made basic with 4 
M NaOH then diluted with saturated NaHC0 3  (20 mL). The bright yellow 
aqueous mixture was extracted with CH2CI2 (3 x 20 mL) and the combined
H H
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extracts dried (K2CO3) and concentrated to provide the crude product that was 
purified by column chromatography (silica gel, four column lengths 
EtOAc:Hexanes, 4:1, then MeOH:CH2Cl2, 1:39 -  1:9) to provide (R)-61 as a 
bright yellow-orange oil (0.070 g, 93%). TLC Rf 0.16 (MeOH:CH2Cl2, 1:9). This 
product was spectroscopically identical to the 61 formed via the alternate N-Boc 
protected route. (R) - [a]^ +111 .6  (c 0 .0 0 2 1 , CHCI3).
fS>)-(-)-2-[2-((3-Fluoropropoxy)methyl)piperazine-1-yl]-6-nitroquinoline (S)- 
61. The title compound was similarly prepared and provided identical 
spectroscopic data. (S) - [ a ] * 5 -113.2 (c 0.0011, CHCI3).
2-[4-(ferf-Butoxycarbonyl)-2-(allyloxymethyl)piperazine-1-yl]-6- 
nitroquinoline 63. To a 0 °C solution of Boc alcohol 58 (0.194 g, 0.50 mmol) in 
dry DMF (8 mL) under argon was added NaH (95%, 0.046 g, 1.92 mmol) in one 
portion. Allyl bromide (0.302 g, 2.5 mmol) was added (dropwise) to the deep red 
mixture and the reaction warmed to ambient temperature. After stirring 1.5 h a 
TLC showed consumption of starting material and the reaction mixture was 
carefully added to a separatory funnel containing ether (30 mL) and 16 mL each 
of water and saturated NaHC0 3 - The aqueous phase was separated and the
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organic phase was washed with brine (2  x 2 0  mL), dried (K2CO3) and 
concentrated to provide the crude material that was purified by column 
chromatography (silica gel, EtOAc:Hexanes, 2:3) to afford 63 as a bright yellow 
foam (0.192 g, 90%). TLC R f  0.33 (EtOAc:Hexanes, 2:3). 1H NMR (400 MHz, 
CDCI3): 5 1.49 (s, 9H), 2.96 -  3.37 (bm, 3H, includes dd at 3.17), 3.49 -  3.68 (m, 
2H, includes t at 3.61), 3.93 -  4.78 (bm, 6 H, includes bs at 4.00 and bd at 4.30), 
5.04 -  5.31 (bm, 2H), 5.82 (bm, 1H), 7.08 (d, J  = 9.2 Hz, 1H), 7.63 (d, J  = 9.2 Hz, 
1H), 7.95 (d, J  = 9.2 Hz, 1H), 8.25 (dd, J  = 2.6, 9.2 Hz, 1H), 8.49 (d, J  = 2.6 Hz, 
1H); 13C NMR (100 MHz, CDCI3): 5 28.3, 40.0 (broad), 42.6 (broad), 43.7 
(broad), 51.6 (broad), 6 6 .6  (broad), 72.2, 80.1, 111.0,117.0, 121.1, 123.5, 124.1,
127.2, 134.3, 138.6, 141.9, 151.1, 154.9, 158.4; HRMS (ESI-TOF) m/z (M + H)+ 
calcd. for C22H29N4O5 429.2138 found 429.2119.
(R)-{+)- and (S)-(-)-2-[4-(ferf-Butoxycarbonyl)-2-(allyloxymethyl)piperazine-1 - 
yl]-6-nitroquinoline (R)-63 and (S)-6Z. The title compounds were similarly 
prepared and provided identical spectroscopic data. (R) -63 - [a ] * 5 +89.4 (c 
0.0086, CHCI3); (S) -63 - [a]*5-8 3 .0  (c 0.010, CHCI3).
(R)-63 (S)- 63  H
144
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2-[4-(fert-Butoxycarbonyl)-2-((3-hydroxypropoxy)methyl)piperazine-1-yl]-6- 
nitroquinoline 64. To the allyl ether 63 (0.075 g, 0.175 mmol) in dry THF (600 
pL) under argon was added a solution of 9-BBN in THF (0.5 M, 950 pL, 0.475 
mmol). The reaction was heated to 55 °C and maintained for 1 h. After cooling 
to 0 °C 0.6 mL of 1 M NaOH was added (dropwise) followed by 0.6 mL of 30% 
H2O2. The mixture was stirred for 5 min and a TLC confirmed consumption of 
starting material. The mixture was poured into 20 mL of saturated NaHC03 and 
the aqueous phase extracted with CH2CI2 ( 3 x 1 0  mL). The combined extracts 
were dried (K2CO3) and concentrated to give the crude material that was purified 
by column chromatography (silica gel, EtOAc:Hexanes, 3:2) to afford 64 as a 
bright yellow foam (0.057 g, 73%). TLC Rf 0.11 (EtOAc:Hexanes, 2:3). 1H NMR 
(400 MHz, CDCI3): 5 1.49 (s, 9H), 1.73 (bm, 2H), 2.98 -  3.37 (bm, 3H), 3.41 -  
3.89 (bm, 7H), 4 .0 2 -4 .5 3  (bm, 3H), 4.71 (bm, 1H), 7.06 (d, J =  9.2 Hz, 1H), 7.64 
(d, J =  9.2 Hz, 1H), 7.96 (d, J = 9.2 Hz, 1H), 8.25 (dd, J =  2.6, 9.2 Hz, 1H), 8.49 
(d, J = 2.6 Hz, 1H); 13C NMR (100 MHz, CDCI3): 5 28.3, 32.1, 40.1, 42.5, 43.8,
51.7, 59.1, 61.2, 66.8, 67.6, 68.5, 70.3, 80.5, 110.8, 121.2, 123.6, 124.2, 127.2, 
138.8, 142.0, 151.0, 154.9, 158.3; HRMS (ESI-TOF) m/z (M + H)+ calcd. for 
C22H31N4O6 447.2244 found 447.2226.
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(R)-64 H
(R)-(+)- and (,SJ)-(-)-2-[4-(tert-Butoxycarbonyl)-2-((3-hydroxypropoxy)methyl) 
piperazine-1-yl]-6-nitroquinoline (R)-64 and (S)-64. The title compounds were 
similarly prepared and provided identical spectroscopic data. (R)-64 - [a]“  +38.9 
(c 0.0055, CHCI3); (S)-64 - [a]“  -37.5 (c 0.0067, CHCI3).
CH2CI2i Pyridine Tl T I
I I Tosyl chloride \ I
HO-^/v^^O^^jJ^^NBoc T s O ^ /^ O ^ A ^ N B o c
2-[4-(tert-Butoxycarbonyl)-2-((3-(4-methylbenzenesulfonate)propoxy) 
methyl)piperazine-1-yl]-6-nitroquinoline 65. To a 0 °C solution of alcohol 64 
(0.095 g, 0.213 mmol) in dry CH2CI2 (1.2 mL) and pyridine (100 pL) was added 
p-toluenesulfonyl chloride (0.170 g, 0.895 mmol) in one portion. The reaction 
was sealed under argon and maintained in an ice bath until the bath warmed to 
ambient temperature. After 24 h the reaction contents were partitioned between 
saturated NaHC0 3  (20 mL) and CH2CI2 (10 mL). The organic phase was 
separated and the aqueous phase was extracted with CH2CI2 ( 2 x 1 0  mL). The 
combined extracts were dried (K2CO3) and concentrated to give the crude 
material that was purified by column chromatography (silica gel, EtOAc:Hexanes, 
1:3 -  2:3) to afford 65 as a bright yellow foam (0.103 g, 80%). TLC Rf 0.22 
(EtOAc:Hexanes, 2:3). 1H NMR (400 MHz, CDCI3): 5 1.48 (s, 9H), 1.79 (bm, 2H),
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2.42 (s, 3H), 2.94 -  3.30 (bm, 3H), 3.44 -  3.60 (bm, d shaped, 4H), 4.02 (bm,
2H), 4.10 - 4.24 (m, 2H, includes d at 4.20), 4.50 (bm, 1H), 4.65 (bm, 1H), 7.07
(d, J =  9.2 Hz, 1H), 7.30 (d, J =  8.1 Hz, 2H), 7.63 (d, J =  9.2 Hz, 1H), 7.72 (d, J =
8.1 Hz, 2H), 7.95 (d, J = 9.2 Hz, 1H), 8.26 (dd, J = 2.6, 9.2 Hz, 1H), 8.50 (d, J =
2.6 Hz, 1H); 13C NMR (100 MHz, CDCI3): 5 21.6, 28.3, 29.2, 39.8 (broad), 42.6
(broad), 43.7 (broad), 51.4 (very broad), 66.7, 67.3, 68.0 (very broad), 80.2,
151.1, 154.8, 158.5; HRMS (ESI-TOF) m/z (M + H)+ calcd. for C29H36N4O8S 
601.2332 found 601.2336.
(R)-(+)- and (rS>)-(-)-2-[4-(fert-Butoxycarbonyl)-2-((3-(4-methylbenzenesulfon- 
ate)propoxy)methyl)piperazine-1-yl]-6-nitroquinoline (R)-65 and (S)-65. The 
title compounds were similarly prepared and provided identical spectroscopic 
data. (R)-65 - [a]“ +42.3 (c 0.00063, CHCI3); (Sj-65 . [a £ 5 - 4 2 .1 (c 0.00057, 
CHCI3).
1,4-Dibenzyl-2-ethenylpiperazine 72. To a -78 °C solution of oxalyl chloride (2 
M in CH2CI2, 14 mL, 28 mmol) in dry CH2CI2 (60 mL) under argon was added 
(dropwise) a solution of DMSO (4 mL, 56 mmol) in CH2CI2 (10 mL). After stirring
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111.2, 121.2, 123.5, 124.2, 127.2, 127.7, 129.8, 133.0, 138.5, 141.9, 144.7,
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Bn' N ^
2. CH3 -P(Ph)3l
n-BuLi u
1. SOCI2, DMSO Bru
H
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20 min at -78 °C, a solution of alcohol 30 (7.45 g, 25 mmol) in CH2CI2 (18 mL) 
was added (dropwise), followed by triethylamine (17.6 mL, 127 mmol) after 
another 20 min. After stirring for 10 min at -78 °C, the mixture was warmed to 
ambient temperature over 2 h. The mixture was diluted with water (75 mL) and 
the organic phase separated. The aqueous phase was extracted with CH2CI2 (2 
x 50 mL) and the combined extracts washed with saturated NaHC0 3  (100 mL), 
dried (K2CO3) and concentrated to provide the crude aldehyde that was pumped 
under high vacuum for 10 min and then used immediately in the next step.
To a 0 °C suspension of methyltriphenylphosphonium iodide (10.0 g, 24.8 mmol) 
in dry THF (70 mL) was added a solution of n-BuLi in hexane (2.4 M, 10.0 mL, 24 
mmol) producing a red-orange solution. Following 1 h, a solution of aldehyde 
(3.60 g, 12.3 mmol) in dry THF (15 mL) was added (dropwise) and the reaction 
warmed slowly to ambient temperature overnight. The reaction was quenched 
by the addition of saturated NaHC0 3  solution (150 mL), and the THF evaporated. 
The aqueous mixture was extracted with CH2CI2 (3 x 50 mL) and the combined 
extracts dried (K2CO3) and concentrated to give the crude material that was 
purified by column chromatography (silica gel, EtOAc:Hexanes, 1:3) to provide 
72 as an oil (2.73 g, 76%). TLC Rf 0.42 (EtOAc:Hexanes, 2:3). 1H NMR (400 
MHz, CDCI3): 5 2.10 -  2.25 (m, 3H), 2.66 -  2.77 (m, 3H), 2.96 (td, J = 2.9, 9.2 
Hz, 1H), 3.10 (d, part of AB pattern, J = 13.6, 1H), 3.51 (m, AB pattern, J = 13.2 
Hz, 2H), 4.08 (d, part of AB pattern, J =  13.6 Hz, 1H), 5.21 (dd, J = 1.8, 10.3 Hz, 
1H), 5.30 (dd, J = 1.8, 17.6 Hz, 1H), 5.86 (m, 1H), 7.22 -  7.40 (m, 10H); 13C
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NMR (100 MHz, CDCI3): 5 50.9, 53.0, 59.0, 59.1, 62.9, 65.0, 117.9, 126.7, 127.0,
128.1, 128.2, 129.07, 129.14, 137.9, 138.6.
1. THF, 9BB-N
2. H20 2> NaOH HO
H
1,4-D,ibenzyl-2-(2-hydroxyethyl)piperazine 73. To a solution of alkene 72 
(2.62 g, 8.97 mmol) in dry THF (50 mL) under argon was added (dropwise) a 
solution of 9-BBN in THF (0.5 M, 27 mL, 13.5 mmol). After stirring 5 min the 
reaction was heated at 50 °C for 1 h then cooled to 0 °C in an ice bath. To the 
reaction was added (dropwise) 1 M NaOH (23 mL), followed by 30% H2O2 (23 
mL). Following the additions, the reaction was warmed to ambient temperature 
and a TLC confirmed consumption of starting material. The THF was evaporated 
and the aqueous mixture extracted with CH2CI2 (3 x 50 mL). The combined 
extracts were dried (K2CO3) and concentrated to provide the crude material that 
was purified by column chromatography (silica gel, EtOAc:Hexanes, 2:3 -  3:2, to 
remove non-polar material then EtOAc:CHCl3, 4:1) to provide 73 as an oil (2.39 
g, 8 6 %). TLC Rf 0.34 (MeOH:CH2CI2, 1:9). 1H NMR (400 MHz, CDCI3): 6  1.81 -  
1.91 (bm, 1H), 1.99 -  2. 09 (bm, 1H), 2.26 -  2.36 (m, 2H), 2.42 (dd, J = 6 .8 , 11.3 
Hz, 1H), 2.51 (m, 1H), 2.64 (dd, J = 2.9, 11.3 Hz, 1H), 2.83 (m, 1H), 2.92 (m, 1H), 
3.39 (bd, J = 12.6 Hz, 1H), 3.49 (m, AB pattern, J = 12.9 Hz, 2H), 3.74 (m, 1H),
3.87 (m, 1H), 4.17 (bd, J = 12.9 Hz, 1H), 4.87 (bs, 0.6H, -OH), 7.23 -  7.29 (m, 
2H), 7.29 -  7.34 (m, 8 H); 13C NMR (100 MHz, CDCI3): 5 30.9, 49.3 (broad), 51.4,
55.7, 57.7, 58.0, 60.7, 63.0, 127.0 (2 overlapped peaks), 128.1, 128.2, 128.88, 
128.93, 137.7, 138.1.
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1,4-Dibenzyl-2-(2-methoxyethyl)piperazine 74. To a 0 °C solution of alcohol 
73 (2.40 g, 7.7 mmol) in dry DMF (25 mL) was added NaH (95%, 0.461 g, 19.2 
mmol) in one portion. After stirring 5 min, iodomethane (0.50 mL, 8.03 mmol) 
was added (dropwise) and the reaction warmed to ambient temperature. After 
stirring for 1 h, the excess NaH was destroyed by the careful addition of water 
and the solution was diluted with 50 mL each of water and saturated NaHC0 3  
solution. The aqueous mixture was extracted with ether (3 x 40 mL) and the 
combined extracts dried (K2CO3) and concentrated to give the crude material that 
was purified by column chromatography (silica gel, EtOAc:Hexanes, 2:3) to 
afford 75 (free base form) as an almost colorless oil (1.74 g, 70%). TLC R f  0.52 
(MeOH:CH2Cl2, 1:9). The oil was dissolved in ether and treated with HCI gas to 
produce a white precipitate that was collected by filtration, washed with ether, 
and dried in vacuo to give 74 as a white solid (2.0 g, 94% from free base). The 
material was characterized as the free base. 1H NMR (400 MHz, CDCI3): 8  1.92 
(bm, 2H), 2.25 (bm, 3H), 2.48 -  2.75 (bm, 4H), 3.22 -  3.32 (m, 4H, includes 3H s 
at 3.28), 3.35 -  3.46 (m, 3H), 3.54 (bd, J  = 13.2 Hz, 1H), 3.98 (m, 1H), 7.20 -  
7.38 (m, 10H); 13C NMR (100 MHz, CDCI3): 8  29.2, 50.3, 52.8, 57.3, 57.5, 57.8, 
63.0, 70.1, 126.7, 126.9, 128.1 (two overlapped peaks), 128.9, 129.0, 138.2,
139.1.
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2-(2-Methoxyethyl)piperazine dihydrochloride 75. To a solution of 74 (2.00 g, 
5.0 mmol) in methanol (100 mL) was added Pd/C (5%, 0.30 g). The flask was 
sealed with a rubber septa and hydrogen gas was bubbled through the solution 
via balloon. The reaction was monitored by TLC until the starting matieral was 
gone then the mixture was filtered (Celite) and the filtrate concentrated to provide 
75 as a white solid (1.05 g, 97%). 1H NMR (400 MHz, D20): 5 1.75 -  1.90 (m, 
2H), 3.06 (dd, J = 12.5, 14.3 Hz, 1H), 3.15 (s, 3H), 3.17 -  3.29 (m, 2H), 3.43 (t, J 
= 5.8 Hz, 2H), 3.50 -  3.62 (m, 4H); 13C NMR (100 MHz, D20 , 1,4-dioxane int. 
std.): 5 30.3, 40.7, 41.4, 45.1, 52.7, 59.1, 68.9.
3-(2-Methoxyethyl)-1-triphenylmethylpiperazine 76. To a stirring suspension 
of piperazine 75 (1.05 g, 4.83 mmol) in dry CH2CI2 under argon (30 mL) was 
added anhydrous triethylamine (2.7 mL, 19.4 mmol). The resultant clear solution 
was cooled to 0 °C and a solution of trityl chloride (1.4 g, 5.02 mmol) in dry 
CH2CI2 (9 mL) was added (dropwise). The reaction was stirred 10 min at 0 °C 
then warmed to ambient temperature and stirred for 4 h. The solution was 
washed with saturated NaHC0 3  solution (30 mL) and brine (2 x 20 mL), dried 
(K2C0 3 ) and the solvent evaporated to provide 76 as a white solid (1.89 g, 
quantitative). 1H NMR (400 MHz, CDCI3): 8  1.21 (bs, 1H), 1.63 (bm, 2H), 2.86 -
1.CH 2CI2, Et3N H N ^
H
2 . Trityl chloride
.2HCI
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3.22 (bm, 7H), 3.31 (s, 3H), 3.41 (m, 2H), 7.10 -  7.58 (m, 15H); 13C NMR (100 
MHz, CDCI3): 5 34.1, 46.3, 48.8, 53.6, 54.6, 58.6, 70.0, 77.1, 125.9, 127.4, 129.3,
142.6.
H N ^ |
No / s ^ k ' NTrit
1. Et2 0 , n-BuLi; 
2 -chloroquinoline
H 2 . HCI
H
2-[2-{2-Methoxyethyl)piperazin-1-yl]quinoline 77. To a 0 °C solution of trityl 
piperazine 76 (0.530 g, 1.37 mmol) in dry ether (15 mL) under argon was added 
(dropwise) n-butyllithium (2.45 M in hexane, 1.37 mmol) producing a slightly 
colored turbid solution. After stirring for 20 min, a solution of 2-chloroquinoline 
(0.150 g, 0.91 mmol) in ether (4 mL) was added (dropwise) and the solution 
allowed to stir for 20 min at 0 °C then at ambient temperature for 14 h. The 
reaction was diluted with ether (10 mL), washed with saturated NaHC0 3  (2 x 25 
mL) and brine (1 x 25 mL), dried (K2CO3) and concentrated to give the crude 
material that was purified by column chromatography (silica gel, EtOAc:Hexanes, 
1:3) to provide the coupled product (TLC R f  0.54; EtOAc:Hexanes, 2:3) that was 
not spectroscopically characterized and immediately deprotected. The 
intermediate product was dissolved in acetone (3 mL) and 3 M HCI (6  mL) and 
the flask swirled. The mixture was further diluted with 1 M HCI (15 mL) and after 
5 min was transferred to a separatory funnel and washed with CH2CI2 ( 4 x 1 5  
mL). The aqueous mixture was made basic with 4 N NaOH, diluted with 
saturated NaHCOs solution (20 mL) and extracted with CH2CI2 (4 x 20 mL). The 
combined extracts were dried and concentrated to afford 77 as a pale colored oil
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(0.227 g, 92%). TLC R, 0.12 (MeOH:CH2CI2, 1:9). 1H NMR (400 MHz, CDCI3): 5 
1.76 (bs, NH, 1H), 2.01 (m, 1H), 2.11 (m, 1H), 2.86 (m, 1H), 3 .0 3 -3 .1 6  (m, 4H),
3.24 (s, 3H), 3.33 (m, 1H), 3.44 (m, 1H), 4.51 (bm, 1H), 4.62 (bm, d shaped, 1H),
7.03 (d, J = 9.5 Hz, 1H), 7.19 (m, 1H), 7.51 (m, 1H), 7.57 (bd, J = 8.1 hz, 1H), 
7.66 (bd, J = 8.4 Hz, 1H), 7.86 (d, J = 9.5 Hz, 1H); 13C NMR (100 MHz, CDCI3): 
5 28.3, 39.7, 46.3, 48.9, 49.3, 58.5, 69.5, 109.5, 121.9, 122.8, 126.3, 127.1,
129.3, 137.2, 147.9, 157.1.
1. ACE-CI, DCE 
reflux
2. MeOH, A
N N ^ i
2-[2-(2-Methoxyethyl)piperazin-1-yl]quinoline 77. To a 0 °C solution of methyl 
ether 190 (0.370 g, 1.02 mmol) in dry dichloroethane (15 mL) under argon was 
added 1-chloroethyl chloroformate (0.293 g, 2.05 mmol). After stirring 10 min, 
the flask was heated at reflux for 3 h then cooled and the solvent evaporated. 
The residue was dissolved in methanol (10 mL) and heated at 60 - 65 °C. After
1.25 h the methanol was evaporated and the residue was dissolved in 20 mL 1 M 
HCI and washed with CH2CI2 ( 4 x 1 5  mL). The aqueous phase was made basic 
with 4 M NaOH, diluted with saturated NaHC03 (20 mL) and extracted with 
CH2CI2 (4 x 20 mL). The combined extracts were dried (K2C 0 3) and 
concentrated to give 77 as a pale colored oil (0.270 g, 97%). This product was 
identical to that synthesized via the N-Trit protected piperazine.
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2-[2-(2-Methoxyethyl)piperazin-1-yl]-6-nitroquinoline 78. To a 0 °C solution 
of 77 (0.196 g, 0.72 mmol) in conc. H2SO4 ( 8  mL) was added HNO3 (15.4 M, 
0.094 mL, 1.45 mmol). The reaction was stirred for 15 min and was then 
quenched by pouring onto ice. The solution was basified with 4 M NaOH and 
diluted with saturated NaHC0 3  (30 mL). The bright yellow aqueous mixture was 
extracted with CH2CI2 (3 x 30 mL) and the combined extracts dried (K2CO3) and 
concentrated to provide 78 as a yellow-orange oily solid (0.220 g, 96%). TLC R f 
0.17 (MeOH:CH2CI2, 1:9). 1H NMR (400 MHz, CDCI3): 8  1.75 (bs, 1H, NH), 2.05 
(m, 1H), 2.16 (m, 1H), 2.85 (m, 1H), 2.97 -  3.19 (m, 4H), 3.24 (s, 3H), 3.30 (m, 
1H), 3.45 (m, 1H), 4.57 (bm, 1H), 4.78 (bm, 1H), 7.15 (d, J =  9.5 Hz, 1H), 7.61 (d, 
J  = 9.5 Hz, 1H), 7.93 (d, J  = 9.5 Hz, 1H), 8.27 (dd, J  = 2.6, 9.5 Hz, 1H), 8.51 (d, J  
= 2.6 Hz, 1H); 13C NMR (100 MHz, CDCI3): 8  28.8, 39.7, 46.2, 48.9, 49.5, 58.4,
69.1, 111.2, 120.8, 123.4, 124.1, 126.7, 138.3, 141.5, 151.5, 158.5; HRMS (ESI- 
TOF) m/z (M + H)+ calcd. for C16H21N4O3 317.1614 found 317.1609.
2-[4-(tert-Butoxycarbonyl)-2-(2-Hydroxyethyl)piperazin-1-yl]-6- 
nitroquinoline 79. To a -78 °C stirring solution of 78 (0.200 g, 0.634 mmol) in 
dry CH2CI2 (100 mL) under argon was added (dropwise) boron tribromide
2. Boc20 , c h 2c i2
3. K2C 0 3, MeOH
1 . BBr3, CH2CI2 
-78 °C
H
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solution (1 M in CH2CI2, 3.17 mL, 3.17 mmol). The reaction was maintained at - 
78 °C until the bath warmed to ambient temperature over 15 h. The reaction was 
quenched with saturated NaHC0 3  (50 mL), transferred to a separatory funnel 
and shaken vigorously. The organic phase was separated and the aqueous 
layer extracted with CH2CI2 (40 mL) and CHCl3:isopropyl alcohol, 4:1 (2 x 40 
mL). The combined organic phases were dried (K2CO3), concentrated and the 
residue dissolved in about 2 0  mL of CH2CI2. To the yellow solution was added a 
solution of di-ferf-butyldicarbonate (0.276 g, 0.1.27 mmol) in CH2CI2 (5 mL). The 
solution was stirred for 2 0  min, concentrated and the residue purified by column 
chromatography (silica gel, EtOAc:Hexanes, 2:3 -  3:2) to afford the di-Boc 80 
and mono-Boc 79 protected products that were combined and the solvent 
evaporated. The residue was dissolved in MeOH ( 8  mL) treated with excess 
K2CO3 and heated at 60 °C until only the mono-Boc product 79 was present by 
TLC. The methanol was evaporated and the residue partitioned between CH2CI2 
and saturated NaHC0 3  (20 mL each). The organic phase was separated and the 
aqueous phase extracted with CH2CI2 ( 2 x 1 0  mL). The combined extracts were 
dried (K2CO3) and concentrated to give the crude material that was purified by 
column chromatography (silica gel, EtOAc:Hexanes, 2:3 -  3:2) to afford 79 as a 
yellow foam (0.119 g, 47 %). TLC Rf 0.17 (EtOAc:Hexanes, 3:2). 1H NMR (400 
MHz, CDCI3): 8  1.47 (s, 9H), 1.81 -  2.10 (bm, 2H, 2 humps), 2.97 -  2.48 (bm, 
4H), 3.66 (bm, 1H), 3.92 -  4.28 (bm, 3H), 4.92 and 5.04 (bm, 1.6H), 7.08 (d, J =
9.2 Hz, 1H), 7.55 (d, J = 9.2 Hz, 1H), 7.95 (d, J = 9.2 Hz, 1H), 8.23 (dd, J = 2.6,
9.2 Hz, 1H), 8.44 (d, J = 2.6 Hz, 1H); 13C NMR (100 MHz, CDCI3): 8  28.3, 32.3,
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40.3, 42.6, 46.2, 47.6, 48.6, 58.0, 80.3, 110.9, 121.0, 124.05, 124.08, 126.1,
139.3, 142.0, 150.5, 154.8, 158.3.
THF, LiAIH4
reflux
H N ^ |
H
Bn
(^M-)-4-Benzyl-2-(hydroxymethyl)piperazine (R)-94. To a 0 °C suspension 
of dione (S)-97 (0.905 g, 3.86 mmol) in dry THF (90 mL) under argon was added 
LiAIH4 (0.600 g, 15.8 mmol) in small portions. After the effervescence subsided 
the flask was heated at reflux for 5 h. The solution was cooled, stirred an 
additional hour then the excess UAIH4 was quenched by the careful, sequential 
addition of 0.6 mL water, 1.2 mL 4 N NaOH and 0.6 mL water. The solids that 
formed will filtered (Celite) and the filtrate concentrated to give (R)-B4 as a pale 
colored oil (0.737 g, 92%). This crude material was used without further 
purification in subsequent reactions. A 0.170 g portion was purified (Biotage 12M 
KP-NH column, MeOH:CHCl3, 1:199) for spectroscopic purposes giving 0.148 g 
of (7?)-94 as a pale colored oil. TLC R f 0.04 (MeOH:CH2Cl2, 1:9). 1H NMR (400 
MHz, CDCI3): 5 1.93 (m, 1H, triplet shape), 2.13 (dd, J  = 2.9, 11.0 Hz, 1H), 2.54 
(bs, 2H), 2.71 (m, 2H, doublet shape), 2 .8 7 -2 .9 8  (m, 2H), 3.03 (dt, 2.9, 12.1 Hz, 
1H), 3.45 -  3.54 (m, 3H), 3.59 (dd, J  = 4.0, 11.0 Hz, 1H), 7.23 -  7.35 (m, 5H); 
13C NMR (100 MHz, CDCI3): S 44.9, 53.4, 55.6, 56.1, 63.3, 63.7, 127, 128.1,
129.1, 137.6; (R ) - [a]“  -16.0  (c 0.015, CHCI3).
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H N ^
ho^ C n
H
fS>)-(+)-4-Benzyl-2-(hydroxymethyl)piperazine (S)-94. The title compound was 
similarly prepared and provided identical spectroscopic data. (S) - [a]“  +16.3 (c 
0.018, CHCh).
N CO H H2° ’ Dioxane Boc
^  2  "  0 _
.HCI NaOH, Boc20  Bn
N-fert-Butoxycarbonyl-N-benzylglycine 95. The synthesis of 95 is adopted 
from the method of Le Bail.83 To a solution of benzyl glycine 100 (15.5 g, 76.8 
mmol) in water and dioxane (190 mL each) was added NaOH (12.3 g, 307 mmol) 
followed by di-fe/f-butyldicarbonate (18.4 g, 84.5 mmol) in portions. The reaction 
was stirred at ambient temperature for 19 h then the contents were reduced to 
half volume by evaporation in vacuo. To the reduced solution was added 140 mL 
of CH2CI2 and the mixture stirred so the biphasic mixture was well mixed. The 
mixture was cooled in an ice bath and 1 M HCI was added (dropwise) until a pH 
of 3 -  4 was reached (~ 240 mL). The mixture was transferred to a separatory 
funnel and the organic phase separated. The aqueous phase was extracted with 
CH2CI2 (3 x 50 mL) and the combined extracts were dried (MgS0 4 , do not use 
K 2 C O 3 )  and concentrated to provide 95 as a pale solid (15.6 g, 76%). TLC Rf 
0.24 (MeOH:CH2Cl2, 1:9). 1H NMR (400 MHz, CDCI3): (approximate 1:1  mixture 
of amide rotamers) 5 1.48 (s, 9H), 3.83 (s, 1H), 3.97 (s, 1H), 4.51 (s, 1H), 4.55 (s, 
1H), 7.21 -  7.37 (m, 5H), 10.90 (bs, 0.7H, -CO2H); 13C NMR (100 MHz, CDCI3):
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(approximate 1:1 mixture of amide rotamers) 6  28.2, 28.3, 47.5, 50.8, 51.6, 80.9, 
81.2, 127.5, 127.6, 128.1, 128.6, 137.0, 137.1, 175.2, 175.8.
COzMe (XI C02M6
J^O H
CH2CI2, Et3N, 
r.t., 20 h
GENERAL PEPTIDE COUPLING PROCEDURE described for: 
N-ferf-Butoxycarbonyl-N-benzylglycyl-D-serine Methyl Ester (R)-96. The 
synthesis of (R)-96 is adapted from the method of Naylor.111 To a stirring 
suspension of EDC.HCI (1.15 g, 6  mmol) in reagent grade CH2CI2 (20 mL) was 
added a solution of pentafluorophenol (1.5g, 8.1 mmol) in CH2CI2 (10 mL) 
followed by a solution of N-Boc-N-Benzyl glycine 95 (1.32 g, 5.0 mmol) in CH2CI2 
(20 mL). The solution was stirred at ambient temperature for 1 h then 
triethylamine (2.5 mL,18 mmol) was added with additional CH2CI2 (10 mL). The 
amino acid methyl ester hydrochloride (serine methyl ester HCI for this example, 
0.93 g, 6  mmol) was then added in small portions. The final solution was stirred 
for 2 0  h at ambient temperature and was then washed with aqueous sodium 
carbonate (1 M, 100 mL), aqueous citric acid (1 M, 100 mL) and water (50 mL). 
The organic phase was dried (K2CO3) and concentrated to afford the crude 
product that was purified by column chromatography (silica gel, EtOAc:Hexanes, 
2:3 -  3:2) to afford (R)-96 as a clear viscous oil (1.72 g, 94% yield). Rf = 0.52
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(MeOHiChfeCfe, 1:9). The spectroscopic data of (R)-96 was consistent with the 
literature.111
( ^ 1  ° Y °
C 0 2Me
O ^ N ^ > H  
H /
HO
N-tert-Butoxycarbonyl-N-benzylglycyl-L-serine Methyl Ester (S)-96. The title 
compound was similarly prepared, and provided identical spectroscopic data.
1. MeOH, SOCI;
,Me 2. NH4OH, MeOH 
.OH
(7?)-1-Benzyl-3-(hydroxymethyl)piperazine-2,5-dione (R)-97. The synthesis of 
(R)-97 is adapted from the method of Naylor.111 To a stirring 0 °C solution of 
dipeptide (R)-B6 (1.76 g, 4.81 mmol) in methanol (10 mL) was slowly added 
excess thionyl chloride (~ 1.7 mL) to avoid sputtering. Following the addition, the 
solution was warmed to ambient temperature and allowed to stir for 2.5 h. The 
solvent was evaporated and the residue triturated with ~20 mL diethyl ether to 
produce a white solid that was collected by filtration. The solid was dissolved in 
methanol (20 mL) and treated with ammonium hydroxide (20 mL) at ambient 
temperature. The solution was stirred for 16 h then the solvent was evaporated. 
The residue was partitioned between saturated NaHCC>3 (20 mL) and
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CHCI3:isopropyl alcohol, 4:1 (50 mL). The organic phase was separated and the 
aqueous phase extracted with CHCI3:isopropyl alcohol, 4:1 (4 x 30 mL). The 
combined organic phases were dried (K2CO3) and concentrated to afford (R)-97 
as a white solid (1 .0 1  g, 90%). R f = 0.19 (MeOhLChfeCh, 1:9). This material was 
of sufficient purity for subsequent reactions and had spectroscopic data 
consistent with the literature.111
HN N-Bn  
HO\ ^
('S)-1-Benzyl-3-(hydroxymethyl)piperazine-2,5-dione (S)-97. The title 
compound was similarly prepared and provided identical spectroscopic data.
1. EtOH/H20  KOH 
H2 N ^ C 0 2H Benzylbromide ^ ^
2. Acetic Acid Bn 
N,N-Dibenzylglycine 99. The synthesis of 99 is adopted from the method of 
Velluz.112 To a 45 °C solution of glycine (10 g, 133 mmol) and KOH (25 g, 445 
mmol) in ethanol and water (75 mL each) was added (dropwise) benzyl bromide 
(48.9 g, 286 mmol) from an addition funnel. Following the addition, the reaction 
was heated at reflux for 2  h then cooled and stirred at ambient temp for 16 h. 
The solvent was evaporated to a volume of 125 mL, transferred to a 400 mL 
beaker and heated to boiling with stirring. To the boiling solution was carefully 
added 10 mL of glacial acetic acid, producing a large mass of white precipitate. 
The solids were collected by filtration, washed with 200 -  300 mL of cold water
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and then dried under vacuum give 99 as a white solid (27.2 g, 80%). 1H NMR
N-Benzylglycine Hydrochloride 100. The synthesis of 100 is adopted from the 
method of Velluz.112 To glycine 99 (10.26 g, 40.2 mmol) suspended in methanol 
(140 mL) was added HCI (12 M, 5 mL, 60 mmol) and Pd/C (5%, 1.5 g). This 
mixture was hydrogenated using a Parr apparatus until no more hydrogen was 
consumed, repressurizing (max. 50 psi) the flask if necessary. The mixture was 
filtered (Celite), and the filtrate concentrated to provide 100 as a white solid (7.8 
g, 96%). 1H NMR (400 MHz, DMSO-d6): 5 3.79 (s, 2H), 4.15 (s, 2H), 7.40 (m, 
3H), 7.57 (m, 2H), 9.87 (bs, 2H), 13.8 (bs, 0.5H); 13C NMR (100 MHz, DMSO- 
d6): 5 46.2, 49.6, 128.6, 128.9, 130.2, 131.6, 167.6.
(rRJ-4-Benzyl-1-(tert-butoxycarbonyl)-2-(hydroxymethyl)piperazine (RJ-101.
To a stirring solution of alcohol (7?>94 (0.138 g, 0.669 mmol) in reagent grade 
CH2CI2 ( 1 0  mL) was added a solution of di-fe/f-butyldicarbonate (0.175 g, 0.803 
mmol) in CH2CI2 (4 mL). The reaction was stirred 2 0  h at ambient temperature 
then the solvent was evaporated leaving an oily residue that was purified by
(400 MHz, DMSO-de): 5 3.16 (s, 2H), 3.74 (s, 4H), 7.21 -  7.38 (m, 10H), 12.4 (bs, 
0.4H); 13C NMR (100 MHz, DMSO-d6): 5 52.9, 56.7, 127.0, 128.2, 128.5, 138.9,
172.2.
Bn MeOH, HCI
Bn’
H
N C 0 2H
Bn’
N .C 02H
H2, Pd/C .HCI
H N ^  CH2CI;c h c i2
H
B ocN '^
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column chromatography (silica gel, EtOAc:Hexanes, 2:3) to provide (R) -101 as a 
colorless oil (0.190 g, 93%). TLC R f 0.35 (EtOAc:Hexanes, 3:2). 1H NMR (400 
MHz, CDCI3): 6 1.44 (s, 9H), 2.07 (td, J =  4.0, 11.7, 1H), 2.27 (dd, J  = 4.0, 11.4, 
1H), 2.80 (bd, 1H), 2.96 (m, 1H, bd shape), 3.30 -  3.55 (m, 3H, overlap of a 
broad multiplit at 3.36 and singlet shape at 3.47), 3.87 (m, 2.5H, possible O H  
overlap), 4.05 (bs, 1H), 7.23 -  7.35 (m, 5H); 13C NMR (100 MHz, CDCI3): 5 28.3,
41.3 (broad), 51.3 (broad), 52.4, 54.8, 62.9, 66.2, 79.8, 127.3, 128.4, 128.8,
137.0, 155.1 (broad).
o
B0Cf|l I DMF, NaH J ^ N ^ i
HCL .ok .NL  :____ ^  C> I I
^  Bn Bnn
(7?)-7-Benzyl-tetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H)-one (7?>102. To a 0
°C solution of Boc alcohol (1R)-101 (0.046 g, 0.15 mmol) in dry DMF was added 
sodium hydride (0.011 g, 0.45 mmol). After stirring 5 min, the reaction was 
stirred at ambient temperature for 4 h then the excess hydride was carefully 
quenched with water and the mixture partitioned between water ( 8  mL) and ether 
(10 mL). The organic phase was separated and the aqueous phase was 
extracted with two additional portions of ether (15 mL). The combined organic 
phases were dried (K2CO3) and concentrated to provide the crude product that 
was purified by column chromatography (silica gel, EtOAc:Hexanes, 1:3 -  4:1) to 
provide (iRJ-102 as a colorless oil (0.025 g, 71%). TLC R f  0.14 (EtOAc:Hexanes, 
3:2). 1H NMR (400 MHz, CDCI3): 5 1.93 (m, triplet shape, 1H), 2.10 (td, J  = 3.7,
11.7 Hz, 1H), 2.78 -  2.91 (m, 2H), 3.11 (td, J  = 3.7, 12.5 Hz, 1H), 3.55 (m, AB
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pattern, J = 13.2 Hz, 2H), 3.78 (m, dd shaped, 1H), 3.83 -  3.91 (m, 2H), 4.35 (m, 
1H), 7.27 -  7.36 (m, 5H); 13C NMR (100 MHz, CDCI3): 5 41.0, 51.8, 53.1, 56.7,
62.8, 65.4, 127.4, 128.4, 129.0, 137.2, 156.9; GC/MS (El) m/z (M)+ 91 (base), 
187, 232 (parent).
Formic Acid
• ‘ N'  Bn Acetic Anhydride HO\  N'  gn
n H
(RM+)-4-Benzyl-2-(hydroxymethyl)piperazine-1-carbaldehyde (7^-106. To a
0 °C solution of alcohol (R)-94 (0.567 g, 2.75 mmol) in formic acid (8 8 %, 8  mL) 
was added (dropwise) acetic anhydride (2.33 mL, 24.7 mmol). The reaction was 
stirred for 30 min at 0 °C then warmed to ambient temperature. Following 1 h a 
TLC showed consumption of starting material and the reaction was diluted with 
ice, placed back in an ice bath and made basic with 4 N NaOH (~50 mL). The 
aqueous mixture was further diluted with saturated NaHC03 (30 mL) and 
extracted with CH2CI2 (4 x 20 mL). The combined extracts were dried (K2C0 3) 
and concentrated to give an orange-brown oil that was purified by column 
chromatography (silica gel, MeOH:CHCI3, 1:199 -  1:49) to afford (7?>106 as an 
almost colorless oil (0.521g, 67%). TLC Rf 0.34 (MeOH:CH2CI2, 1:9). 1H NMR 
(400 MHz, CDCI3): (approximate 1:1 mixture of amide rotamers) 8  2.05 (td, J = 
3.7, 11.7 Hz, 0.5H), 2.13 (td, J = 3.7, 11.7 Hz, 0.5H), 2.28 (dd, J = 4.0, 11.7 Hz, 
1H), 2.87 (m, 1H), 2.90 -  3.02 (m, 1H, looks like dd), 3.12 (td, J = 4.0, 12.8 Hz, 
0.5H), 3.41 -  3.59 (m, 3.5H), 3.64 -  3.75 (m, 1H), 3.85 (m, 0.5H, looks like dd),
3.97 (dd, J = 5.5, 11.4 Hz, 0.5H), 4.08 (dd, J = 7.3, 11.4 Hz, 0.5H), 4.20 (bd, 
0.5H), 4.38 (m, 0.5H), 7.25 -  7.36 (m, 5H), 8.06 (s, 0.5H), 8.08 (s, 0.5H); 13C
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NMR (100 MHz, CDCI3): 5 37.3, 43.9, 49.1, 52.1, 52.9, 54.36, 54.44, 55.5, 62.7,
62.8, 63.6, 65.2, 127.5, 127.6, 128.4, 128.5, 128.8, 128.9, 136.8, 137.2, 161.8, 
161.9; (R) - [a ] * 5 +56.1 (c 0.050, CHCI3); HRMS (ESI-TOF) m/z (M + H)+ calcd. 
for C13H19N2O2 235.1447 found 235.1446.
0 HC' N ^
H
(S>(-)-4-Benzyl-2-(hydroxymethyl)piperazine-1 -carbaldehyde (S)-106. The
title compound was similarly prepared and provided identical spectroscopic data. 
(S) - [a ]*5 -53 .8  (c 0.052, CHCI3).
0 HCS ^  DMF, NaH ° HC' N ^
HCk . > ' ' l ^ N' Bn CH3-I
H H
(RM+)-4-Benzyl-2-(methoxymethyl)piperazine-1-carbaldehyde (RJ-107. To a
0 °C solution of alcohol fiRJ-106 (0.502 g, 2.14 mmol) in dry DMF (20 mL) was 
added NaH (95%, 0.154 g, 6.43 mmol) in one portion. After stirring 5 min, 
iodomethane (0.319g, 2.25 mmol) was added (dropwise) and the mixture stirred 
for 20 min at 0°C then at ambient temp for 1.5 h. The excess NaH was 
destroyed by the careful addition of water and the solution was diluted with 40 
mL each of water and saturated NaHCCh. The aqueous mixture was extracted 
with ether (2 x 40 mL) and ethyl acetate (2 x 40 mL). The combined extracts 
were washed with brine (50 mL), dried (K2CO3) and concentrated to give a brown 
oil that was purified by column chromatography (silica gel, MeOH.CHCb, 1:199 -  
1:49) to afford (R) -107 as an almost colorless oil (0.360 g, 69%). TLC Rf 0.49
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(MeOH:CH2CI2, 1:9). 1H NMR (400 MHz, CDCI3): (approximate 3:7 mixture of 
amide rotamers) 5 2.00 -  2.12 (m, 1.3H), 2.18 (dd, J=  3.7, 11.7 Hz, 0.7H), 2.80 -  
2.92 (m, 2H), 2.93 -  3.02 (m, 1H), 3.29 -  3.38 (m, 3H, two singlets overlapped), 
3.41 -  3.76 (m, 5H, many intermixed peaks), 4.16 (bd, 0.7H), 4.60 (m, 0.3H),
7.25 -  7.35 (m, 5H, overlapped with CDCI3), 8.04 (s, 0.7H), 8.07 (s, 0.3H); 13C 
NMR (100 MHz, CDCI3): 5 36.7, 42.7, 47.0, 52.3, 53.2, 53.7, 54.1, 58.8, 59.0, 
62.5, 62.6, 69.5, 70.6, 127.2, 128.3, 128.7, 137.7, 161.3, 161.9; (R) - [a ]*5 +39.8 
(c 0.036, CHCI3); HRMS (ESI-TOF) m/z (M + H)+ calcd. for Ci4H2iN20 2 249.1603 
found 249.1598.
O H C .
p
H
fS)-(-)-4-Benzy l-2-(methoxy methy l)piperazine-1 -carbaldehyde (S)-107. The
title compound was similarly prepared and provided identical spectroscopic data. 
(S) - [ct]*5 -37 .6  (c 0.036, CHCI3).
0 HC' V ^  THF, H2 SO4
H H
(R)-(-)-1-Benzyl-3-(methoxymethyl)piperazine (R)-108. A solution of the
protected methylether (1R)-107 (0.320 g, 1.29 mmol) in THF (3 mL) and 4 M
H2S 0 4 (9 mL) was heated at 55 °C for 5 h. After cooling, the reaction contents
were poured into 20 mL of cold (-10 °C) 4 M NaOH and diluted with 20 mL of
saturated NaHCC>3. The mixture was extracted with CH2CI2 ( 4 x 1 5  mL) and the
combined extracts dried (K2COs) and concentrated to provide (7?)-108 as a pale
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oily solid (0.274 g, 96%). This product was of adequate purity for the subsequent 
transformations. TLC R,0.14 (MeOH:CH2CI2, 1:9). 1H NMR (400 MHz, CDCI3): 
6  1.85 (t, J = 10.3 Hz, 1H), 2.11 (td, J = 3.3, 11.0 Hz, 1H), 2.35 (bs, 1H, NH), 2.74 
(m, 2H, triplet shape), 2.90 (m, 1H, td shape), 2.96 -  3.06 (m, 2H), 3.25 -  3.36 
(m, 5H, OC /-/3 singlet present at 3.33), 3.50 (m, AB pattern, J = 13.2 Hz, 2H),
7.22 -  7.33 (m, 5H, overlapped with CDCI3); 13C NMR (100 MHz, CDCI3): 8  45.2,
53.8, 54.4, 55.9, 59.0, 63.4, 75.1, 126.9, 128.1, 129.1, 138.0; (R) - [ct]*5-17 .4  (c 
0.027, CHCI3); HRMS (ESI-TOF) m/z (M + H)+ calcd. for Ci3H2iN20  221.1654 
found 221.1654.
H N ^
H
(,S>(+)-1-Benzyl-3-(methoxymethyl)piperazine (SJ-108. The title compound 
was similarly prepared and provided identical spectroscopic data. (S) - [a]“  
+14.4 (c 0.030, CHCI3).
HN' Et20 , o-BuLi;
4*
H^  Bn 2-chloroquinoline
N N
(,R)-(+)-2-[4-Benzyl-2-(methoxymethyl)piperazin-1-yl]quinoline (7?J-109. To a
0 °C solution of piperazine (R)-108 (0.273 g, 1.24 mmol) in dry ether (16 mL) 
under argon was added (dropwise) a solution of n-butyllithium in hexane (2.45 M,
1.24 mmol) producing a clear yellow solution. After stirring 20 min a solution of 
2-chloroquinoline (0.134 g, 0.821 mmol) in ether (3 mL) was added (dropwise) 
and the solution allowed to stir for 10 min at 0 °C then at ambient temperature for
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16 h. The reaction contents were diluted with ether (15 mL), washed with 
saturated NaHC0 3  (2 x 20 mL) and brine (20 mL), dried (K2CO3) and 
concentrated to give the crude material that was purified by column 
chromatography (silica gel, EtOAc:Hexanes, 1:3) to provide (7?>109 as a thick, 
light yellow oil (0.275 g, 96%). TLC Rf 0.42 (EtOAc:Hexanes, 2:3). 1H NMR (400 
MHz, CDCI3): 5 2.17 -  2.27 (m, 2H), 2.95 (bd, J = 10.3 Hz, 1H), 3.11 (bd, J =
11.7 Hz, 1H), 3.21 (m, 1H), 3.33 (s, 3H), 3 .4 9 -3 .6 3  (m, 3H), 3.87 (m, 1H), 4.45 
(bd, 1H), 4.57 (bs, 1H), 6.98 (d, J = 9.2 Hz, 1H), 7.21 (m, 1H), 7.27 (m, 1H, 
overlapped with CDCI3), 7.31 -  7.39 (m, 4H), 7.52 (m, 1H), 7.59 (d, J = 8.1 Hz, 
1H), 7.68 (d, J =  8.4 Hz, 1H), 7.87 (d, J =  9.2 Hz); 13C NMR (100 MHz, CDCI3): 5
40.8, 51.6, 53.1, 59.0, 62.7, 69.8, 109.4, 122.1, 122.9, 126.5, 127.0, 127.1,
128.2, 128.8, 129.4, 137.3, 138.3, 147.9, 156.8; (R) - [cr]*5 +53.2 (c 0.028,
fS)-(-)-2-[4-Benzyl-2-(methoxymethyl)piperazin-1-yl]quinoline (S)-109. The
title compound was similarly prepared and provided identical spectroscopic data. 
(S) - [a ]*5 -52.8 (c 0.027, CHCI3).
CHCI3).
H
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v  0
HN N -Bn -----------------
H0X „ W  cat. p-TsOH,
H O
fS)-1-Benzyl-3-((tetrahydro-2H-pyran-2-yloxy)methyl)piperazine-2,5-dione 
(S)-119. To a 0 °C suspension of piperazinedione (SJ-97 (0.913 g, 3.90 mmol) in 
HPLC grade CH2CI2 (40 mL) under argon was added dihydropyran (1.64 g, 19.5 
mmol) followed by p-toluenesulfonic acid monohydrate (0.025 g, 0.13 mmol). 
The flask was swirled to remove solids stuck to the sides and the sides were 
rinsed with CH2CI2 as needed. After ~30 minutes, all solids had dissolved and 
the reaction was shown complete by a TLC that showed a new, more non-polar 
spot. The reaction was poured into an aqueous mixture of 30 mL each of 
saturated NaHC0 3 , brine and water. The organic phase was separated and the 
aqueous phase extracted with CH2CI2 ( 3 x 1 5  mL). The combined extracts were 
dried (K2CO3) and concentrated giving ~ 2 g of crude material. The crude 
material was dissolved in ~ 2 0  mL CH2CI2 and 4 g of silica gel was added. The 
mixture was concentrated and the solid was loaded onto a silica gel column and 
chromatographed with MeOI-LChhCh, 1:39, as eluent. When the product began 
to elute the solvent was switched to MeOhLChhCh, 1:19, to provide (SJ-119 as a 
white solid (1.153 g, 93%) and a 6:4 diastereomeric mixture. TLC Rf 0.32 
(MeOH:CH2CI2> 1:9). 1H NMR (400 MHz, CDCI3): (approximately 6:4 mixture of 
diastereomers) 5 1.40 -  1.70 (m, 6 H), 3.50 (m, 1H), 3.69 -  3.77 (m, 2H), 3.79 -  
3.85 (m, 1H), 3.92 (s, 0.6H), 3.96 (s, 0.4H), 4.05 (dd, J = 2.9, 9.9 Hz, 0.4H), 4.12 
(dd, J = 5.5, 10.3 Hz, 0.6H), 4.23 (m, 1H), 4.33 (d, J = 14.7 Hz, 0.4H), 4.38 (d, J
168
■ K
 ► HN N-Bn
CH2CI2 THP0\ , . W
H O
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= 14.7 Hz, 0.6H), 4.62 (m, 1H), 4.83 (d, J = 14.7 Hz, 0.6H), 4.90 (d, J = 14.7 Hz, 
0.4H), 6.41 (bs, 0.4H, NH), 6.52 (bs, 0.6H, NH), 7.24 -  7.36 (m, 5H); 13C NMR 
(100 MHz, CDCI3): 5 18.9, 19.0, 25.1, 30.1, 30.2, 49.2, 49.3, 49.7, 49.8, 55.9,
62.0, 62.1, 69.5, 69.8, 98.9, 99.1, 128.1, 128.2, 128.5, 128.8, 128.9, 135.0,
164.4, 164.6, 166.0, 166.3.
‘K
HN N-Bn
THPCT
(7^-1-Benzyl-3-((tetrahydro-2H-pyran-2-yloxy)methyl)piperazine-2,5-dione 
(R)-119. The title compound was similarly prepared and provided identical 
spectroscopic data.
O
/ " V  THF, UAIH4 HI)Ĵ
HN N -Bn ----------------► THPCL
T H P O ^ , . . ^  reflux2h Bn
H O
(R)A -Benzyl-3-[(tetrahydro-2H-pyran-2-yloxy)methyl]piperazine 20. To
a 0 °C suspension of THP ether (S) -119 (1.153 g, 3.62 mmol) in dry THF (60 mL) 
under argon was added LiAIH4 (0.566 g, 14.89 mmol) in small portions, 
producing a gentle effervescence. The mixture was maintained on ice until the 
bubbling stopped, then heated at reflux for 2 h. The solution was cooled, stirred 
1 h then the excess LiAIH4 was quenched by the careful, sequential addition of 
0.6 mL water, 1.2 mL 4 M NaOH solution and 0.6 mL water. The solids that 
formed will filtered (Celite) and the filtrate concentrated to give (R) -120 as a pale
colored oil (1.076 g, quantitative). TLC Rf 0.14 (MeOH:CH2CI2, 1:9). 1H NMR
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(400 MHz, CDCI3): 6 1.44 -  1.62 (m, 4H), 1.64 -  1.74 (m, 1H), 1.74 -  1.94 (m,
2H), 2.08 -  2.17 (m, 1H), 2.35 (bs, 1H, NH), 2.71 -  2.79 (m, 2H), 2.87 -  2.95 (m,
1H), 2.95 -  3.08 (m, 2H), 3.26 (m, 0.5H), 3.36 (dd, J = 4.0, 9.9 Hz, 0.5H), 3.45 -
3.52 (m, 3H, large singlet like peak overlapped), 3.61 -  3.73 (m, 1H), 3.78 -  3.86
fSJ-1 -Benzy l-3-[(tetrahydro-2H-pyran-2-y loxy)methyl]piperazine fS)-120.
The title compound was similarly prepared and provided identical spectroscopic 
data.
(7?>2-[4-Benzyl-2-[(tetrahydro-2H-pyran-2-yloxy)methyl]piperazin-1- 
yl]quinoline (iRJ-121. To a 0 °C solution of THP piperazine (iRJ-120 (0.533 g, 
1.84 mmol) in dry ether (25 mL) under argon was added (dropwise) n-butyllithium 
(2.33 M in hexane, 1.84 mmol) producing a brown-yellow turbid solution that 
stirred 20 min. A solution of 2-chloroquinoline (0.200 g, 1.22 mmol) in ether (5 
mL) was slowly added (dropwise) and the solution was then allowed to stir for 20 
min at 0 °C then at ambient temperature for 16 h. The reaction contents were
(m, 1 H), 4.56 (m, 1H); 13C NMR (100 MHz, CDCI3): 6 19.4, 19.5, 25.3, 30.5,
128.2, 129.1, 137.9.
T H P O ^ / N
H
T H P O ^   N
THPO^sJv^N
2-CI-quinoline
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diluted with ether (15 mL), washed with saturated NaHC0 3  (2 x 20 mL) and brine 
( 2 x 1 0  mL), dried (K2CO3) and concentrated to give the crude material that was 
purified by column chromatography (silica gel, EtOAc:Hexanes, 1:3) to provide 
(R)-121 as a light yellow oil (0.471 g, 93%). TLC Rf 0.41 (EtOAc:Hexanes, 2:3). 
1H NMR (400 MHz, CDCI3): (approximately 6:4 mixture of diastereomers) 8 1.30 
-  1.86 (m, 6 H), 2.18 -  2.34 (m, 2H), 2.99 (m, 1H), 3.13 (m, 0.6H, doublet shape), 
3 .1 9 -3 .3 4  (m, 1.4H), 3 .4 2 -3 .5 9  (m, 2.3H), 3.60 -  3.71 (m, 1H), 3 .7 4 -3 .8 4  (m, 
1H), 3.90 (m, 1.3H, leaning doublet shape), 4.19 (m, 0.3H, triplet shaped), 4.48 -  
4.68 (m, 3H, broad overlaps), 7.04 (d, J = 9.2 Hz, 1H), 7.23 (m, 1H), 7.30 (m, 
1H), 7 .3 4 -7 .4 4  (m, 4H), 7.55 (m, 1H), 7.60 (m, 1H, doublet shape), 7.73 (m, 1H, 
doublet shape), 7.87 (m, 1H, two unsymmetrical doublets offset); 13C NMR (100 
MHz, CDCI3): 8 18.9, 19.1, 25.2, 25.3, 30.3, 40.4, 40.5, 51.8, 52.0, 52.6, 53.1,
53.4, 61.6, 61.9, 62.7, 62.9, 64.2, 64.6, 98.2, 99.2, 109.4, 109.7, 121.9, 122.8,
126.4, 126.9, 127.0, 128.1, 128.8, 128.9, 129.2, 136.8, 137.0 138.2, 138.3,
147.8, 156.9.
fS)-2-[4-Benzyl-2-[(tetrahydro-2H-pyran-2-yloxy)methyl]piperazin-1- 
yl]quinoline (S)-121. The title compound was similarly prepared and provided 
identical spectroscopic data.
N ^ |
T H P O ^ ^ NN
Bn
H
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MeOH, HCI N
T H P O ^ ...^ N .Bn
H
(R)-(+)-2-[4-Benzyl-2-(hydroxymethyl)piperazin-1-yl]quinoline (R)A22. To a
solution of starting material (iRJ-121 (0.302 g, 0.723 mmol) in reagent grade 
methanol (15 mL) was added conc. HCI (1.3 mL,1.6 mmol). The solution was 
stirred overnight (2 1  h) and was then diluted carefully with saturated NaHCC>3 ( 2 0  
mL). The methanol was evaporated and the aqueous mixture extracted with 
CH2CI2 ( 3 x 8  mL). The combined extracts were dried (K2CO3) and concentrated 
to give (R)-122 as an amber solid (0.250 g, quantitative). This material was pure 
enough for subsequent transformations. TLC Rf 0.12 (EtOAc:Hexanes, 2:3). 1H 
NMR (400 MHz, CDCI3): 8  2.26 (td, J =  3.7, 11.4 Hz, 1H), 2.41 (dd, J = 4.0, 11.4 
Hz, 1H), 2.97 (m, 1H), 3.09 (m, 1H), 3.45 -  3.65 (m, 3H), 3.99 (dd, J = 3.3, 11 
Hz, 1H), 4.10 (bd, 1H), 4.17 (dd, J = 5.9, 11 Hz, 1H, overlapped with previous bd 
at 4.10), 4.80 (bm, 1H), 4.97 (bs, 0.2H, -OH), 6.96 (d, J = 9.2 Hz, 1H), 7.24 (m, 
1H, overlapped with CDCI3), 7.31 (m, 1H), 7.33 -  7.40 (m, 4H), 7.54 (m, 1H), 
7.60 (bd, J =  8.1 Hz, 1H), 7.69 (bd, J = 8.4 Hz, 1H), 7.87 (d, J =  9.2 Hz, 1H); 13C 
NMR (100 MHz, CDCI3): 8  42.4, 52.5, 53.0, 55.4, 62.9, 65.2, 109.9, 122.4, 122.9,
126.1, 127.1, 127.3, 128.4, 128.8, 129.5, 137.4, 137.5, 147.2, 157.4; (R) - [0 ]“  
+226.1 (c 0.025, CHCI3).
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H
('S>(-)-2-[4-Benzyl-2-(hydroxymethyl)piperazin-1-yl]quinoline (S)-122. The 
title compound was similarly prepared and provided identical spectroscopic data. 
(S) - [a ]*5 -226.3 (c 0.016, CHCI3).
(7?X+)-2-[4-Benzyl-2-(allyloxymethyl)piperazin-1-yl]quinoline (R)-123. To a 0
°C solution of the alcohol (R)-122 (0.241 g, 0.723 mmol) in dry DMF (11 mL) 
under argon was added sodium hydride (95%, 0.052 g, 2.17 mmol). The turbid 
solution was stirred 15 min then allyl bromide (0.092 g, 0.759 mmol) was added 
(dropwise). The reaction was stirred 10 min at 0 °C then warmed to ambient 
temperature and stirred for 18 h. The excess hydride was destroyed by the 
careful addition of 8  mL of saturated NaHC0 3  solution and the mixture diluted 
further with 8  mL of water. This aqueous mixture was extracted with ether (4 x 
15 mL) and the combined extracts were washed with brine ( 2 x 1 0  mL), dried 
(K2CO3) and concentrated to give the crude product that was purified by column 
chromatography (silica gel, EtOAc:Hexanes, 1:9 -  1:3) to provide (R^-123 an an 
amber oil (0.214 g, 79%). TLC Rf 0.46 (EtOAc:Hexanes, 2:3). 1H NMR (400 
MHz, CDCI3): 5 2.20 -  2.29 (m, 2H), 2.98 (m, 1H, doublet shape), 3.17 -  3.27 (m,
Allyl bromide
DMF, NaH
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2 H), 3.51 -  3.66 (m, 3H), 3.94 -  4.05 (m, 3H), 4.48 (bd, J = 12.8 Hz, 1H), 4.61 
(bs, 1H), 5.13 (dq, J =  1.5, 10.4 Hz, 1H), 5.20 (dq, J = 1.5, 17.2 Hz, 1H), 5.83 (m, 
1H), 7.01 (d, J = 9.2 Hz, 1H), 7.23 (m, 1H), 7.30 (m, 1H), 7.34 -  7.42 (m, 4H), 
7.55 (m, 1H), 7.61 (dd, J =  1.1, 8.1 Hz, 1H), 7.73 (d, J =  8.4 Hz, 1H), 7.87 (d, J =
9.2 Hz, 1H); 13C NMR (100 MHz, CDCI3): 5 40.8, 51.8, 53.0, 53.1, 62.8, 67.2,
72.0, 109.4, 116.7, 122.1, 122.9, 126.5, 127.0, 127.1, 128.2, 128.8, 129.3, 134.7,
137.3, 138.3, 147.9, 156.8; (R) - [a ]*  +51.3 (c 0.017, CHCI3).
Bn
H
('S>(-)-2-[4-Benzyl-2-(allyloxymethyl)piperazin-1-yl]quinoline (S)-123. The
title compound was similarly prepared and provided identical spectroscopic data. 
(S) - [a ]*5 -51 .4  (c 0.015, CHCI3).
(iR>(+)-2-[4-Benzyl-2-[(3-hydroxypropoxy)methyl]piperazin-1-yl]quinoline 
(iRJ-124. To a 0 °C solution of the allyl ether (R)-MZ (0.214 g, 0.57 mmol) in dry 
THF ( 6  mL) under argon was added 9-BBN (0.5 M in THF, 1.55 mmol). 
Following the addition, the reaction was heated to 60 °C and maintained for 1 h. 
The contents were cooled to 0 °C and 3.5 mL of 1 M NaOH was added 
(dropwise) followed by an equal volume of 30% H2O2. After stirring ~10 min the 
THF was evaporated and the residue partitioned between CH2CI2 and saturated
2. H20 2, NaOH
.. N ^ |
N '  R_
H
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NaHC0 3  (25 mL each). The organic phase was separated and the aqueous 
phase extracted with CH2CI2 ( 3 x 1 5  mL). The combined organic extracts were 
dried (K2CO3) and concentrated to give the crude material that was purified by 
column chromatography (silica gel, EtOAc:Hexanes, 1:9 -  3:2) to afford (iRJ-124 
as an amber oil (0.163g, 73%). TLC Rf 0.1 (EtOAc:Hexanes, 2:3). 1H NMR (400 
MHz, CDCI3): 5 1.67 (p, J = 5.9 Hz, 2H), 2.17 -  2.27 (m, 2H), 2.40 (bs, 1H), 2.97 
(bd, J = 11.0 Hz, 1H), 3.07 (bd, J = 11.4 Hz, 1H), 3.25 (td, J = 2.9, 12.5 Hz, 1H), 
3.44 -  3.69 (m, 7H), 3.87 (m, 1H, triplet shape), 4.39 (bd, J = 12.8 Hz, 1H), 4.64 
(bs, 1H), 6.97 (d, J = 9.2 Hz, 1H), 7.21 (m, 1H), 7.26 -  7.32 (m, 1H), 7.32 -  7.40 
(m, 4H), 7.53 (m, 1H), 7.59 (m, 1H), 7.69 (d, J = 8.4 Hz, 1H), 7.87 (d, J = 9.2 Hz, 
1H); 13C NMR (100 MHz, CDCI3): 5 32.0, 40.8, 51.5, 53.1, 53.2, 61.3, 62.8, 68.5,
70.1, 109.4, 122.1, 122.9, 126.4, 127.06, 127.12, 128.2, 128.9, 129.4, 137.3,
138.2, 147.8, 156.8; (R) - [a]“  +46.3 (c 0.016, CHCI3).
(rS>(-)-2-[4-Benzyl-2-[(3-hydroxypropoxy)methyl]piperazin-1-yl]quinoline 
(S)-124. The title compound was similarly prepared and provided identical 
spectroscopic data. (S) - [a]“  -47.2 (c 0.013, CHCI3).
H
175
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
HO 'Bn
CH2CI2 , Pyridine
Tosyl chloride
'Bn
fSM-)-2-[4-Benzyl-2-[(3-(4-methylbenzenesulfonate)propoxy)methyl] 
piperazin-1-yl]quinoline fSJ-125. To a 0 °C solution of alcohol (SJ-124 (0.196 
g, 0.50 mmol) in dry CH2CI2 (4 mL) and pyridine (400 pL) was added p- 
toluenesulfonyl chloride (0.114 g, 0.60 mmol) in one portion. The flask was 
sealed under argon and maintained in the ice bath until the ice bath warmed to 
ambient temperature. Following 26 h, the reaction contents were partitioned 
between saturated NaHC0 3  (20 mL) and CH2CI2 (10 mL). The organic phase 
was separated and the aqueous phase was extracted with CH2CI2 (3 x 1 0  mL). 
The combined organic extracts were dried (K2CO3) and concentrated to give the 
crude material that was purified by column chromatography (silica gel, 
EtOAc:Hexanes, 1:9 -  1:3) to afford fSJ-125 as a pale colored oil (0.127 g, 47%). 
TLC Rf 0.27 (EtOAc:Hexanes, 2:3). 1H NMR (400 MHz, CDCI3): 5 1.73 (p, J =
6.2 Hz, 2H), 2 .1 6 -2 .2 5  (m, 2H), 2.4 (s, 3H), 2.94 (bd, J =  11.0 Hz, 1H), 3.02 (bd, 
J = 11.4 Hz, 1H), 3.18 (m, 1H), 3 .3 8 -3 .6 2  (m, 5H), 3.78 (t, J =  8 .8  Hz, 1H), 3.97 
(t, J = 6.2 Hz, 2H), 4.42 (bd, 1H), 4.52 (bs, 1H), 6.95 (d, J = 9.5 Hz, 1H), 7.19 -
7.24 (m, 1H), 7.25 -  7.30 (m, 3H, tosylate doublet dominates shape), 7.30 -  7.38 
(m, 4H), 7.52 (m, 1H), 7.59 (m, 1H), 7.67 (bd, J = 8.1 Hz, 1H), 7.73 (d, J = 8.1 
Hz, 2H), 7.85 (d, J =  9.2 Hz, 1H); 13C NMR (100 MHz, CDCI3): 5 21.5, 29.2, 40.6,
51.5, 53.0, 53.1, 62.7, 66.4, 67.6, 67.9, 109.4, 122.1, 122.8, 126.4, 127.0, 127.1,
127.8, 128.2, 128.8, 129.3, 129.7, 133.0, 137.2, 138.3, 144.5, 147.8, 156.8; (S) - 
[a]“  -25.0 (c 0.0075, CHCI3).
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fR>(+)-2-[4-Benzyl-2-[(3-(4-methylbenzenesulfonate)propoxy)methyl] 
piperazin-1-yl]quinoline (R)-125. The title compound was similarly prepared 
and provided identical spectroscopic data. (R) - [a f*  This compounds optical 
rotation was never evaluated.
('Sy)-(-)-2-[4-Benzyl-2-[(3-fluoropropoxy)methyl]piperazin-1-yl]quinoline (S)- 
126. To a solution of tosylate (SJ-125 (0.128 g, 0.234 mmol) in dry THF (2.5 mL) 
was added a solution of TBAF in THF (1 M, 0.35 mL, 0.352 mmol). The flask 
was sealed under argon and heated at 55 -  60 °C for 3.5 h. After cooling, the 
solvent was evaporated and the residue purified by column chromatography 
(silica gel, EtOAc:Hexanes, 1:9 -  1:3) to afford (S)-126 as a pale colored oil 
(0.071 g, 78%). TLC Rf 0.45 (EtOAc:Hexanes, 2:3). 1H NMR (400 MHz, CDCI3): 
5  1.80 (dp, J F-h  = 25.6 Hz, FCH2CH2-, J H-h  = 6.2 Hz, 2H), 2.20 -  2.28 (m, 2H),
2.98 (m, 1H), 3.11 (m, 1H), 3.23 (td, J = 3.7, 12.8 Hz, 1H), 3.46 -  3.66 (m, 5H), 
3.89 (t, J =  8 .8  Hz, 1H), 4.35 (dt, J F-h = 46.9, FCH2-, Jh-h =  5.9 Hz, 2 H), 4.45 (bd, 
1H, overlapped with signal at 4.35), 4.59 (bm, 1H), 6.99 (d, J = 9.2 Hz, 1H), 7.22 
(m, 1H), 7.26 -  7.32 (m, 1H), 7.32 -  7.41 (m, 4H), 7.53 (m, 1H), 7.60 (m, 1H), 
7.70 (d, J = 8.4 Hz, 1H), 7.87 (d, J = 9.2 Hz, 1H); 13C NMR (100 MHz, CDCI3): 6
THF, TBAF
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30.7 (d, JC-f = 19.8 Hz, FCH2CH2-), 40.7, 51.6, 52.9, 53.3, 62.8, 66.7 (d, JC-f =
4.6 Hz, FCH2CH2CH2-), 67.8, 81.1 (d, JC-f = 163.3 Hz, FCH2-), 109.4, 122.1,
122.9, 126.5, 127.0, 127.1, 128.2, 128.8, 129.4, 137.2, 138.3, 147.8, 156.8; (S) -
[a£ 5 -39 .9  (c 0.0048, CHCI3).
'Bn
(7?>(+)-2-[4-Benzyl-2-[(3-fluoropropoxy)methyl]piperazin-1-yl]quinoline (R)- 
126. The title compound was similarly prepared and provided identical 
spectroscopic data. (R) - [a]“  +40.2 (c 0.0098, CHCI3).
(ft)-(+)-2-[4-Benzyl-2-[(3-fluoropropoxy)methyl]piperazin-1-yl]quinoline (R)- 
126. ALTERNATE ROUTE To a -78 °C solution of alcohol (R )-U 4  (0.111 g, 
0.283 mmol) in dry CH2CI2 (9 mL) under argon was added DAST (0.061 g, 0.38 
mmol). The insulated bath was allowed to warm to ambient temperature over 24 
h then the reaction was diluted with CH2CI2 (10 mL) and saturated NaHC0 3  
solution (20 mL). The organic phase was separated and the aqueous phase 
extracted with CH2CI2 ( 2 x 1 0  mL). The combined organic extracts were dried 
(K2C0 3 ), and concentrated to give the crude product that was purified by column 
chromatography (silica gel, EtOAc:Hexanes, 1:3) to provide (R)-126 as a pale oil
CH2CI2, DAST
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(0.069 g, 62%). TLC Rf 0.45 (EtOAc:Hexanes, 2:3). Spectroscopic data for (R)- 
126 with DAST was identical to that reported for (SJ-126 generated via TBAF 
fluorination.
fR>(+)-2-[2-[(3-fluoropropoxy)methyl]piperazin-1-yl]quinoline (RJ-127. To a
0 °C solution of fluoride (R)-126 (0.098 g, 0.249 mmol) in dry dichloroethane (5 
mL) under argon was added 1-chloroethyl chloroformate (0.142 g, 0.994 mmol). 
After stirring 5 min, the reaction was heated at reflux for 7 h, cooled, then stirred 
at ambient temperature for 10 h. The volatile components were evaporated and 
the residue was dissolved in methanol (10 mL) and heated at 60 °C for 1.5 h. 
The solvent was evaporated to dryness and the residue partitioned between 
CH2CI2 and saturated NaHCC>3 ( 1 0  mL each). The organic phase was separated 
and the aqueous phase was extracted with three additional portions of CH2CI2. 
The combined organic extracts were dried (K2CO3) and concentrated to give the 
crude product that was immediately purified by column chromatography (silica 
gel, EtOAc:Hexanes, 4:1, then MeOH:CH2Cl2, 1:39 -  1:9) to provide (7?>127 as a 
pale colored oil (0.065 g, 87%). TLC Rf 0.13 (MeOH:CH2CI2, 1:9). 1H NMR (400 
MHz, CDCI3): 6  1.89 (dp, J F-h  = 25.6 Hz, FCH2CH2-, J H-h  = 6.2 Hz, 2H), 2.20 (bs, 
1H, NH), 2.88 (m, 1H), 3.00 (m, 1H), 3.12 -  3.21 (m, 2H), 3.32 (bd, J = 12.1 Hz, 
1H), 3.55 -  3.61 (m, 3H), 3.90 (m, 1H), 4.36 (bd, 1H), 4.47 (dt, J F-h  = 47.2, FCH2, 
J h -h  = 5.9 Hz, 2H), 4.59 (bm, 1H), 6.97 (d, J =  9.5 Hz, 1H), 7.21 (m, 1H), 7.52 (m,
2. MeOH, A
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1H), 7.59 (d, J  = 8.1 Hz, 1H), 7.68 (d, J  = 8.4 Hz, 1H), 7.88 (d, J  = 9.2 Hz, 1H); 
13C NMR (100 MHz, CDCI3): 5 30.7 (d, JC-f = 19.8 Hz, FCH 2 CH2-), 41.3, 46.0,
46.2, 50.7, 66.9 (d, JC-f  = 6.1 Hz, FCH2 CH2 CH2-), 68.0, 81.2 (d, JC- f=  163.2 Hz, 
FCH2-), 109.2, 122.2, 122.9, 126.5, 127.1, 129.4, 137.3, 147.8, 156.9; (R )  - [cr] * 5 
+56.2 (c 0.0065, CHCI3).
n
fS>(-)-2-[2-[(3-fluoropropoxy)methyl]piperazin-1-yl]quinoline (SJ-127. The
title compound was similarly prepared and provided identical spectroscopic data. 
(S )  - [«]£ -56.7 (c 0.0031, CHCI3).
CH2CI2, Pyr, 
DMAP (cat.)
Ac20
(7?>2-[2-(acetoxymethyl)-4-benzylpiperazin-1-yl]quinoline (R)-i28. To a 0 °C
solution of alcohol (R)-M 2  (0.212 g, 0.64 mmol) in dry CH2CI2 (14 mL) under 
argon was added pyridine (0.1 mL, 1.27 mmol), acetic anhydride (0.072 mL, 0.76 
mmol) and 4-dimethylaminopyridine (DMAP, 0.004 g, 0.03 mmol). After stirring 
at 0  °C for 4 h, the reaction was shown complete by TLC, with the formation of a 
new, non-polar spot. The reaction contents were diluted with 10 mL of CH2CI2 
and washed with saturated NaHCC>3 (2  x 20 mL). The organic phase was dried 
(K2CC>3) and concentrated to provide the crude material that was purified by
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column chromatography (silica gel, EtOAc:Hexanes, 1:3) to provide (R)-128 as 
an oil that slowly formed a pale solid upon standing (0.226 g, 95%). TLC R f  0.42 
(EtOAc:Hexanes, 2:3). 1H NMR (400 MHz, CDCI3): 5 1.76 (s, 3H), 2.21 -  2.30
fiR)-2-[2-(acetoxymethyl)piperazin-1-yl]quinoline (R)-129. To a 0 °C solution 
of acetate (R)-128 (0.150 g, 0.4 mmol) in dry dichloroethane ( 6  mL) under argon 
was added 1-chloroethyl chloroformate (0.114 g, 0.8 mmol). After stirring 10 min, 
the flask was heated at reflux for 2  h then cooled and the solvent evaporated. 
The residue was dissolved in methanol (6  mL) and heated at 60 - 65 °C for 1.25 
h then the methanol was evaporated. The residue was dissolved in 20 mL 1 M 
HCI and washed with CH2CI2 ( 3 x 1 0  mL). The aqueous phase was carefully 
made basic with saturated NaHC03 and extracted with CH2CI2 ( 4 x 1 0  mL). The 
combined extracts were dried (Na2SC>4) and concentrated to give (R )-M 9  as a 
pale colored oil that formed a solid upon standing (0.108 g, 95%). TLC Rf  0.22 
(MeOH:CH2CI2, 1:9). 1H NMR (400 MHz, CDCI3): 8  1.80 (bs, 1H), 1.86 (s, 3H),
(m, 2H), 2.96 -  3.03 (m, 2H), 3.35 (td, J  = 3.3, 12.5 Hz, 1H), 3.45 (d, J  = 13.2 Hz,
1H), 3.65 (d, J  = 13.2 Hz, 1H), 4.37 -  4.51 (m, 3H), 4.85 (bm, 1H), 6.99 (d, J  =
9.2 Hz, 1H), 7.23 (m, 1H), 7.29 (m, 1H), 7.32 -  7.41 (m, 3H), 7.54 (m, 1H), 7.60 
(bd, J  = 8.1 Hz, 1H), 7.70 (bd, J  = 8.4 Hz, 1H), 7.89 (bd, J  = 9.2 Hz, 1H); 13C
NMR (100 MHz, CDCI3): 8  20.7, 40.4, 50.3, 52.8, 53.2, 61.4, 62.7, 109.2, 122.2,
122.9, 126.6, 127.1, 128.2, 128.8, 129.4, 137.3, 138.2, 147.7, 156.8, 171.0.
O
2. MeOH, A
1. ACE-CI, DCE 
reflux
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2.84 (td, J = 2.9, 11.7 Hz, 1H), 2.99 (dd, J = 3.3, 12.5 Hz, 1H), 3.09 -  3.23 (m,
3H), 4 .3 0 -4 .4 0  (m, 2H), 4.46 (dd, J =  8.1, 11.0 Hz, 1H), 4.77 (bm, 1H), 6.96 (d, 
J = 9.2 Hz, 1H), 7.20 (m, 1H), 7.51 (m, 1H), 7.58 (bd, J = 7.7 Hz, 1H), 7.68 (bd, J 
= 8.4 Hz, 1H), 7.87 (d, J = 9.2 Hz, 1H); 13C NMR (100 MHz, CDCI3): 5 20.7,
40.8, 45.9, 46.0, 49.7, 60.5, 109.0, 122.2, 122.8, 126.5, 127.0, 129.4, 137.3,
147.6, 156.9, 170.9.
0 2N o 2n
1. ACE-CI, DCE 
reflux
Bn 2. MeOH, A
NH
2-[2-Phenylpiperazin-1-yl]-6-nitroquinoline 135. To a solution of quipazine 
174 (0.097 g, 0.23 mmol) in dry dichloroethane (4 mL) under argon was added 1- 
chloroethyl chloroformate (0.066 g, 0.46 mmol). After stirring for 5 min the 
reaction was heated at reflux for 2 h, then stirred at ambient temp for 16 h. The 
solvent was evaporated and the residue dissolved in methanol (8  mL) and 
heated at 65 °C for 2 h. The methanol was evaporated and the residue was 
dissolved in 1 M HCI (20 mL) and washed with CH2CI2 ( 4 x 1 5  mL). The aqueous 
phase was made basic with 4 M NaOH, diluted with saturated NaHC03 (20 mL) 
and extracted with CH2CI2 (4 x 20 mL). The combined organic extracts were 
dried (K2C0 3) and concentrated to give 135 as a yellow foam (0.070 g, 91%). 
TLC 0.31 (MeOH:CH2CI2, 1:9). 1H NMR (400 MHz, CDCI3): 5 1.89 (bs, NH, 
1H), 3.02 (td, J = 3.7, 12.1 Hz, 1H), 3.18 (bm, doublet shape, J = 12.1 Hz, 1H), 
3.32 -  3.42 (m, 2H), 3.71 (bd, J = 13.2 Hz, 1H), 4.68 (bd, J = 13.2 Hz, 1H), 5.69
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(bs, 1H), 6.98 (d, J = 9.5 Hz, 1H), 7.24 -  7.29 (m, 1H, overlapped with CDCI3), 
7.29 -  7.38 (m, 4H), 7.65 (d, J = 9.5 Hz, 1H), 7.93 (d, J = 9.2 Hz, 1H), 8.29 (dd, J 
= 2.6, 9.5 Hz, 1H), 8.52 (d, J =  2.6 Hz, 1H); 13C NMR (400 MHz, CDCI3): 5 41.3,
45.7, 49.5, 54.8, 110.7, 121.1, 123.6, 124.2, 127.0, 127.1, 127.2, 128.9, 138.8,
138.9, 141.8, 151.5, 158.8; HRMS (ESI-TOF) m/z (M + H)+ calcd. for Ci9Hi9N40 2  
355.1508 found 355.1507.
1. ACE-CI, DCE 
reflux
NH2. MeOH, A
2-[2-Benzylpiperazin-1-yl]-6-nitroquinoline 136. To a solution of quipazine
175 (0.083 g, 0.19 mmol) in dry dichloroethane (4 mL) under argon was added 1-
chloroethyl chloroformate (0.054 g, 0.38 mmol). The reaction was heated at
reflux for 2 h then stirred at ambient temperature for 16 h. The solvent was
evaporated and the residue dissolved in methanol (8  mL) and heated at 65 °C for
2 h. The mixture was concentrated and the residue was dissolved in 20 mL 1 M
HCI and washed with CH2CI2 ( 4 x 8  mL). The aqueous phase was made basic
with 4 M NaOH, diluted with saturated NaHC03 (10 mL) and extracted with
CH2CI2 ( 3 x 8  mL). The combined extracts were dried (K2C0 3) and concentrated
to give 136 as a yellow-orange foam (0.056 g, 85%). Rf 0.24 (MeOH:CH2Cl2,
1:9). 1H NMR (400 MHz, CDCI3): 5 2.05 (bs, NH, 1H), 2.83 -  2.98 (m, 3H), 3.05
(m, broad doublet shape, 1H), 3.21 -  3.29 (m, 2H), 3.38 (td, J = 2.9, 12.8 Hz,
1H), 4.45 (bs, 1H), 4.78 (bs, 1H), 6.96 (d, J = 9.2 Hz, 1H), 7.19 (m, 1H), 7.27 -
7.35 (m, 4H), 7.69 (d, J = 9.5 Hz, 1H), 7.90 (d, J = 9.2 Hz, 1H), 8.31 (d, J = 2.6,
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9.5 Hz, 1H), 8.52 (d, J = 2.6 Hz, 1H); 13C NMR (100 MHz, CDCI3): 5 34.4, 40.9,
46.2, 46.8, 54.0, 110.8, 121.0, 123.6, 124.2, 126.4, 127.1, 128.5, 129.4, 138.4,
138.9, 141.8, 151.5, 158.4; HRMS (ESI-TOF) m/z (M + H)+ calcd. for C20H21N4O2 
349.1665 found 349.1678.
Ethyl Bromophenylacetate 147. The synthesis of 147 is adapted from the 
method of Epstein.138 To a solution of ethyl phenylacetate (1.03 g, 6.28 mmol) in 
CCU (16 mL) was added NBS (1.15 g, 6.47 mmol) and two drops of HBr (48%). 
The mixture was heated to reflux and maintained until the solids floated on top of 
the solvent. This mixture was cooled and filtered through a pad of Fluorosil 
(Magnesium silicate) the pad was rinsed with CH2CI2 and the filtrate concentrated 
to give the crude product that was purified by column chromatography (silica gel, 
EtOAc:Hexanes, 1:3) to afford 147 as a clear, loose oil (1.50 g, 98%). TLC Rf 
0.60 (EtOAc:Hexanes, 2:3). 1H NMR (400 MHz, CDCI3): 5 1.28 (t, 3H), 4.24 (m, 
AB pattern 0-CH 2-CH3, 2H), 5.35 (s, 1H), 7.34 -  7.40 (m, 3H), 7.53 -  7.58 (m, 
2H); 13C NMR (100 MHz, CDCI3): 5 13.9, 46.8, 62.5, 128.6, 128.8, 129.2, 135.8,
168.2.
1,4-Dibenzyl-3-phenylpiperazine-2-one 151. To a stirred solution of N,N- 
dibenzyl ethylenediamine (10.2 g, 42.5 mmol) in acetonitrile (55 mL) under argon
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was added a solution of bromo ester 147 (5.17 g, 21.3 mmol). This solution was 
heated at reflux for 6  h then stirred for 38 h at ambient temperature. The solvent 
was evaporated and the residue partitioned between 1 M NaOH (60 mL) and 
ether (50 mL). The organic phase was separated and the aqueous phase 
extracted with ether (2 x 40 mL). The combined organic phases were washed 
with brine (2 x 30 mL), dried (Na2SC>4) and the solvent evaporated to give 12.5 g 
of crude material that was purified by column chromatography (silica gel, 
EtOAc:Hexanes, 1:9 -  1:3) to afford 151 as a very thick oil (5.85 g, 77%). TLC Rf 
0.29 (EtOAc:Hexanes, 2:3). 1H NMR (400 MHz, CDCI3): 8  2.47 (td, J = 3.7, 12.1 
Hz, 1H), 2.97 (dt, J = 3.3, 12.1 Hz, 1H), 3.09 -  3.18 (m, 2H), 3.47 (td, J = 3.7,
11.0, 1H), 3.75 (d, J =  13.2 Hz, 1H), 4.14 (s, 1H), 4.59 (m, AB pattern, J = 14.3 
Hz, 2H), 7.22 -  7.42 (m, 15H); 13C NMR (400 MHz, CDCI3): 8  45.8, 46.6, 50.2,
58.8, 71.2, 127.2, 127.5, 127.8, 128.2 (two overlapped peaks), 128.4, 128.6,
128.7, 129.0, 136.8, 137.7, 139.4, 168.3.
1,4-Dibenzyl-2-phenylpiperazine 152. To a solution of amide 151 (1.19 g, 3.34 
mmol) in dry THF (20 mL) was added LiAIH4 (0.597 g, 15.7 mmol) in one portion. 
The mixture was heated at reflux for 5 h. After cooling, the excess LiAIH4 was 
quenched by the careful, sequential addition of 0.25 mL water, 0.5 mL 4 N NaOH 
and 0.25 mL water. The mixture was stirred 15 min and the solids that formed 
were filtered (Celite) and the filtrate concentrated to give the crude material that
LiAlH4, Et20
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was purified by column chromatography (silica gel, EtOAc:Hexanes, 2:3) to 
provide 152 as a white solid 0.922 g, 81%). TLC Rf 0.52 (EtOAc:Hexanes, 2:3). 
1H NMR (400 MHz, CDCI3): 5 2.14 -  2.21 (m, 1H), 2.22 -  2.32 (m, 2H), 2.78 (m, 
1H), 2 .8 3 -2 .9 1  (m, 3H), 3.43 (dd, J = 2.6, 10.3 Hz, 1H), 3.50 (m, singlet shape, 
2H), 3.79 (d, J = 13.2 Hz, 1H), 7.17 -  7.52 (m, 15H); 13C NMR (100 MHz, 
CDCI3): 5 51.7, 53.2, 58.9, 62.0, 62.9, 67.3, 126.7, 127.0, 127.4, 128.0, 128.2,
128.4, 128.7, 129.2, 137.8, 139.0, 142.2.
MeOH, HCI
2-Phenylpiperazine dihydrochloride 153. To a suspension of dibenzyl 
piperazine 152 (0.500 g, 1.46 mmol) in methanol (25 mL) was added HCI (12 M, 
0.24 mL, 2.92 mmol) and 5% Pd/C (0.075 g). The flask was sealed with a septa 
and H2 was bubbled through the solution via balloon. The reaction was 
monitored by TLC until 152 was consumed, refilling H2 if necessary. The 
reaction mixture was filtered (Celite) and the filtrate concentrated to provide 153 
as a white solid (0.345 g, quantitative). 1H NMR (400 MHz, D20): 5 3.37 (m, 1H),
3.49 (m, 1H), 3.57 (m, 1H), 3.63 -  3.76 (m, 3H), 4.59 (m, 1H, overlapped with 
HOD), 7.31 -  7.40 (m, 5H); 13C NMR (100 MHz, DMSO-cfe): 5 39.0, 41.0, 44.5,
55.4, 128.1, 129.0, 129.8, 133.1.
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H N ^ |
^ l H 1 .C H 2CI2 . B 3N 
H .2HCI 2. Trityl chloride
NTrit
3-Phenyl-1-triphenylmethylpiperazine 154. To a stirring suspension of 
piperazine 153 (0.433 g, 1.84 mmol) in dry CH2CI2 ( 2 0  mL) under argon was 
added anhydrous triethylamine (1.0 mL, 7.4 mmol). The resultant clear solution 
was cooled to 0 °C and a solution of trityl chloride (0.514 g, 1.84 mmol) in dry 
CH2CI2 (5 mL) was added (dropwise). The reaction was stirred an additional 10 
min at 0 °C then warmed to ambient temperature and stirred for 1.5 h. The 
solution was washed with saturated NaHC0 3  (30 mL) and the aqueous solution 
extracted with CH2CI2 ( 2 x 1 5  mL). The combined organic extracts were dried 
(K2CO3) and concentrated to provide 154 as a white solid (0.760 g, quantitative). 
TLC Rf 0.50 (MeOH:CH2CI2, 1:9). 1H NMR (400 MHz, CDCI3): 5 1.23 (bs, 1H), 
1.53 (m, t shape, 1H), 1.67 (m, t shape, 1H), 3.06 -  3.14 (m, 2H), 3.20 (m, 1H),
3.35 (m, 1H), 4.20 (m, 1H), 7 .1 5 -7 .6 5  (m, 20H); 13C NMR (100 MHz, CDCI3): 8
46.7, 48.2, 56.0, 61.2, 77.1, 126.0, 126.9, 127.3, 127.5, 127.9, 128.3, 129.3 
(broad), 142.6.
2-(2-Phenylpiperazin-1-yl)quinoline 155. To a 0 °C solution of N-trityl 
piperazine 154 (0.605 g, 1.49 mmol) in dry ether (20 mL) under argon was added 
(dropwise) a solution of n-butyllithium in hexanes (2.33 M, 0.64 mL, 1.49 mmol).
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2. HCI, EtOH
1. Et20 , n-BuLi, 0 °C; 
2 -chloroquinoline
NH
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The orange turbid solution was stirred for 20 min. then a solution of 2 - 
chloroquinoline (0.163 g, 1.0 mmol) in dry ether (4 mL) was added dropwise 
forming a green-blue solution. The reaction was maintained at 0 °C for an 
additional 50 min then stirred at ambient temperature for 19 h. The solution was 
diluted with ether (10 mL) and washed with saturated NaHC0 3  (2 x 20 mL) and 
brine ( 2 x 1 5  mL), dried (K2CO3) and concentrated to provide the crude material 
that was purified by column chromatography (silica gel, EtOAc:Hexanes, 1:3) to 
afford a yellow foam intermediate (0.555 g, 104%) TLC Rf  0.58 (EtOAc:Hexanes 
2:3) that was not spectroscopically characterized and immediately deprotected. 
To a suspension of the crude intermediate (0.555g, 1.04 mmol) in 95% ethanol 
(20 mL) was added 6  M HCI (4 mL). The flask was swirled until the sides were 
cleared of solids and a homogenous solution resulted. Stirring continued at 
ambient temperature for 1 0  min then the reaction contents were diluted with ~ 2 0  
mL of CH2CI2. The mixture was made basic with 4 M NaOH and diluted with 20 
mL saturated NaHC0 3 - The organic phase was separated and the aqueous 
phase extracted with CH2CI2 ( 3 x 1 5  mL). The combined organic extracts were 
dried (K2CO3) and concentrated to provide the crude product that was purified by 
column chromatography (silica gel, eluting first with EtOAc:CHCl3, 4:1, to remove 
non-polar impurities, then MeOH:CH2Cl2, 1:9) to provide 155 as a pale colored oil 
(0.260 g, 8 6  %). TLC R f 0.24 (MeOH:CH2CI2, 1:9). 1H NMR (400 MHz, CDCI3): 5
1.79 (bs, NH, 1H), 3.02 (td, J  = 3.7, 12.1 Hz, 1H), 3.15 (m, 1H), 3.32 -  3.41 (m, 
2H), 3.65 (m, 1H), 4.63 (m, 1H), 5.56 (m, singlet shape, 1H), 6.87 (d, J  = 9.2 Hz, 
1H), 7.17 -  7.25 (m, 2H), 7.29 -  7.34 (m, 4H), 7.53 (m, 1H), 7.58 (m, doublet
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shape, 1H), 7.69 (d, J = 9.2 Hz, 1H), 7.84 (d, J = 9.2 Hz, 1H); 13C NMR (100 
MHz, CDCIs): 5 41.4, 45.9, 50.0, 54.7, 109.1, 122.1, 122.9, 126.5, 126.7, 127.1,
127.2, 128.7, 129.5, 137.6, 139.7, 147.9, 157.3.
3,4-Dihydro-6-nitroquinolin-2(1H)-one 158. To a -5 °C solution of hydro- 
carbostyril 157 (1.089 g, 7.4 mmol) in conc. H2SO4 (20 mL) was slowly added 
water (5 mL). After the solution cooled back to -5 °C, nitric acid (15.4 M, 0.49 
mL, 7.5 mmol) was added, three drops at a time, in three minute increments to 
minimize heating. Ten minutes following the addition, the reaction contents were 
transferred to a beaker and 60 mL of cold water was slowly added with stirring, 
forming a white precipitate. The precipitate mixture was cooled on ice for 15 min, 
and the solids were collected by filtration and washed sparingly with a few 
portions of cold EtOAc. The solids were dried under high vacuum providing 158 
as a pale colored solid (1.258 g, 8 8 %). 1H NMR (400 MHz, CDCI3): 6  2.73 (m, 
2H, triplet shape), 3.10 (m, 2H, triplet shape), 6.93 (m, 1H, doublet shape), 8.08 
-  8.13 (m, 2H), 9.28 (bs, NH, 1H); 13C NMR (100 MHz, CDCI3): 5 25.0, 29.9,
115.5, 123.85, 123.93, 124.1, 142.8, 143.2, 171.7.
D D Q , P O C I3
2-Chloro-6-nitroquinoline 159. To a suspension of 158 (1.06 g, 5.5 mmol) in 
benzene (20 mL) under argon was added DDQ (1.25 g, 5.5 mmol) followed by
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POCb (2.55 mL, 4.20 g, 27.4 mmol) in a dropwise manner. The bright yellow- 
orange mixture was heated at reflux for 3 h. After cooling, 20 mL of cold water 
was added and the mixture was brought to neutral pH with 4 M NaOH. The 
solids were collected by filtration and washed with cold water and -2 0  mL of cold 
ether. The filtrate was extracted with EtOAc (3 x 60 mL) and the combined 
extracts were dried (K2CO3) and concentrated to give a solid. Both batches of 
solids were combined and dissolved with heating in -30  mL of THF. Silica gel ( 6  
g) was added and the solvent evaporated to adsorb the crude product onto the 
silica gel. The material was loaded onto a chromatography column, and purified 
(silica gel, EtOAc:Hexane, 1:9) to provide 159 as a tan solid (1.13 g, 98 %). TLC 
R f  0.45 (EtOAc:Hexanes, 2:3). 1H NMR (400 MHz, DMSO-de): 5 7.84 (d, J  = 8 .8  
Hz, 1H), 8.16 (d, J =  9.2 Hz, 1H), 8.52 (dd, J =  2.6, 9.2 Hz, 1H), 8.79 (d, J =  8 .8  
Hz, 1H), 9.14 (d, J  = 2.6 Hz, 1H); 13C NMR (100 MHz, DMSO-d6): 5 124.1,
124.4, 125.1, 125.9, 129.7, 141.9, 145.3, 149.2, 153.6.
N-ferf-Butoxycarbonyl-N-benzylglycyl-DL-phenylglycine Methyl Ester 162.
The general peptide coupling procedure was used as described above for 96. 
Column chromatography of the crude product (silica gel, EtOAc:Hexanes, 1:3, to 
remove non-polar material, then EtOAc:Hexanes, 2:3, to elute the product)
CO2MG
CH 2CI2, r.t., 1 h
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provided 162 as a clear, viscous oil (1.87 g, 93%, solvent heavy). TLC Rf 0.33 
(EtOAc:Hexanes, 2:3). 1H NMR (400 MHz, CDCI3): 5 1.47 (bs, 9H), 3.71 (s, 3H), 
3.76 -  3.94 (bm, 2H), 4.42 (d, J = 15 Hz, 1H), 4.52 -  4.68 (bm, 1H), 5.50 (d, J =
7.3 Hz, 1H), 6.78 (bs, NH, 0.4H), 7.18 -  7.42 (m, 10H); 13C NMR (100 MHz, 
CDCI3): 5 28.2, 50.7, 51.7 (broad), 52.7, 56.1, 81.2, 127.1, 127.6, 128.2, 128.5,
128.7, 128.8, 136.2, 137.1, 155.4 (broad), 168.7 (broad), 170.8.
n v-
C02Me
1 . MeOH, SOCI2
2. NH4 OH, MeOH
1-Benzyl-3-phenylpiperazine-2,5-dione 163. To a 0 °C solution of dipeptide 
162 (1.873 g, 4.54 mmol) in methanol (25 mL) was slowly added excess thionyl 
chloride (1.5 mL) to avoid sputtering. Following the addition, the solution stirred 
at ambient temperature for 21 h. The solvent was evaporated and the residue 
was triturated with -3 0  mL of ether to produce a solid that was collected by 
filtration. The solid was dissolved in methanol (~30 mL) and treated with 
ammonium hydroxide (29%, 10 mL) at ambient temperature. The solution was 
stirred for 2 0  h then concentrated (the flask sat sealed, in the hood for 2  months). 
The residue was partitioned between saturated NaHC03 (20 mL) and 
CHCI3:isopropyl alcohol, 4:1 (50 mL). The organic phase was separated and the 
aqueous phase extracted with CHCI3:isopropyl alcohol, 4:1 (4 x 50 mL). The 
combined organic phases were dried (K2C0 3) and concentrated to afford 163 as 
a white solid (1.098 g, 8 6 %) with adequate purity for subsequent transformations.
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TLC Rf 0 .5 4  (MeOH:CH2CI2, 1:9). 1H NMR (400 MHz, CDCI3): 8  3.87 (m, quartet
1-Benzyl-3-Phenylpiperazine 164. To a suspension of diamide 163 (1.16 g, 
4.15 mmol) in dry THF (75 mL) was added L1AIH4 (0.630 g, 16.6 mmol) in one 
portion, producing a gentle effervescence. The mixture was maintained on ice 
until the bubbling stopped, then the flask was heated at reflux for 5 h. The 
mixture was cooled and stirred an additional hour, then the excess UAIH4 was 
quenched by the careful, sequential addition of 0.6 mL water, 1.2 mL 4 M NaOH 
solution and 0.6 mL water. After stirring 10 min, the solids were filtered (Celite) 
and the filtrate concentrated. The crude material was purified by column 
chromatography (silica gel, MeOHiCHCb, 1:49) to provide 164 as a pale colored 
oily solid (0.780 g, 74 %). TLC R f 0.24 (MeOH:CH2CI2, 1:9). 1H NMR (400 MHz, 
CDCI3): 8  2.08 (m, triplet shape, 1H), 2.20 (dd, J  = 4.4, 11 Hz, 1H, overlapped 
with bs, NH, 1H), 2.84 (m, doublet shaped, 1H), 2.91 (m, doublet shape, 1H),
3.02 -  3.12 (m, 2H), 3.55 (s, 2H), 3.89 (dd, J  = 2.9, 10.3 Hz, 1H) 7.22 -  7.40 (m, 
10H); 13C NMR (100 MHz, CDCI3): 8  46.2, 53.1, 60.3, 61.1, 63.3, 127.0, 127.4,
128.2, 128.3, 129.2, 137.8, 142.4
shape, AB pattern, J  = 17.9 Hz, 2H), 4.55 (m, AB pattern, J  = 14.3 Hz, 2H), 5.17 
(bd, 1H), 6.89 (bs, NH, 1H), 7.14 -  7.18 (m, 2H), 7.26 -  7.41 (m, 8 H); 13C NMR 
(100 MHz, CDCI3): 8  48.7, 49.8, 59.5, 126.4, 128.1, 128.2, 128.8, 128.9, 129.1,
135.0, 137.0, 164.6, 166.0.
O
□Aim , THF
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.0 co2M©
0  OH C 0 2Me
F
CH2CI2, r.t., 1 h CH2CI2, Et3 N, 
r.t., 2 0  h
N-te/t-Butoxycarbonyl-N-benzylglycyl-DL-phenylalanine Methyl Ester 166.
The general peptide coupling procedure was used as described above for 96. 
Column chromatography of the crude product (silica gel, EtOAc:Hexanes, 1:3, to 
remove non-polar material, then EtOAc:Hexanes, 3:2, to elute the product) 
provided 166 as a clear, viscous oil (2.17 g, 102%, solvent heavy). TLC R f  0.33 
(EtOAc:Hexanes, 2:3). 1H NMR (400 MHz, CDCI3): 5 1.45 (s, 9H), 2.99 -  3.16 
(bm, 2H), 3.72 (s, 3H), 3.79 (bd, J  = 16.1 Hz, overlapped with bm, 2H), 4.30 -
4.50 (bm, 2H), 4.85 (m, 1H, quartet shaped), 6.27 (bs, 0.3H), 6.63 (bs, 0.3H),
7.05 -  7.11 (bm, 2H), 7.17 -  7.34 (m, 8 H); 13C NMR (100 MHz, CDCI3): 5 28.2,
37.8, 50.2, 51.2 (v. broad), 52.3, 52.8 (broad), 81.1, 127.1, 127.6, 128.1 (broad),
128.6, 129.1, 135.6, 136.9, 155.3 (broad), 168.9 (broad), 171.5.
1,3-Dibenzylpiperazine-2,5-dione 167. To a 0 °C solution of dipeptide 166 
(2.18 g, 5.11 mmol) in methanol (30 mL) was slowly added excess thionyl 
chloride (1.9 mL) to avoid sputtering. Following the addition, the solution stirred 
at ambient temperature for 2.5 h. The solvent was evaporated and the residue
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was triturated with -3 0  mL of ether, producing a white solid that was collected by 
filtration. The solid was dissolved in methanol (40 mL) and treated with 
ammonium hydroxide (29%, 10 mL) at ambient temperature. The solution was 
stirred for 18 h then concentrated. The solid residue was partitioned between 
saturated NaHC0 3  (40 mL), water (20 mL) and CHCbiisopropyl alcohol, 4:1 (40 
mL). The organic phase was separated and the aqueous phase extracted with 
CHCbMsopropyl alcohol, 4:1 (3 x 40 mL). The combined organic phases were 
dried (K2CO3) and concentrated to afford 167 as a white solid (1.382 g, 92%) with 
adequate purity for subsequent transformations. TLC Rf 0.49 (MeOH:CH2Cl2 , 
1:9). 1H NMR (400 MHz, CDCI3): 5 2.99 (d, part of AB pattern, J = 17.6 Hz, 1H), 
3.17 (m, AB pattern, 2H), 3.52 (d, part of AB pattern, J = 17.6 Hz, 1H), 4.35 (m, 
1H), 4.48 (m, AB pattern, J = 14.7 Hz, 1H), 6.39 (bs, NH, 1H), 7.13 -  7.35 (m, 
10H, overlapped with CDCI3); 13C NMR (100 MHz, CDCI3): 5 40.5, 48.2, 49.6,
56.4, 127.4, 128.1, 128.59, 128.63, 128.8, 130.0, 134.65, 134.68, 165.2, 166.3.
1,3-Dibenzylpiperazine 168. To a 0 °C suspension of dione 167 (1.38 g, 4.7 
mmol) in dry THF (120 mL) was added LiAIH4 (0.713 g, 18.8 mmol) in two 
portions, producing a gentle effervescence. The mixture was maintained on ice 
until the bubbling stopped, then the reaction was heated at reflux for 2.5 h. The 
solution was cooled and stirred for an additional 19 h then the excess LiAIH4 was 
quenched by the careful, sequential addition of 0.7 mL water, 1.3 mL 4 M NaOH
O
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and 0.7 mL water. The solids that formed will filtered (Celite) and the filtrate 
concentrated to provide 168 as a pale colored solid (1.29 g, 103%, with THF) that 
slowly formed from an oil. TLC R f  0.21 (MeOH:CH2Cl2, 1:9). 1H NMR (400 MHz, 
CDCI3): S 1.93 (m, triplet shape, 1 H), 2.11 (td, J  = 2.9, 11.0 Hz, 1H, overlapped 
with bs, NH, 1H), 2.58 (dd, 8 .8 , 13.2 Hz, 1H), 2.70 -  2.77 (m, 2H), 2.79 -  2.87 
(m, 2H), 2.92 (dt, J  = 2.3, 11.7 Hz, 1H), 3.02 (m, 1H), 3.51 (dd, AB pattern, J  =
12.8 Hz, 2H), 7.18 -  7.33 (m, 10H); 13C NMR (100 MHz, CDCI3): 5 40.7, 45.6,
53.3, 56.2, 59.6, 63.3, 126.3, 127.0, 128.1, 128.4, 129.2, 137.9, 138.5.
MeOH, HCI
2-Benzylpiperazine dihydrochloride 169. To a solution of piperazine 168 (1.25 
g, 4.69 mmol) in methanol (20 mL) was added HCI (12 M, 0.78 mL, 9.38 mmol) 
and 5% Pd/C (0.188 g). The flask was sealed with a sepum and H2 was bubbled 
through the solution via balloon. The reaction was monitored by TLC until 168 
was consumed, refilling H2 if necessary. The mixture was filtered (Celite) and the 
filtrate concentrated to provide 169 as a white solid (1.10 g, 94%). 1H NMR (400 
MHz, D20): 5 2.90 (dd, AB pattern, J  = 7.7, 14.3 Hz, 1H), 2.97 (dd, AB pattern, J  
= 7.0, 14.3 Hz, 1H), 3.13 (m, triplet shape, 1H), 3.22 (m, 2H), 3.52 -  3.59 (m, 
3H), 3.72 (m, 1H), 7.15 -  7.32 (m, 5H); 13C NMR (100 MHz, D20 , dioxane int. 
std 67.4 ppm): 5 36.8, 40.9, 41.4, 45.1, 54.6, 129.0, 130.3 (overlapped peaks),
133.9.
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H 2HCI methylformate
CH2 CI2, Et3N H N ^ |
CHO
3-Phenylpiperazine-1-carbaldehyde 170. To a suspension of powdered 
piperazine 153 (0.206 g, 0 .8 8  mmol) in CH2CI2 (2 mL) was added triethylamine 
(0.26 mL, 1.85 mmol) followed by additional CH2CI2 to facilitate stirring. The 
mixture was cooled to 0 °C and methylformate (0.06 mL, 0.96 mmol) was added. 
Stirring continued for 20 min at 0 °C then 24 h at ambient temperature. The 
mixture was diluted with saturated NaHC0 3  (6  mL) and extracted with CH2CI2 (3 
x 10 mL). The combined extracts were dried (K2CO3) and concentrated to 
provide the crude material that was purified by column chromatography (silica 
gel, MeOH:CH2CI2, 1:39) to provide 170 as a oil (0.103 g, 62%). TLC Rf 0.35 
(MeOH:CH2Cl2, 1:9). 1H NMR (400 MHz, CDCI3): (approximate 1:1 mixture of 
amide rotamers) 5 2.71 (dd, J = 10.6, 12.8 Hz, 0.5H), 2.83 -  2.93 (m, 1.5H), 3.11 
-  3.22 (m, 1.5H), 3.34 (td, J = 2.9, 11.7 Hz, 0.5H), 3.55 (m, 1H), 3.70 (td, J = 3.3, 
10.6 Hz, 1H), 4.40 (m, 1H), 7.27 -  7.44 (m, 5H), 8.07 (s, CHO, 0.5H), 8.10 (s, 
CHO, 0.5H); 13C NMR (100 MHz, CDCI3): 5 40.2, 45.5, 45.9, 46.8, 47.2, 53.1,
59.8, 61.4, 126.8, 126.9, 127.9, 128.1, 128.5, 128.6, 140.4, 140.7, 160.7, 160.8.
3-Benzylpiperazine-1-carbaldehyde 171. To a suspension of powdered 
piperazine 169 (0.304 g, 1.22 mmol) in dimethoxyethane (1.5 mL) was added 
triethylamine (0.35 mL, 2.56 mmol). The stirred mixture was cooled to 10 °C,
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methylformate
methylformate (0.11 mL, 1.83 mmol) was added and stirring was continued for 1 
h at 10 °C then 24 h at ambient temperature. The mixture was diluted with 
saturated NaHC0 3  ( 6  mL) and extracted with CHCb-isopropyl alcohol, 4:1 ( 3 x 1 5  
mL). The combined extracts were dried (K2CO3) and concentrated and the crude 
product was purified by column chromatography (silica gel, MeOH:CH2CI2, 1:19 — 
1:9) to provide 171 as an oil (0.189 g, 76%). TLC Rf 0.27 (MeOH:CH2CI2, 1:9). 
1H NMR (400 MHz, CDCI3): (approximate 1:1 mixture of amide rotamers) 5 2.0 
(bs, NH, 1H), 2.54 -  2.72 (m, 2.5H), 2.75 -  2.89 (m, 2.5H), 2.96 (m, dd shape, 
0.5H), 3.00 -  3.06 (m, 1H), 3.24 (td, J = 3.3, 11.7 Hz, 0.5H), 3.45 -  3.52 (m, 1H),
4.25 (m, doublet shape, 0.5H), 4.35 (m, doublet shape, 0.5H), 7.17 -  7.36 (m, 
5H), 7.98 (s, 0.5H), 8.04 (s, 0.5H); 13C NMR (100 MHz, CDCI3): 5 39.9, 40.0,
40.4, 45.0, 45.7, 46.1, 46.3, 51.3, 55.8, 57.1, 126.6, 126.7, 128.6, 128.7, 129.0,
129.1, 137.0, 137.3, 160.70, 160.75.
Trityl chloride
3-Benzyl-1-triphenylmethylpiperazine 172. To a stirred suspension of 
piperazine 169 (0.396 g, 1.59 mmol) in dry CH2CI2 (20 mL) under argon was 
added anhydrous triethylamine (0.88 mL, 6.4 mmol). The resultant clear solution 
was cooled to 0 °C and a solution of trityl chloride (0.443 g, 1.59 mmol) in dry 
CH2CI2 (7 mL) was added (dropwise). The reaction was stirred an additional 5 
min at 0 °C then warmed to ambient temperature and stirred for 16 h. The 
solution was washed with saturated NaHC0 3  (40 mL) and brine (40 mL), and 
then dried (K2C0 3 ) and concentrated to provide 172 as a white solid (0.650 g,
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98%). TLC Rf 0.42 (MeOH:CH2CI2) 1:9). 1H NMR (400 MHz, CDCI3): 8  1.35 (bs,
(bm, 4H), 3.27 (m, 1H), 7.12 -  7.56 (m, 20H); 13C NMR (100 MHz, CDCI3): 8
2-(4-Benzyl-2-phenylpiperazin-1-yl)-6-nitroquinoline 174. A suspension of 
quinoline 159 (0.0382 g, 0.183 mmol) and piperazine 164 (0.092 g, 0.365 mmol) 
in dry DMSO (0.5 mL) was sealed under argon in a vial and placed in a 120 °C 
oil bath for 24 h. The reaction mixture was pipetted into water (20 mL) and 
saturated NaHC03 (10 mL), then extracted with ether (2 x 20 mL). The 
combined ether extracts were washed with water ( 5 x 8  mL) and brine (20 mL), 
then dried (K2C 03) and concentrated. The crude material was purified by column 
chromatography (silica gel, EtOAc:Hexanes, 1:19 -  1:9) to provide 174 as an 
orange oil (0.060 g, 76%). TLC Rf 0.50 (EtOAc:Hexanes, 2:3). 1H NMR (400 
MHz, CDCI3): 8  2.36 (td, J = 2.9, 11.4 Hz, 1H), 2.58 (dd, J = 3.7, 11.7 Hz, 1H),
3.02 (bd, J = 10.3 Hz, 1H), 3.66 (bd, J = 12.8 Hz, 1H), 3.41 -  3.54 (m, 3H), 4.54 
(bd, J = 12.8 Hz, 1H), 5.86 (bs, 1H), 7.03 (d, J = 9.2 Hz, 1H), 7.22 -  7.43 (m, 
10H), 7.65 (d, J = 9.2 Hz, 1H), 7.93 (d, J = 9.2 Hz, 1H), 8.29 (dd, J = 2.6, 9.2 Hz, 
1H), 8.51 (d, J = 2.6 Hz, 1H); 13C NMR (100 MHz, CDCI3): 8  40.9, 53.3, 54.1,
1H), 1.59 (bs, 2H), 2.42 (bs, 1H), 2.65 (dd, J = 3.7, 13.2 Hz, 1H), 2.85 -  3.16
40.8, 46.4, 48.3, 54.4, 56.9 (all broad), 77.05, 125.9, 126.2, 127.4 (broad, 2
peaks), 128.4, 129.1,129.3 (broad), 138.7.
DMSO
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55.5, 62.8, 110.8, 121.0, 123.6, 124.3, 126.9, 127.0, 127.2, 127.5, 128.2, 128.3,
129.0, 137.6, 138.8, 139.7, 141.7, 151.5, 158.3.
0 2N
o 2n
Cl
+
Bn 120 °C
DMSO
H Bn
2-(2,4-Dibenzylpiperazin-1-yl)-6-nitroquinoline 175. A suspension of quinoline 
159 (0.035 g, 0.172 mmol) and piperazine 168 (0.090 g, 0.338 mmol) in dry 
DMSO (1.0 mL) was sealed under argon in a vial and placed in a 120 °C oil bath 
for 24 h. The reaction was pipetted into water (20 mL) and saturated NaHC0 3  
(10 mL), and then extracted with ether (2 x 20 mL). The combined extracts were 
washed with water ( 5 x 5  mL) and brine (20 mL), then dried (K2CO3) and 
concentrated. The crude material was purified by column chromatography (silica 
gel, EtOAc:Hexanes, 1:9 -  2:3) to provide 175 as an orange oil (0.056 g, 74%). 
TLC Rf 0.39 (EtOAc:Hexanes, 2:3). 1H NMR (400 MHz, CDCI3): 5 2.08 (dd, J =
3.7, 11.7 Hz, 1H), 2.26 (td, J  = 3.7, 11.7 Hz, 1H), 2.80 -  2.87 (m, 2H), 3.07 (m, 
bd shaped, 1H), 3.27 (dd, J  = 9.9, 12.5 Hz, 1H), 3.40 -  3.50 (m, 2H, an AB 
doublet is overlapped here J  = 12.8 Hz), 3.62 (d, part of AB pattern, J  = 12.8 Hz, 
1H), 4.45 (bs, 1H), 4.71 (bs, 1H), 6.98 (d, J  = 9.2 Hz, 1H), 7.09 -  7.19 (m, 5H), 
7.31 -  7.43 (m, 5H), 7.70 (d, J  = 9.2 Hz, 1H), 7.92 (d, J  = 9.2 Hz, 1H), 8.31 (dd, J  
= 2.6, 9.2 Hz, 1H), 8.53 (d, J =  2.6 Hz, 1H); 13C NMR (100 MHz, CDCI3): 8 35.3,
40.7, 53.4, 54.5, 62.9, 110.8, 120.9, 123.6, 124.3, 126.2, 127.1, 127.3, 128.31, 
128.34, 129.3, 129.4, 138.0, 138.4, 139.1, 141.7, 151.6, 158.1.
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o 2n
Polar column CH2CI2, Boc20 ;
fraction from ------------------------ *■
Entry 1 (Table 4.1) Chromatography
Boc
2-[4-(tert-Butoxycarbonyl)-3-phenylpiperazin-1 -yl]-6-nitroquinoline 176. To
the polar column fraction from Entry 1 , Table 4.1 (0 .1 1 1  g) dissolved in CH2CI2 (5 
mL) is added a solution of di-fe/f-butyldicarbonate (~0 . 1 1 g, 0.5 mmol) in CH2CI2 
(2 mL). The reaction was allowed to proceed for 5 h and TLC analysis showed 
the formation of a non-polar product (R f  0.38, EtOAc:Hexanes, 2:3) consistent 
with Boc-protected quipazines. The solvent was evaporated and the residue 
purified by column chromatography (silica gel, EtOAc:Hexanes, 2:3) to provide 
176 as a yellow foam (0.045 g). TLC R f 0.38 (EtOAc:Hexanes, 2:3). 1H NMR 
(400 MHz, CDCI3): 5 1.40 (s, 9H), 3.43 -  3.53 (bm, 2H), 4.05 -  4.16 (bm, 2H), 
4.21 -  4.28 (bm, 1H), 4.57 -  4.67 (bm, 1H), 5.32 (bs, 1H), 6.97 (d, J  = 9.2 Hz, 
1H), 7.21 -7 .2 6  (m, 1H), 7 .2 8 -7 .3 7  (m, 4H), 7.72 (bs, 1H), 7.98 (d, J =  9.2 Hz, 
1H), 8.32 (dd, J =  2.6, 9.2 Hz, 1H), 8.55 (d, J =  2.6 Hz, 1H).
2-(3-Phenylpiperazin-1-yl)-6-nitroquinoline 177. A solution of quipazine 176 
(0.045 g, 0.10 mmol) in THF (0.5 mL) and 4 M H 2 S O 4  (3 mL) was stirred at 
ambient temperature. The deprotection of the Boc group was found to be slow, 
so 3 drops of conc. H 2 S O 4  was added. After 1 h, the reaction was complete (176 
gone by TLC) and the reaction was pipetted onto ice, made basic with 4 M N a O H  
and diluted with saturated NaHCOs (10 mL). The aqueous mixture was extracted
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with CH2CI2 ( 2  x 2 0  mL) and the combined extracts dried (K2CO3) and 
concentrated to provide 177 as a yellow-orange solid (0.032 g, 94%). TLC R f  
0.44 (MeOH:CH2CI2, 1:9). 1H NMR (400 MHz, CDCI3): 5 2.12 (bs, NH, 1H), 3.00 
-3 .1 1  (m, 2H), 3 .1 9 -3 .3 2  (m, 2H), 3.88 (dd, J  = 2.9, 10.6 Hz, 1H), 4.63 (bd, J  =
12.8 Hz, 2H), 7.08 (d, J  = 9.2 Hz, 1H), 7.31 -  7.43 (m, 3H), 7.50 (m, doublet 
shape, 2H), 7.64 (d, J  = 9.2 Hz, 1H), 7.96 (d, J  = 9.2 Hz, 1H), 8.28 (dd, J  = 2.6,
9.2 Hz, 1H), 8.52 (d, J  = 2.6 Hz, 1H); 13C NMR (100 MHz, CDCI3): 5 44.9, 46.1,
52.1, 60.5, 110.9, 121.0, 123.6, 124.2, 127.1 (shouldered, 2 overlapping peaks),
128.1, 128.7, 138.7, 141.2, 141.9, 151.5, 158.4.
C 0 2Me Oy l
i^00̂  ULX
c o 2m ©
CH2CI2. Et3N,
r.t., 20 h
N-ferf-Butoxycarbonyl-N-benzylglycyl-DL-aspartate Dimethyl Ester 183. The
general peptide coupling procedure was used as described above for 96.
Column chromatography of the crude product (silica gel, EtOAc:Hexanes, 1:3, to 
remove non-polar material, then EtOAc:Hexanes, 2:3, to elute product) provided 
183 as a clear, viscous oil (1.96 g, 96%). TLC Rf 0.18 (EtOAc:Hexanes, 2:3). 1H 
NMR (400 MHz, CDCI3): 8  1.49 (s, 9H), 2.72 (bm, 1H), 2.99 (dd, J  = 3.6, 16.8, 
1H), 3.67 (s, 3H), 3.74 (s, 3H), 3.77 -  3.97 (bm, 2H), 4.42 (d, J  = 15.4, 1H), 4.59 
(bd, J  = 15.4, 1H), 4.82 (bm, 1H), 6.82 (bs, 0.4H), 7.12 (bs, 0.3H), 7.20 -  7.34 
(m, 5H); 13C NMR (100 MHz, CDCI3):8  28.2, 35.9, 48.1, 50.3, 51.6 (broad), 51.9,
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52.7, 81.1, 127.6, 128.2 (broad), 128.6, 137.1, 155.3 (broad), 169.1, 170.8
(broad), 171.2 (broad).
1. MeOH, SOCI2  
0 °C - r.t., 2 h
C 0 2Me 2. MeOH, NH4OH
4 \ ^ C 0 2Me r.t. 20 h
HN N-Bn
M e02C '  O
H H
Methyl 2-(1 -Benzyl-2,5-dioxopiperazin-3-yl)acetate 184. To a 0 °C solution of 
dipeptide 183 (1.9 g, 4.4 mmol) in methanol (25 mL) was added slowly excess 
thionyl chloride (2 mL) to avoid sputtering. Following the addition, the solution 
stirred at ambient temperature for 4.5 h. The solvent was evaporated and the 
oily residue was triturated with ether (20 mL). The ether was decanted and the 
process repeated. The still oily residue was dissolved in methanol (~45 mL) and 
treated with ammonium hydroxide (29%, 10 mL) at ambient temperature. The 
solution stirred for 16 h and the solvent was evaporated. The residue was 
partitioned between saturated NaHC0 3  (25 mL) and CHCb:isopropyl alcohol, 4:1 
(20 mL). The organic phase was separated and the aqueous phase extracted 
with CHCI3:isopropyl alcohol, 4:1 (3 x 20 mL). The combined organic phases 
were dried (K2CO3) and concentrated to afford 184 as a white solid (1.15 g, 97%) 
of adequate purity for subsequent steps. TLC Rf 0.38 (MeOH:CH2CI2, 1:9). 1H 
NMR (400 MHz, CDCI3): 5 2.86 (dd, J = 8.1, 17.2 Hz, 1H), 3.06 (dd, J = 3.7, 17.2 
Hz, 1H), 3.68 (s, 3H), 3.87 (m, 2H, qd shape), 4.40 (m, 1H), 4.59 (m, AB pattern, 
s shape), 7.05 (bs, 1H), 7.24 -  7.37 (m, 5H); 13C NMR (100 MHz, CDCI3):6  25.3, 
38.0, 48.8, 49.8, 51.8, 52.2, 128.1, 128.4, 128.9, 134.8, 164.6, 165.2, 170.9.
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o
/ “ A  THF, UAIH4 H N ^ I
HN N-Bn ------------------- ► 7  1
" - - 7  \ \  reflux, 5 h
M e0 2C —' O H
1-Benzyl-3-(2-hydroxyethyl)piperazine-2,5-dione 186. To a 0 °C suspension 
of amide 184 (1.15 g, 4.16 mmol) in dry THF (100 mL) under argon was added 
UAIH4 (0.949 g, 25 mmol) in 3 small portions. The mixture was heated at reflux 
for 5 h, then cooled. The excess LiAIH4 was destroyed by the careful, sequential 
addition of 1 mL water, 2 mL 4 N NaOH and 1 mL water. After stirring 1 h, the 
solids that formed were filtered (Celite) and the filtrate concentrated to give 186 
as a pale colored oil (0.896 g, 98%). The crude material was used without 
purification in subsequent reactions.
A pure sample of 186 was generated through the deprotection of N-formyl 
protected alcohol 187 (0.067g, 0.27 mmol) by dissolving 187 in THF (1 mL) and 4 
M H2SO4 (3 mL) and heating at 55 °C for 3 h. The reaction was made basic with 
4 M NaOH, diluted with saturated NaHC0 3  (10 mL) and extracted with CH2CI2 (5 
x 10 mL). The combined extracts were dried (K2CO3) and concentrated to 
provide pure 186 as an oily solid that solidified upon standing (0.052 g, 8 8 %). 
TLC Rf 0.07 (MeOH:CH2CI2, 1:9). 1H NMR (400 MHz, CDCI3): 5 1.55 (m, 2H),
1.80 (m, 1H), 1.99 (m, 1H), 2.70 -  3.06 (m, 6 H, overlapped d at 2.73), 3.47 (s, 
2H), 3.76 (m, 2H), 7.20 -  7.36 (m, 5H); 13C NMR (100 MHz, CDCI3): 6  35.3,
45.3, 54.0, 55.4, 59.6, 61.7, 63.4, 127.0, 128.1, 129.1, 137.8.
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HO
H N ^ j
H
Acetic anhydride
Formic Acid ohc' n^
Bn
H
4-Benzyl-2-(2-hydroxyethyl)piperazine-1-carbaldehyde 187. To a 0 °C
solution of amino alcohol 186 (0.853 g, 3.87 mmol) in formic acid (8 8 %, 11 mL) 
was added (dropwise) acetic anhydride (3.25 g, 31.8 mmol). The reaction stirred 
at 0 °C for 30 min then at ambient temperature for an additional 45 min. Ice (~15 
g) was added and the contents were transferred to a beaker and placed in an ice 
bath before the solution was brought to basic pH by the addition of 4 N NaOH. 
The contents were diluted with saturated NaHCOs (20 mL) and extracted with 
CH2CI2 (5 x 2 0  mL). The combined extracts were dried (K2CO3) and 
concentrated to give the crude material that was purified by column 
chromatography (silica gel, MeOHiCHCb, 1:49) to afford 187 as an almost 
colorless oil (0.582g, 61%). TLC Rf 0.47 (MeOH:CH2CI2, 1:9). 1H NMR (400 
MHz, CDCI3): (approximate 7:3 mixture of amide rotamers) 6  1.66 -  1.85 (m, 1H),
1.95 -  2.12 (m, 1H), 2.14 -  2.34 (m, 2H), 2.72 -  2.97 (m, 2.7H), 3.08 (bm, 0.3H),
3.26 -  3.74 (m, 5.7H), 3.84 (m, 0.3H), 4.20 (m, 0.3H), 4.50 (m, 0.7H), 7.21 -  7.37 
(m, 5H), 8.07 (m, 2 overlapped -CHO, 1H); 13C NMR (100 MHz, CDCI3): 8  32.6,
33.6, 36.5, 42.6, 45.3, 51.0, 52.3, 52.9, 56.1, 56.7, 58.1, 58.2, 62.5, 62.6, 127.3,
128.3, 128.7, 128.8, 137.5, 161.6, 162.2.
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OHC' N ^  DMF, NaH 0H C ' N ^ |
H O ^ ^ I ^ N 'Bn CHg-l ^ N '  Bn
H rl
4-Benzyl-2-(2-methoxyethyl)piperazine-1-carbaldehyde 188. To a 0 °C
solution of alcohol 187 (0.500 g, 2.01 mmol) in dry DMF (8  mL) was added NaH 
(95%, 0.145 g, 6.04 mmol) in one portion. After stirring 5 min, iodomethane 
(0.300 g, 2.11 mmol) was added and the mixture stirred for 15 min at 0°C then at 
ambient temperature for 1.5 h. The excess NaH was destroyed by the careful 
addition of water and the mixture was diluted with 20 mL each of water and 
saturated NaHC0 3 . The aqueous mixture was extracted with EtOAc (4 x 30 mL) 
and the combined extracts washed with brine (2 x 20 mL), dried (K2CO3) and 
concentrated to give the crude product that was purified by column 
chromatography (silica gel, MeOH:CHCI3, 1:199 -  1:49) to afford 188 as a loose, 
almost colorless oil (0.493 g, 93%). TLC Rf 0.Q2 (MeOH:CH2CI2, 1:9). 1H NMR 
(400 MHz, CDCI3): (approximate 7:3 mixture of amide rotamers) 6  1.81 (m, 0.7H), 
1.91 (m, 0.3H), 1 .97 -2 .11  (m, 1.3H), 2.14 -  2.34 (m, 1.7H), 2.74 (m, 1H), 2 .7 9 -
2.95 (m, 1.7H), 3.17 -  3.36 (m, 5.7H), 3.39 -  3.57 (m, 2H), 3.75 (m, 0.7H), 4.20 
(m, 0.7H), 4.50 (m, 0.3H), 7.22 -  7.38 (m, 5H), 8.03 (s, 1H); 13C NMR (100 MHz, 
CDCI3): 5 29.8, 30.2, 36.2, 42.3, 46.0, 51.2, 52.7, 53.8, 55.7, 56.7, 58.5, 58.6,
62.7, 68.5, 69.9, 127.2, 128.3, 128.7, 138.0, 161.0, 161.4.
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H
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THF, H2S 0 4
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H
Bn
1-Benzyl-3-(2-methoxyethyl)piperazine 189. The N-formyl methylether 188 
(0.493 g, 1.8 8  mmol) was dissolved in THF (3 mL) and 4 M H2SO4 (8  mL) and 
heated at 60 °C for 4 h. After cooling, the reaction was poured into 16 mL of cold 
(0 °C) 4 M NaOH and diluted with 10 mL of saturated NaHC0 3 . The mixture was 
extracted with CH2CI2 (4 x 2 0  mL) and the combined extracts were dried (K2CO3) 
and concentrated to provide 189 as a pale colored oil (0.420 g, 95%) with 
adequate purity for the subsequent transformations. TLC R f  0.16 (MeOH:CH2Cl2, 
1:9). 1H NMR (400 MHz, CDCI3): 8  1 .5 4 -1 .6 3  (m, 3H), 1.75 (m, 1H), 2.02 (td, J  
= 3.7, 10.6 Hz, 1H), 2.69 -  2.79 (m, 2H), 2.83 -  2.95 (m, 3H), 3.29 (s, 3H), 3.44 
(t, J  = 6 .6  Hz, 2H), 3.47 (m, AB pattern, J  = 13.2 Hz, 2H), 7.20 -  7.33 (m, 5H); 
13C NMR (100 MHz, CDCI3): 6  34.2, 45.7, 53.3, 53.8, 58.6, 60.0, 63.3, 70.3,
126.9, 128.1, 129.0, 138.1.
2-[4-Benzyl-2-(2-methoxyethyl)piperazin-1-yl]quinoline 190. To a 0 °C
solution of piperazine 189 (0.420 g, 1.79 mmol) in dry ether (20 mL) under argon 
was added (dropwise) a solution of n-butyllithium in hexane (2.45 M, 1.79 mmol) 
producing a clear amber solution. After stirring at 0 °C for 20 min, a solution of 2- 
chloroquinoline (0.195 g, 1.20 mmol) in ether (3.5 mL) was added (dropwise), 
producing a blood red solution. The reaction was stirred at 0 °C for 20 min then
'Bn 2-chloroquinoline, Et20
Et20 , n-BuLi, 0 °C;
H
Bn
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at ambient temperature for 3 h. The solution was diluted with ether (10 mL), 
washed with saturated NaHC0 3  (1 x 20 mL) and brine (1 x 20 mL), then dried 
(K2CO3) and concentrated. The crude product was purified by column 
chromatography (silica gel, EtOAc:Hexanes, 1:3) to provide 190 as a thick yellow 
oil (0.378 g, 8 8 %). TLC Rf 0.37 (EtOAc:Hexanes, 2:3). 1H NMR (400 MHz, 
CDCI3): 5 2.12 (m, 1H), 2 .1 7 -2 .3 2  (m, 3H), 2.89 (m, 1H), 2.99 (m, 1 H), 3.23 (s, 
3H, overlapped with), 3.22 -  3.41 (m, 3H), 3.46 (d, J = 13.2 Hz, 1H), 3.65 (d, J =
13.2 Hz, 1H), 4.59 (bm, 1H), 4.72 (bm, 1H), 7.06 (d, J = 9.2 Hz, 1H), 7.24 (m, 
1H), 7.32 (m, 1H), 7.36 -  7.46 (m, 4H), 7.56 (m, 1H), 7.62 (m, 1H), 7.75 (d, J =
8.4 Hz, 1H), 7.88 (d, J =  9.2 Hz, 1H); 13C NMR (100 MHz, CDCI3): 8  29.2, 39.3,
49.4, 53.5, 55.6, 58.2, 62.8, 69.5, 109.5, 121.8, 122.7, 126.3, 126.9 (two peaks),
128.1, 128.7, 129.2, 137.0, 138.4, 147.9, 156.8.
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APPENDIX:
Select 1H and 13C NMR Spectra of Target Compounds.
0 ,N 1 T
55 HOM -NQP  
H
2-[2-(Hydroxymethyl)piperzin-1 -yl]-6-nitroquinoline 55. 
1H NMR:
1
13C NMR:
■ U M«Mpi
160 150 140 130 120 110 100 90 80 70 60 50 40 30
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N ' 'N ''j 58 N-Boc-HOM-NQP
H
2-[4-(ferf-Butoxycarbonyl)-2-(hydroxymethyl)piperazin-1-yl]-6-nitroquinoline 
58. 
1H NMR:
J—I—A .
T
9
~ T
8
~F
6
~T~
5
~r~A T3 r2 "T17
13C NMR:
«Nm JL l i
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209
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
N' 61 MeProF-NQP
' _  NH 
H ^
2-[2-((3-Fluoropropoxy)methyl)piperazine-1-yl]-6-nitroquinoline 61. 
1H NMR:
Full spectrum:
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OoN
61 MeProF-NQP
13C NMR:
Full spectrum:
J-F J-F
J-F
160 ISO 140 130 120 110 100 90 80 70 60
— i—
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Zoomed spectrum:
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N N ^ ^ | 65 MeProF-Tosylate-NQP
Boc
2-[4-(fert-Butoxycarbonyl)-2-((3-(4-methylbenzenesulfonate)propoxy) 
methyl)piperazine-1-yl]-6-nitroquinoline 65.
1H NMR:
13C NMR:
160 150 140 130 120 110 100 90 80 70 60 50 40 30 20
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\
N N '^ ' l  78 EtOMe-NQP
H
2-[2-(2-Methoxyethyl)piperazin-1-yl]-6-nitroquinoline 78. 
1H NMR:
13C NMR:
ppm 160 ISO 140 130 120 110 100 90 80 70 60 SO 40 30
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NH
2-[2-Phenylpiperazin-1 -y l]-6-nitroquinoline 135.
'H NMR:
11 J_____K
13,C NMR:
70 60 so 40 30160 150 140 130 120 110 100 90 80
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2-[2-Benzylpiperazin-1-yl]-6-nitroquinoline 136. 
1H NMR:
13C NMR:
l» l»  'I*  —I >« M>
160 150 140 130 120 110 100 90 80 70 60 50 40 30
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